AU2001236140A1 - Pyrrolopyrimidinone derivatives, process of preparation and use - Google Patents
Pyrrolopyrimidinone derivatives, process of preparation and useInfo
- Publication number
- AU2001236140A1 AU2001236140A1 AU2001236140A AU2001236140A AU2001236140A1 AU 2001236140 A1 AU2001236140 A1 AU 2001236140A1 AU 2001236140 A AU2001236140 A AU 2001236140A AU 2001236140 A AU2001236140 A AU 2001236140A AU 2001236140 A1 AU2001236140 A1 AU 2001236140A1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- nch
- dihydro
- pyrrolo
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION
AND USE
BACKGROUND OF THE INVENTION Field of the Invention
The invention relates to a series of pyrrolopyrimidinone derivatives of the formula (1), processes for their preparation, intermediates in their preparation, their use as therapeutic agents, and pharmaceutical compositions containing them,
(1)
wherein R' is H; C,-C3 alkyl optionally substituted with one or more fluoro atoms; or C3-C6 cycloalkyl;
R2 is H; a halogen atom; C,-C6 alkyl optionally substituted with OH, C,-C3 alkoxy, C3-C6 cycloalkyl, or with one or more fluoro atoms; C3-C6 cycloalkyl; C2-C6 alkenyl; or C2-C6 alkynyl;
R3 is H; C,-C6 alkyl optionally substituted with OH, C,-C3 alkoxy, C3-C6 cycloalkyl, or with one or more fluoro atoms; C3-Cό cycloalkyl; C2-C6 alkenyl; or C2-C6 alkynyl; R4 is C,-C6 alkyl optionally substituted with C3-C6 cycloalkyl or with one or more fluoro atoms; C2-C6 alkenyl; C2-C6 alkynyl; or C3-C6 cycloalkyl;
R5 is SO2NR6R7; NHSO2NR6R7; NHCOCONR6R7; NHSO2R8; NHCOR8; or phenyl or heterocyclyl either of which is optionally substituted with one or more fluoro atoms or C — C3 alkyl;
R6 and R7 are each independently H or C,-C6 alkyl optionally substituted with OH, CO2H, C,-C3 alkoxy, C3-C6 cycloalkyl, or with one or more fluoro atoms; or together with the nitrogen atom to which they are attached form either a mono-cyclic ring such as imidazole, aziridene (aziridine), azeridine (azetidine), pyrroiidine, piperidine, morpholine, piperazine and homopiperazine, or a bicyclic ring such as 2,5-diazabicyclo[2. 2. l]heptane and 3,7-diazabicyclo[3. 3. 0]octane, wherein said group is optionally substituted with R9;
R8 is C,-C6 alkyl optionally substituted with one or more fluoro atoms; or C3-C7 cycloalkyl; R9 is C,-C6 alkyl optionally substituted with one or more halide atoms, OH,
C,-C3 alkoxy which is optionally substituted with one or more fluoro atoms, CO2R10, NR1 'R12, C=NR13(NR14R15), or with a tetrazole group which is optionally substituted with C,-C3 alkyl; or one or more nitrogen containing heteroaryl group which is optionally substituted with one or more fluoro atoms; R10 is H; or C,-C4 alkyl optionally substituted with OH, NR"R12, one or more fluoro atoms, or with a nitrogen containing heterocyclic ring such as pyrroiidine, piperidine, piperazine, morpholine, pyrrole, and imidazole wherein nitrogen atom is directly bound to C -C4 alkyl;
R11 and R12 are each independently H or C,-C4 alkyl; R13 is H; C,-C4 alkyl optionally substituted with one or more fluoro atoms; or C3-C6 cycloalkyl;
R14 and R15 are each independently H or C,-C4 alkyl optionally substituted with one or more fluoro atoms; C3-C6 cycloalkyl; or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, piperazinyl, or homopiperazinyl group wherein said group is optionally substituted with C,-C3 alkyl.
Description of the Prior Art
European patent applications EP-A-0463756 and EP-A-0526004 disclose certain pyrazolo[4,3-< Jpyrimidin-7-ones as cGMP PDE inhibitors, useful in the treatment of
cardiovascular disorders such as angina, hypertension and heart failure. International application WO 94/28902 discloses their use for the treatment of impotence.
The present inventors have recently disclosed a series of pyrazolo[4,3- ]pyrimidin-7-one derivatives as PDE V inhibitors (Appln. No. KR
98-60436 and KR 99-7580). Herein a new series of pyrrolo[4,3-< ]pyrimidin-7-one derivatives are prepared as PDE V inhibitors. However, none of the compounds of this invention are specifically disclosed.
SUMMARY OF THE INVENTION
The compounds (1) of this invention are potent and selective inhibitors of cyclic guanosine 3',5'~monophosphate specific phosphodiesterase (cGMP specific PDE; PDE V) having utility in a variety of therapeutic areas where such inhibition is thought to be beneficial, including the treatment of impotence (male erectile dysfunction), sexual dysfunction in female, and various cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
As a consequence of the selective PDE V inhibition exhibited by compounds of this invention, cGMP levels are elevated, which in turn can give rise to beneficial vasodilatory, anti-vasospastic, anti-platelet, anti-neutrophil, natriuretic and diuretic activities as well as potentiation of the effects of endothelium-derived relaxing factor (EDRF), nitrovasodilators, atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and endothelium-dependent relaxing agents such as bradykinin, acetylcholine and 5-HT,.
The compounds of this invention therefore have utility in the treatment of a number of disorders, including impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease,
inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome).
Detailed Description of the Invention
Thus, according to a first aspect, this invention provides compounds of the formula (1) and pharmaceutically acceptable salts and solvates (e.g. hydrates) thereof,
(1)
wherein R', R2, R3, R4 and R5 are as previously defined.
In the above definition, unless otherwise indicated, alkyl groups having three or more carbon atoms may be straight or branched chain. In addition, alkenyl or alkynyl groups having four or more carbon atoms, or alkoxy groups having three carbon atoms, may be straight or branched chain.
Compounds of the formula (1) may contain one or more asymmetric centers and thus can exist as enantiomers or diastereomers. It. is to be understood that the invention includes both mixtures and separate individual isomers of compounds of the formula (1). Furthermore certain compounds of the formula (1) which contain alkenyl groups may exist as cis- or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers.
Compounds of the formula (1) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers thereof.
Also included in the invention are radiolabelled derivatives of compounds of
formula (1) which are suitable for biological studies.
Compounds of the formula (1) wherein one or more basic nitrogen atoms are present may form pharmaceutically acceptable salts with acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, acetic, citric, fumaric, lactic, maleic, succinic and tartaric acids.
Compounds of the formula (1) may form pharmaceutically acceptable salts with metal ions, such as alkali metals for example sodium and potassium, or with an ammonium ion.
A preferred group of compounds of the formula (1) is that wherein
R' is H; methyl; or ethyl;
R2 is H; methyl; or a halogen atom;
R3 is C -C4 alkyl;
R4 is ethyl; /.-propyl; or allyl; R5 is SO2NR6R7; or NHSO2R8;
R6 and R7 taken together with the nitrogen atom to which they are attached form a piperidino, piperazinyl or homopiperazinyl group wherein said group is substituted with R9;
R8 is methyl; R9 is C,-C4 alkyl optionally substituted with one or more halide atoms, OH, CO2R10, or with a tetrazole group which is optionally substituted with C,-C3 alkyl;
R10 is H.
A particularly preferred group of compounds of the formula (1) is that wherein R' is methyl;
R2 is H;
R3 is ethyl; π-propyl; 3-fluoropiOpyl; or cyclopropyl methyl;
R4 is ethyl; or /.-propyl;
R5 is SO2 R6R7; or NHSO2R8;
R6 and R7 taken together with the nitrogen atom to which they are attached form a piperidino or piperazinyl group wherein said group is substituted with R9; R8 is methyl;
R9 is C,-C4 alkyl optionally substituted with one or more fluoro or chloro atoms, CO2R10, or with a tetrazole group; R10 is H.
Especially preferred individual compounds of the invention include: 5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-/7-propyl-l,6-di hydro-7H-pyrrolo[4,3-_/Jpyrimidin-7-one; 5-(5-(4-methylpiperazinylsulfonyl)-2-«-propoxyphenyl)-l -methyl-3-τ.-propyl-l ,6- dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one;
5-(2-ethoxy-5-(4-/.-propylpiperazinylsulfonyl)phenyl)-l -methyl-3-/7-propyl- 1 ,6-di hydro-7H-pyrrolo[4,3-<f]pyrimidin-7-one;
5-(2-ethoxy-5-(4-isopropylpiperazinylsulfonyl)phenyl)-l-methyl-3-/7-propyl-l ,6-d ihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one;
5-(2-ethoxy-5-(4-(2-fluoroethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-r7-propyl- l,6-dihydro-7H-pyriOlo[4,3-_f|pyrimidin-7-one;
5-(5-(4-(2-fluoroethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-/7-pro pyl- 1 ,6-dihydro-7H-pyrrolo[4,3-_/|pyrimidin-7-one; 5-(2-ethoxy-5 -(4-(3 -fluoropropy l)piperaziny lsulfonyl)phenyl)- 1 -methyl-3 -/7-propy
1- 1 ,6-dihydro-7H-pyrrolo[4,3-_f|pyrimidin-7-one;
5-(2-ethoxy-5-(4-(3-fluoiOpropyl)piperazinylsulfonyl)phenyl)-3-ethyl-l-ιτιethyl-l , 6-dihydro-7H-pyπOlo[4,3-c |pyrimiclin-7-one;
5-(2-ethoxy-5-(4-(3-fluoiOptOpyl)piperazinylsLilfonyl)phenyl)-3-(3-fluoiOpiOpyl )- 1 -me thyl- 1 ,6-dihydro-7H-pyrrolo[4,3-_/]pyi'imidm-7-one;
3-cyclopropylmethyl-5-(2-ethoxy-5-(4-(3-[luoiOpiOpyl)piperazinylsulfonyl)phenyl)- 1 -methyl- 1 ,6-dihydro-7H-pyπOlo[4,3-_ ]pyrimidin-7-one;
5-(5-(4-(3-fluoropropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-/7-pr opyl-l,6-dihydro-7H-pyrrolo[4,3-_f|pyrimidin-7-one;
5-(2-ethoxy-5-(4-(2-hydroxyethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-«-prop yl-l,6-dihydro-7H-pyrrolo[4,3-(i]pyrimidin-7-one;
5-(5-(4-(2-hydroxyethyl)piperazinylsulfonyl)-2-/7-propoxyphenyl)-l-methyl-3-/7-p ropyl- 1 ,6-dihydro-7H-pyrrolo[4,3-<^pyrimidin-7-one; 5-(5-(2-ethoxy-4-(3-hydroxypropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-r/-pro pyl- 1 ,6-dihydro-7H-pyrrolo[4,3-^pyrimidin-7-one;
5-(5-(4-(3-hydroxypropyl)piperazinylsulfonyl)-2-/7-propoxyphenyl)-l-methyl-3-77- propyl- 1 ,6-dihydro-7H-pyrrolo [4,3-<f]pyrimidin-7-one;
5-(2-ethoxy-5-(4-(hydroxycarbonylmethyl)piperidinylsulfonyl)phenyl)-l-methyl- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3--t]pyrimidin-7-one;
5-(5-(4-(hydroxycarbonylmethyl)piperidinylsulfonyl)-2-/7-propoxyphenyl)-l-meth yl-3-/7-propyl-l,6-dihydro-7H-pyrrolo[4,3-^pyrimidin-7-one;
5-(2-ethoxy-5-(4-(2-hydroxycarbonylethyl)piperidinylsulfonyl)phenyI)-l-methyI- 3-/7-propyl-l ,6-dihydro-7H-pyrrolo[4,3-_i]pyrimidin-7-one; 5-(5-(4-(2-hydroxycarbonylethyl)piperidinylsulfony l)-2-π-propoxyphenyl)- 1 -meth yl-3-«-propyl-l,6-dihydro-7H-pyrrolo[4,3-(JJpyrimidin-7-one;
5-(2-ethoxy-5-(4-( lH-tetrazol-5-ylmethyl)piperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl-l,6-dihydro-7H-pyrrolo[4,3-(JJpyrimidin-7-one; l-methyl-5-(2-77-propoxy-5-(4-(2-(lH-tetrazol-5-yl)ethyl)piperazinylsulfonyl)phe nyl)-3-/7-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-<JJpyrimidin-7-one;
5-(2-ethoxy-5-(4-(lH-tetrazol-5-ylmethyl)piperidinylsulfonyl)phenyl)-l -methyl-3 -77-piOpyl-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one; l-methyl-5-(2-«-propoxy-5-(4-(lH-tetrazol-5-ylmethyl)piperidinylsulfonyl)phen yl)-3~?7-propyl-l,6-dihydro-7H-pyrrolo[4,3-tt]pyrimidin-7-one; and physiologically acceptable salts and solvates (e. g. hydrates) thereof.
In another aspect, this invention provides processes for the preparation of compounds of the formula (1) or pharmaceutically acceptable salts thereof. Compounds of the formula (1) may be prepared from compounds of the formula (2),
(3) or (4):
(2): X = S02Y (3): X = NB, (4): X = CN~
wherein R1, R2, R3 and R4 are as previously defined, and X represents sulfonyl halide, cyano or amino group, and Y represents a halogen atom, preferably a chloro atom. The coupling reaction of compounds of the formula (2) with a compound of the formula (5) (wherein R6 and R7 are as previously defined) is generally carried out at 0 °C to room temperature for 1-24 hours in a suitable solvent such as a C -C3 alkanol,' dichloromethane, DMF, or water using an excess amount of (5) or in the presence of an organic tertiary amine, preferably triethylamine to scavenge the acid by-product. For compounds of the formula (1) wherein R9 is C,-C6 alkyl substituted with C=NRI3(NR14R15), a cyano group in the precursor compound may be transformed into the amidine functionality. The reaction can be affected by treating a cyano compound with saturated HCl gas in an anhydrous alcohol such as methanol and ethanol, at -20 ° to 0 °C, and the subsequent reaction of the resulting alkyl imidate intermediate with an appropriate amine at 0 °C to room temperature.
The reaction of amine compounds of the formula (3) with a compound of the formula (6), (7) or (8):
(6) (O (8)
(wherein R8 is as previously defined, and Y represents a halogen atom, preferably a chloro atom) is conveniently carried out at 0 °C to room temperature for 1-24 hours in an inert anhydrous solvent such as dichloromethane or THF using an excess amount of (6), (7) or (8), in the presence of an organic tertiary amine, preferably triethylamine to scavenge the acid by-product. The sulfonyl halide of the formula (6), the carboxylic acid anhydride of the formula (7) and the acyl halide of the formula (8) are either commercially available or readily obtainable by conventional synthetic procedures.
The cyano compounds of the formula (4) can be effectively converted to the corresponding tetrazole derivatives by reacting with NaN3 in the presence of 77-Bu3SnCl as a Lewis acid at refluxing temperature in an anhydrous hydrocarbon solvent such as toluene.
Compounds of the formula (2), (3) and (4) may be prepared from compounds of the formula (9), (10) and (11), respectively:
(wherein R i 1 , τ R>2 , R D3 a n„ndA R D are as previously defined, and X represents hydrogen, nitro or bromide group) by adopting precedent procedures.
Compounds of the formula (2) may be prepared from compounds of the formula (9) by using known methods for the introduction of a sulfonyl halide group into an aromatic ring, for example, when halide represents a chloro atom, by the action of chlorosulfonic acid at 0 °C to room temperature for 3-24 hours without any solvent.
The amines of the formula (3) can be readily obtained by reduction of the corresponding nitro compounds of the formula (10) using well-known methods such as catalytic hydrogenation in an alcoholic solvent, or tin(II) chloride reduction, and so
on.
The cyano compounds of the formula (4) may be readily prepared from the bromide compounds of the formula (11) by displacement of the bromide with CuCN at 150-200 °C in a high boiling solvent such as l-methyl-2-pyrrolidinone.
Compounds of the formula (9), (10) and (11) may be prepared from compounds of the formula (12), (13) and (14), respectively:
(wherein R1, R2, R3 and R4 are as previously defined, and X represents hydrogen, nitro or bromide group) by the application of known cyclization methods for pyrimidinone ring formation.
A cyclization reaction is generally carried out by heating at an elevated temperature, for example 50-150 °C, in the presence of an acid or a base in a suitable solvent such as an aqueous C,-C4 alkanol, water, a halogenated hydrocarbon, or acetonitrile. Thus, for example, the cyclization may be affected by treatment of a compound of the formulae (12)-(14) with an inorganic or organic base such as sodium hydroxide, potassium carbonate or potassium tert-butoxide, in an alcoholic aqueous medium, preferably potassium tert-butoxide in tert-butanol at 60 °C to reflux temperature.
For compounds of the formula (9) (wherein R1, R3 and R4 are as previously defined, and R2 is halide), the introduction of a halide atom to compounds of the formula (12) is carried out prior to subsequent cyclization. Halogenations may be affected by applying appropriate conditions for each halide, for example, N-chlorosuccinimide (NCS) in a halogenated solvent such as CH2C12 at -10 °C to room temperature for chlorination, bromine in acetic acid in the presence of sodium
acetate at room temperature for bromination, and iodine along with mercuric oxide (HgO) in a hydrocarbon solvent such as benzene at 0 °C to room temperature for iodination.
Compounds of the formulae (12)-(14) may be prepared from compounds of the formula (15) and (16), (17) or (18), respectively:
(15) Y = OH or halide
wherein R1, R2, R3 and R4 are as previously defined, X represents hydrogen, nitro or bromide group and Y represents a hydroxyl group or a halogen atom, preferably a chloro atom.
The reaction is generally carried out by first converting a carboxylic acid of the formulae (16)-(18) (Y = OH) to the corresponding acyl chloride using excess amounts of well-known reagents in the literature, preferably thionyl chloride or oxalyl chloride, in the presence of an inert solvent such as dichloromethane or benzene, at room temperature to reflux temperature. The coupling reaction with a compound of the formula (15) is generally affected by using an excess of the resulting acyl chloride (16)-(18) (Y = Cl) in the presence of an excess of an organic tertiary amine such as triethylamine to act as scavenger for the acid by-product (HY), optionally in the presence of a catalyst such as 4-dimethylaminopyridine (DMAP), in an inert anliydrous solvent such as dichloromethane at 0 °C to room temperature for 2-6 hours. The starting materials of the formulae (16)-(18) (Y = OH) are either commercially available or readily obtainable from the compound of the formula (16) by the methods known in the literature. For example, the nitro compounds of the formula (17) can be efficiently prepared from compounds of the formula (16) by using known methods
for the nitration of an aromatic ring, and the reaction is generally carried out using sodium nitrite or fuming nitric acid under a strongly acidic medium such as concentrated sulfuric acid or trifluoroacetic acid, preferably trifluoroacetic acid, at -10 °C to room temperature for 1-24 hours.
Compounds of the formula (15) may be prepared from compounds of the formula (20) in two steps:
(19) (20)
(wherein R1, R2 and R3 are as previously defined) by converting compounds of the formula (20) into the corresponding amide compounds of the formula (19) and the subsequent cyclization of compounds of the formula (19) for pyrrole ring formation. Amide formation may be affected by using ammonia either in an alcoholic solvent or water, preferably water, at room temperature to 100 °C, in the presence or absence of sodium cyanide as a catalyst.
A cyclization reaction is effectively carried out by heating at an elevated temperature, for example 50-150 °C, in the presence of a base in a suitable solvent such as aqueous C,-C4 alkanol or acetonitrile. Thus, for example, the cyclization may be affected by treatment of a compound of the formula (20) with an alkoxide base such as sodium ethoxide or potassium tert-butoxide, in an alcoholic medium, preferably sodium ethoxide in ethanol at 60 °C. Compounds of the formula (20) may be prepared from compounds of the formula
(21) and (22):
(21) . (22)
wherein R', R2 and R3 are as previously defined.
A condensation reaction between compounds of the fonnula (21) and (22) is generally performed in a mixture of an alcohol and water, preferably methanol alone, in the presence of a weak base such as sodium acetate, at room temperature for 1-3 days. Compounds of the formula (21) are either commercially available or readily obtainable from glycine using well-documented synthetic methods.
Compounds of the formula (22) may be prepared from compounds of the formula
(23) and (24):
O R^CN R2Λ0R
(23) (24)
wherein R2 and R3 are as previously defined, and R is C,-C3 alkyl.
Acylation reaction of compounds of the formula (23) is efficiently carried out by trapping the anionic species of compounds of the formula (23) with compounds of the formula (24) at -78 °C to room temperature. Generation of the anionic intermediate from compounds of the formula (23) may be affected by the action of a strong amide base such as sodium amide, alkali metal hexamethyldisilazide (Li, Na, or KHMDS) or lithium diisopropylamide (LDA), preferably LDA, in an anhydrous etheral solvent such as tetrahydrofuran, at low temperature, ranging from -78 ° to 0 °C. Compounds of the formula (1) may be also prepared by cyclizing compounds of the formula (25):
wherein R1, R2, R3 and R4 are as previously defined, and R16 is a group R5 as hereinbefore defined or a precursor to a group R5.
A cyclization reaction is generally carried out by heating at an elevated temperature, for example 50-150 °C, in the presence of an acid or a base in a suitable solvent such as an aqueous C,-C4 alkanol, water, a halogenated hydrocarbon, or acetonitrile. Thus, for example, the cyclization may be affected by treatment of a compound of the formula (25) with an inorganic or organic base such as sodium hydroxide, potassium carbonate or potassium tert-butoxide, in an aqueous alcoholic medium. Examples of R'6 being a precursor to a group R5 are when R5 contains a carboxylic acid since an ester group of the formula (25) can be converted to the corresponding carboxylic acid under the basic cyclization condition.
Compounds of the formula (25) may be prepared from compounds of the formula (15) and (26):
(26) (15) Y = OH or halide
wherein R1, R2, R3, R4 and R16 are as previously defined, and Y represents a hydroxyl group or a halogen atom, preferably a chloro atom.
The reaction is generally carried out by first converting a carboxylic acid of the formula (26) (Y = OH) to the corresponding acyl chloride using excess amounts of well-known reagents in the literature, preferably thionyl chloride or oxalyl chloride, in the presence or absence of an inert solvent such as dichloromethane or benzene, at room temperature to reflux temperature. The coupling reaction with a compound of the formula (15) is generally affected by using an excess of the resulting acyl chloride
(26) (Y = Cl) in the presence of an excess of an organic tertiary amine such as triethylamine to act as scavenger for the acid by-product (HY), optionally in the presence of a catalyst such as 4-dimethylaminopyridine (DMAP), in an inert anliydrous solvent such as dichloromethane at 0 °C to room temperature for 2-6 hours. The starting materials of the formula (26) (Y = OH) are readily obtainable from compound of the formula (16) (X = H, Y = OH) by the methods known in the literature.
Amines of the formula (5), when not commercially available, can be prepared by conventional synthetic procedures, in accordance with literature precedents, from readily accessible starting materials using standard reagents and reaction conditions.
Certain compounds of the formula (5), wherein R6 and R7 taken together with the nitrogen atom to which they are attached form a piperazinyl or homopiperazin l group substituted with R9 (R9 is as previously defined), can be synthesized readily from the compounds of the formula (27):
HN N-(CH2)nZ P-N N-(CH2)nZ P-N NH
(5) (27) (28) =°(M Z = CF3, halide or OH P = Protecting Group
wherein Z is a group CF3, hydroxyl, or a halogen, preferably fluoro atom and P represents an appropriate protecting group, for example, benzyl, benzyloxycarbonyl (Cbz) or tert-butoxycarbonyl (Boc).
Removal of benzyl or benzyloxycarbonyl (Cbz) group in the compounds of the formula (27) can be performed under a hydrogenation condition using a catalytic amount of palladium on carbon in an alcoholic solvent such as methanol or ethanol, at room temperature to afford the corresponding compound of the formula (5). Cleavage of tert-butoxycarbonyl (Boc) group in the compounds of the formula (27) can be affected under the acidic conditions using aqueous HCl or trifluoroacetic acid in an aprotic solvent such as tetrahydrofuran or dichloromethane at room temperature
to afford the corresponding salt of the formula (5). Starting materials of the formula (27) can be prepared from 1-benzylpiperazine or
1-tert-butoxycarbonylhomepiperazine of the formula (28) by direct N-alkylation with an appropriate alkyl halide containing a CF3, hydroxyl or halogen group.
Another compounds of the formula (5), wherein R6 and R7 taken together with the nitrogen atom to which they are attached form a piperazinyl or piperidino group substituted with R9 (R9 is as previously defined and is substituted with a lH-(tetrazol-5-yl) group), can be synthesized readily from the compounds of the formula (29):
(5) (29)
X = CH, N P = Protecting Group n = 0-4
wherein X is a group methine or nitrogen atom and P represents an appropriate protecting group, for example, preferably tert-butoxycarbonyl (Boc).
Removal of tert-butoxycarbonyl (Boc) and triphenylmethyl (Trityl) groups in the compounds of the formula (29) can be affected simultaneously under the acidic conditions using aqueous HCl or trifluoroacetic acid in an aprotic solvent such as tetrahydrofuran at room temperatm-e, in the presence of excess lH-tetrazole as a carbocation scavenger, to afford the corresponding salt of the formula (5).
Compounds of the formula (29) can be prepared from the compounds of the formula (30):
(30) (31) (32)
X = CH, N P = Protecting Group n = 0-4
wherein X and P are as previously defined.
Conversion of the cyano group of the formula (30) is generally affected by using tributyltin chloride and sodium azide in a hydrocarbon solvent, preferably toluene, at refluxing temperature to afford corresponding tetrazole compounds of the formula (29). Compounds of the formula (30) are readily prepared either from 1-tert-butoxycarbonylpiperazine of the formula (31) by direct N-alkylation with an appropriate alkyl halide containing a cyano group, or by conversion of the hydroxyl functionality of the formula (32) to a cyano group, using well-documented procedures. Starting materials of the formula (31) and (32) are either commercially available or readily accessible by conventional synthetic procedures in accordance with literature precedents.
The resulting compounds of this invention represented by the formula (l)-(5), (9)-(15) and (19)-(22), can be separated and purified by appropriate conventional methods such as column chromatography and recrystallization. Compounds of the invention may be administered by any suitable route, for example by oral, buccal, sub-lingual, rectal, vaginal, nasal, topical or parenteral (including intravenous, intramuscular, subcutaneous and intracoronary) administration.
For administration to man in the curative or prophylactic treatment of the disorders identified above, oral, buccal or sub-lingual dosages of a compound of the formula (1) will generally be in the range of from 0. 1-400 mg daily for an average adult patient (70 Kg). Thus for a typical adult patient, individual tablets or capsules contain from 0. 05-200 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day. Dosages for parenteral administration will typically be within the range of from 0. 01-100 mg per single dose as required. In practice the physician will determine the actual dosing regimen which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can be .
individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention.
For human use, a compound of the formula (1) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, the compound may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. Such liquid preparations may be prepared with pharmaceutically acceptable additives such as suspending agent (e. g. methylcellulose, a semi-synthetic glyceride such as witepsol or mixtures of glycerides such as a mixture of apricot kernel oil and PEG-6 esters or mixtures of PEG-8 and caprylic/capric glycerides). A compound may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously oiintracoronarily. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which may contain other substances, for example salts, or monosaccharides such as mannitol or glucose, to make the solution isotonic with blood.
Thus, the invention provides in a further aspect a pharmaceutical composition comprising a compound of the formula (1), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier therefor.
The invention also provides a compound of the formula (1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for use in the treatment of impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases
characterized by disorders of gut motility (e. g. irritable bowel syndrome).
The invention further provides the use of a compound of the formula (1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the treatment of impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous trans luminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome).
In a further aspect, the invention provides a method of treating or preventing impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome), in a mammal (including a human being), which comprises administering to said mammal a therapeutically effective amount of a compound of formula (1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity.
The invention also includes any novel intermediates of the formulae (2)-(4), (9)-(15) and (25) disclosed herein.
EXAMPLE
The present invention is further illustrated in the following Preparative Examples and Examples, which should not be taken to limit the scope of the invention.
Preparative Example 1
Preparation of l-tert-butoxycarbonyl-4-(4-fluoro-«-butyl)piperazine (a compound of the formula (27) wherein n = 4, m = 0, Z = F) A mixture of 1-tert-butoxycarbonylpiperazine (200 mg, 1. 07 mmol), l-bromo-4-fluoropiOpane (170 mg, 1. 13 mmol) and sodium bicarbonate (680 mg, 8.
06 mmol) in anhydrous N,N-dimethylforamide (DMF) (6 mL) was stirred overnight at
40-50 °C and was cooled to room temperature. The reaction mixture was filtered tlirough a Celite pad, and the filtrate was evaporated to dryness under vacuum to afford yellowish oil. The crude product was purified by MPLC on silica gel (1%
MeOH in CHC13) to afford the titled compound (182 mg, 66%) as a pale yellow oil.
IR (neat) 1700 (C=O), 1 176 (C-F) cm"1;
]H ΝMR (DMSO-_i6) δ 1. 46 (s, 9 H, C(CH3)3), 1. 58-1. 78 (m, 4 H,
ΝCH2CH2CH2CH2F), 2. 35-2. 42 (m, 6 H, 3 NCH2), 3. 43 (dd, J= 5. 4 Hz, 4. 8 Hz, 4 H, 2 BocNCH2), 4. 46 (dt, J= 47. 4 Hz, 6. 0 Hz, 2 H, CH2CH2F); MS (FAB) m/z 261
(MΗ÷).
Preparative Example 2
Preparation of l-(4-fluoro-τ.-butyl)piperazine trifluoroacetic acid (a compound of the formula (5) wherein n = 4, m = 0, Z = F)
A mixture of 1 -te7"t-butoxycarbonyl-4~(4-fluoiO-/.-butyl)piperazine (3. 50 g, 10. 74 mmol) in trifluoroacetic acid (20 mL) was stirred at room temperature for 1 h. The reaction mixture was evaporated to dryness under vacuum and the resulting residue was triturated from Et2O to afford the titled compound (2. 61 g, 87%) as a white solid. mp 108. 5-109. 5 °C;
IR (neat) 1665 (C=O), 1118 (C-F) cm4;
Η NMR (CDC1/TMS) δ 1. 58-1. 78 (m, 4 Η, NCΗ2CH2CH2CΗ2F), 3. 11 (t, J= 6. 9 Hz, NCH2CH2), 3. 30-3. 50 (m, 8 H, 2 NCH2 and 2 BocNCH2), 4. 46 (dt, J= 47. 7 Hz, 5. 4 Hz, 2 H, CH2CH2F); MS (FAB) m/z 161 (MΗ+).
Preparative Example 3
Preparation of l-tert-butoxycarbonyl-4-(2-fluoroethyl)homopiperazine (a compound of the formula (27) wherein n = 2, m = 1, Z = F) A mixture of 1-tert-butoxycarbonylhomopiperazine (800 mg, 3. 99 mmol),
1 -bromo-2-fluoroethane (0. 46 mL, 11. 98 mmol) and potassium carbonate (1. 10 g, 7.
98 mmol) in anhydrous tetrahydrofuran (20 mL) was stirred overnight at 70 °C and was cooled to room temperature. The reaction mixture was filtered through a Celite pad, and the filtrate was evaporated to dryness under vacuum to afford yellowish oil. The crude product was purified by MPLC on silica gel (3% MeOH in CHC13) to afford the titled compound (653 mg, 67%) as a pale yellow oil.
IR (neat) 1686 (CO), 1163 (C-F) cm"1;
Η NMR (CDCL/TMS) δ 1. 46 (s, 9 H, C(CH3)3), 1. 78-1. 90 (m, 2 H,
NCH2CH2CH2N), 2. 68-2. 78 (m, 4 H, 2 NCH2), 2. 84 (dt, J= 26. 7 Hz, 5. 1 Hz, 2 H, NCH2CH2F), 3. 40-3. 54 (m, 4 H, 2 BocNCH2), 4. 53 (dt, J= 47. 7 Hz, 5. 1 Hz, 2 H,
NCH2CH2F); MS (FAB) m/z 247 (MΗ+).
Preparative Example 4
Preparation of l-(2-fluoroethyl)homopiperazine dihydrochloride (a compound of the formula (5) wherein n = 2, m = 1 , Z = F)
A mixture of l-tert-butoxycarbonyl-4-(2-fluoroethyl)homopiperazine (550 mg, 2. 23 mmol) in 10% aqueous hydrochloric acid (2 mL) and tetrahydrofuran (4 mL) was stirred at room temperature for 2 h, and the reaction mixture was evaporated to dryness under vacuum. Resulting residue was triturated from Et2O/MeOH to afford the titled compound (475 mg, 97%) as a white solid, mp 185-186 °C; IR (neat) 1069 (C-F) cm"1;
'HNMR (DMSO- ) δ 2. 06-2. 14 (m, 2 H, NCH2CH2CH2N), 3. 16-3. 76 (m, 10 H, 5 NCH2), 4. 54 (dt, J= 47. 1 Hz, 5. 7 Hz, 2 H, NCH2CH2F), 9. 57 (br s, 1 Η, NΗ+), 9. 91
(br s, 1 H, NH+), 11. 70 (br s, 1 H, NIL); MS (FAB) m/z 147 (MH+).
Preparative Example 5
Preparation of l-tert-butoxycarbonyl-4-(3-fluoro-«-propyl)homopiperazine (a compound of the formula (27) wherein n = 3, m = 1 , Z = F)
The titled compound was prepared as described in Preparative Example 3 by using l-bromo-3-fluoropropane in place of l-bromo-2-fluoroethane. yield: 76%
IR (neat) 1700 (C=O), 1174 (C-F) cm"1; Η NMR (CDC1/TMS) δ 1. 46 (s, 9 H, C(CH3)3), 1. 78-1. 91 (m, 4 H, NCH2CH2CH2N and NCH2CH2CH2F), 2. 58-2. 68 (m, 4 H, 2 NCH2), 2. 61 (t, J= 7. 2 Hz, 2 H, NCH2CH2), 3. 40-3. 52 (m, 4 H, 2 BocNCH2), 4. 50 (dt, J= 47. 1 Hz, 6. 0 Hz, 2 H, CH2CH2F); MS (FAB) m/z 261 (MΗ+).
Preparative Example 6
Preparation of l-(3-fluoro-«-propyl)homopiperazine dihydrochloride (a compound of the formula (5) wherein n = 3, m = 1 , Z = F)
The titled compound was prepared as described in Preparative Example 4 by using l-tert~butoxycarbonyl-4-(3-fluoro-/.-propyl)homopiperazine in place of l-tert-butoxycarbonyl-4-(2-fluoroethyl)homopiperazine. yield: 88% mp 194-195 °C (Et2O/MeOH);
IR (neat) 1053 (C-F) cm"';
Η NMR (DMSO- ) δ 2. 06-2. 14 (m, 4 H, NCH2CH2CH2N and NCH2CH2CH2F), 3. 16-3. 76 (m, 10 H, 5 NCH2), 4. 54 (dt, J= 47. 1 Hz, 5. 7 Hz, 2 H, NCH2CH2F), 9. 58
(br s, 1 Η, NΗ+), 9. 91 (br s, 1 H, NH+), 11. 70 (br s, 1 H, NH+); MS (FAB) m/z 161
(MH+).
Preparative Example 7
Preparation of N-(2-cyano-2-«-propylvinyl)-N-methylglycine ethyl ester (a compound of the formula (20) wherein R2 = H, R3 = /.-propyl)
A suspension of 2-cyanopentanal (33. 12 g, 0. 30 mol), N-methylglycine ethyl ester hydrochloride (62. 39 g, 0. 45 mol) and sodium acetate (36. 67 g, 0. 45 mol) in MeOH (600 mL) was stirred at room temperature for 21 h, and the mixture was evaporated to dryness under reduced pressure. Resulting residue was diluted with water (200 mL) and was extracted with ethyl acetate (200 mL x 3). Combined organic layer was dried (Ν-^SO^, filtered and the filtrate was evaporated to dryness under reduced pressure to give yellow oil. The crude product was purified by MPLC on silica gel (1% MeOH in CHC13) to afford the titled compound (47. 02 g, 80%) as a pale yellow oil.
IR (neat) 2180 (CΝ), 1745 (C=O) cm"1;
'H ΝMR (CDCl/TMS) δ O. 90 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 30 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 45-1. 57 (m, 2 Η, CΗ2CH2CΗ3), 2. 03 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 12 (s, 3 H, ΝCH3), 3. 97 (s, 2 H, NCH2CO), 4. 24 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 12 (s, 1 H, CH); MS (FAB) m/z 211 (MH+).
Preparative Example 8
Preparation of N-(2-cyano-2-ethylvinyI)-N-rnethylglycine methyl ester (a compound of the formula (20) wherein R2 = H, R3 = ethyl)
The titled compound was prepared as described in Preparative Example 7 by using 2-cyanobutyraldehyde and N-methylglycine methyl ester hydrochloride in place of 2-cyanopentanal and N-methylglycine ethyl ester hydrochloride. yield: 62% IR (neat) 2184 (CΝ), 1751 (C=0) cm'1;
Η ΝMR (CDCl/TMS) δ 1.10 (1, J= 7. 5 Hz, 3 H, CH2CH3), 2.10 (q, J= 7. 5 Hz, 2 H,
CH2CH3), 3.12 (s, 3 H, ΝCH3), 3.78 (s, 3 H, OCH3), 3.99 (s, 2 H, NCH2CO), 6.12 (s, 1
H, CH); MS (FAB) m/z 183 (MH+).
Preparative Example 9
Preparation of N-(2-cyano-2-(3-fluoropropyl)vinyl)-N-metl ylglycine methyl ester (a compound of the formula (20) wherein R2 = H, R3 = 3-fluoropropyl)
The titled compound was prepared as described in Preparative Example 7 by using 2-cyano-5-fluoropentanal and N-methylglycine methyl ester hydrochloride in place of 2-cyanopentanal and N-methylglycine ethyl ester hydrochloride. yield: 73%
IR (neat) 2180 (CΝ), 1741 (0=0) cm"1;
Η ΝMR (CDCl/TMS) δ 1.78-1.97 (m, 2 H, CH2CH2CH2F , 2.22 (t, J= 7.2 Hz, 2 H, CH2CH2CH2F), 3.13 (s, 3 H, ΝCH3), 3.79 (s, 3 H, OCH3), 4.01 (s, 2 H, NCH,CO), 4.48 (dt, J = 47.1 Hz, 5.7 Hz, 2 H, CH2CH2CH2F), 6.28 (s, 1 IT, CH); MS (FAB) m/z 215 (MH+).
Preparative Example 10 Preparation of N-(2-cyano-2-(cyclopropylmethyl)vinyl)-N-methylglycine methyl ester
(a compound of the formula (20) wherein R2 = H, R3 = cyclopropylmethyl)
The titled compound was prepared as described in Preparative Example 7 by using 3-cyclopropyl-2-cyanopropionaIdehyde and N-methylglycine methyl ester hydrochloride in place of 2-cyanopentanal and N-methylglycine ethyl ester hydrochloride. yield: 70%
IR (neat) 2185 (CΝ), 1759 (C=O) cm"';
'H ΝMR (CDCl TMS) δ 0.13-0.18 (m, 2 H, c-C3H5), 0.46-0.53 (m, 2 H, c-C,l hJ,
0.79-0.93 (m, 1 H, c-C3Hs), 1.99 (d, J = 6.9 Hz, 2 H, CHCH2), 3.13 (s, 3 H, ΝCH3), 3.78 (s, 3 H, OCHj), 4.01 (s, 2 H, NCH2CO), 6.27 (s, 1 H, CH); MS (FAB) m/z 209
(MI-T ).
Preparative Example 11
Preparation of N-(2-cyano-2-7.-propyTvinyl)-N-methylgTycine amide (a compound of
the formula (19) wherein R2 = H, R3 = τ.-propyl)
A suspension of N-(2-cyano-2-/7-propylvinyl)-N-methylglycine ethyl ester (6. 00 g, 28. 53 mmol) in 29% aqueous ammonia solution (50 mL) was stirred overnight at room temperature. Resulting precipitates were collected by filtration, which were washed with cold water and diethyl ether to afford the titled compound (3. 20 g, 62%) as a white solid. Ether layer was separated from the filtrate, and the aqueous layer was further extracted with 3% MeOH in CHC13 (50 mL). Combined organic layer was dried (Νa^SO^, filtered and the filtrate was evaporated to dryness under reduced pressure to give a pale yellow solid (1. 31 g, 25%). mp 106-106. 5 °C;
IR (neat) 3375, 3188 (ΝH2), 2179 (CN), 1660, 1636 (C=O) cm"1; Η NMR (CDCl/TMS) δ 0. 91 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 47-1. 55 (m, 2 Η, CΗ2CH2CΗ3), 2. 05 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 17 (s, 3 H, NCH3), 3. 92 (s, 2 H, NCH2CO), 5. 67 (br s, 1 H, CONH), 5. 91 (br s, 1 H, CONH), 6. 27 (s, 1 H, CH); MS (FAB) m/z 182 (MH+).
Preparative Example 12
Preparation of N-(2-cyano-2-ethylvinyl)-N-methylglycine amide (a compound of the formula (19) wherein R2 = I , R3 = ethyl) The titled compound was prepared as described in Preparative Example 1 1 by using N-(2-cyano-2-ethylvinyI)-N-methyIglycine methyl ester in place of
N-(2-cyano-2-/7-propylvinyl)-N-methylglycine ethyl ester. yield: 81 % mp 10 I-102°C (MeOH/CH2Cl2/ether); IR (neat) 3429, 3300 (ΝH), 2173 (CΝ), 1694, 1669 (C=O) cm'1; lH ΝMR (CDCl TMS) δ 1.1 1 (I, J= 7.5 Hz, 3 H, CH2CH3), 2.1 1 (q, J= 7.5 Ηz, 2 Η,
CH2CΗ3), 3.16 (s, 3 H, ΝCH3), 3.92 (s, 2 H, NCILCO), 5.90 (br s, 1 H, CONΗ), 5.99
(br s, 1 H, CONH), 6.29 (s, 1 H, CH); MS (FAB) m/z 168 (MH+).
Preparative Example 13
Preparation of N-(2-cyano-2-(3-lluoropropyl)vinyl)-N-methylglycine amide (a compound of the formula (19) wherein R2 = H, R3 = 3 -fluoro propyl)
The titled compound was prepared as described in Preparative Example 1 1 by using N-(2-cyano-2-(3-fluoropropyl)vinyl)-N-methylglycine methyl ester in place of N-(2-cyano-2-«-propylvinyl)-N-methylglycine ethyl ester, yield: 70% mp 83.5-85°C (CH2CI2/EtOAc/hexanes); IR (neat) 3346, 3173 (ΝH), 2183 (CΝ), 1653, 1633 (C=O) cm'1; 'H ΝMR (CDC13/TMS) δ 1.89-1.99 (m, 2 H, CH2CH2CH2F), 2.23 (t, J= 7.8 Hz, 2 H, CH2CH2CH2F), 3.17 (s, 3 H, ΝCH3), 3.94 (s, 2 H, NCH2CO), 4.49 (dt, J = 47.4 Hz, 5.7 Hz, 2 H, CH2CH2CH2F), 5.94 (br s, 2 H, CONH2), 6.35 (s, 1 H, CH); MS (.FAB) m/z 180 (MH+ - H2O).
Preparative Example 14
Preparation of N-(2-cyano-2-(cycIopropylmethyI)vinyI)-N-methylglycine amide (a compound of the formula (19) wherein R2 = Ii, R3 = cyclopropylmethyl)
The titled compound was prepared as described in Preparative Example 1 1 by using N-(2-cyano-2-(cyclopropylmethyI)vinyl)-N-methyIglycine methyl ester in place of N-(2-cyano-2-w-propylvinyl)-N-methylglycine ethyl ester. yield: 85% mp 100.5-102°C (CH,Cl2/ether);
IR (neat) 3352, 3173 (ΝH), 2179 (CΝ), 1656, 1639 (C=0) cm 1;
Η ΝMR (CDCl TMS) δ 0.13-0.19 (m. 2 H, c~C,Hs), 0.48-0.56 (m. 2 Ii, c-C3li5), 0.79-0.93 (m, I Ii, c-C3H5), 2.00 (d, J = 6.9 Hz, 2 H, CHCH), 3.18 (s, 3 Ii, NCR,),
3.93 (s, 2 Ii, NCIi2CO), 5.81 (br s, 1 Ii, CONH), 5.98 (br s, 1 Ii, CONH), 6.32 (s, I Ii,
CH); MS (FAB) m/z 194 (MH ).
Preparative Example 15
Preparation of 4-amino-l-methyl-3-/7-propylpyrrole-5-carboxamide (a compound of the formula (15) wherein R1 = CH3, R2 = H, R3 = CH2CH2CH3)
A solution of N-(2-cyano-2-n-propylvinyl)-N-methylglycine amide (8. 26 g, 45.
57 mmol) in freshly prepared ΝaOEt in EtOH (0. 5 M, 190 mL, 95. 71 mmol) was heated at 60 °C for 1. 5 h, cooled to room temperature and then the mixture was quenched with acetic acid (5. 4 mL). Resulting mixture was diluted with water (50 mL) and was extracted with CH2C12 (100 mL x 3). Combined organic layer was dried (Νa2SO4), filtered and the filtrate was evaporated to dryness under reduced pressure. The crude product was dissolved in a minimum amount of CH2C12, and then solidified by adding diethyl ether and hexanes to afford the titled compound (7.
64 g, 92%) as a pale violet solid. mp 123-124°C;
IR (neat) 3353, 3181 (NH2), 1647 (CO) cm'1;
1 H NMR (CDC13/TMS) δ 0. 96 (t, J = 7. 5 Hz, 3 H, CH2CH2CH3), 1. 49-1. 61 (m, 2 Η, CΗ2CH2CΗ3), 2. 31 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 17 (br s, 2 H, NH2), 3. 83 (s,
3 H, NCH3), 6. 34 (br s, 2 H, CONH2), 6. 37 (s, 1 H, H-2); MS (FAB) m/z 182 (MI-T).
Preparative Example 16
Preparation of 4-amino-3-ethyl-l -methylpyrroIe-5-carboxamide (a compound of the formula (15) wherein R1 = CH3, R2 = Ii, R3 = CH2CH3)
The titled compound was prepared as described in Preparative Example 15 by using N-(2-cyano-2-ethylvinyl)-N-methylglyclne amide in place of
N-(2-cyano-2-?7-propylvinyl)-N-methylglycine amide. yield: 79% mp 1 13.5-1 15°C (MeOH/ EtOAc/hexanes);
IR (neat) 3373, 3180 (ΝH), 1653, 161 1 (C=0) cm'1;
Η ΝMR (CDC13/TMS) δ 1.18 (t, J= 7.5 Hz, 3 H, CH2CH3), 2.36 (q, J= 7.5 Hz, 2 H,
CH2CH3), 3.18 (br s, 2 Ii, ΝH2), 3.83 (s, 3 H, NCH3), 6.35 (br s, 2 H, CONTi,)., 6.38 (s,
1 H, CH); MS (FAB) m/z 168 (MH+).
Preparative Example 17
Preparation of 4-amino-3-(3-fluoropropyl)-l -methylpyrrole-5-carboxamide (a compound of the formula (15) wherein R1 = CH„ R2 = Ii, R3 = CH2CH2CH2F) The titled compound was prepared as described in Preparative Example 15 by using
N-(2-cyano-2-(3-fluoropropyl)vinyl)-N-methylglycine amide in place of
N-(2-cyano-2-.7-propy_vinyl)-N-methylglycine amide. yield: 66% mp 124-125.5°C (CH2Cl2/EtO Ac/ether); IR (neat) 3347, 3175 (ΝH), 1642. 1601 (C=0) cm'1;
Mi ΝMR (CDCl TMS) δ 1.91-2.00 (m, 2 H, CH2CH2CH2F), 2.50 (t, J= 7.5 Hz, 2 Ii,
CH2CH2CH2F), 3.16 (br s, 2 H, ΝH2), 3.84 (s, 3 H, NCH3), 4.47 (dt, J= 47.1 Hz, 5.7
Hz, 2 Ii, CH,CH,CH,F), 6.34 (br s, 2 H, CONH2), 6.40 (s, 1 H, CH); MS (FAB) m/z
200 (MIi+).
Preparative Example 18
Preparation of 4-amino-3-cyclopropylmethyl- l-methylpyrrole-5-carboxamide (a compound of the formula (15) wherein R1 = CH3, R2 - H, R3 = cyclopropylmethyl)
The titled compound was prepared as described in Preparative Example 15 by using N-(2-cyano-2-(cyclopropylmethyl)vinyl)-N-methylglycine amide in place of
N-(2-cyano-2-77-propylvinyl)-N-methylglycinc amide. yield: 73% mp 135-137°C (Cli2Cl2/ether/hexanes);
IR (neat) 3348, 3150 (ΝH), 1655 (C=0) cm'1; Η ΝMR (CDCl/TMS) δ 0.1 1-0.16 (m, 2 H, c-C,H5), 0.48-0.54 (m, 2 H, c-C,H5),
0.83-0.97 (m, 1 Ii, c-C H5), 2.30 (cl, J= 6.3 Hz, 2 Ii, CHCH2), 3.20 (br s, 2 Ii, Νli2),
3.84 (s, 3 H, NCH3), 6.34 (br s, 2 H, CONH,), 6.47 (s, 1 H, CH); MS (FAB) m/z 193
(M+).
Preparative Example 19
Preparation of 4-(2-ethoxybenzamido)-l-methyl-3-?7-propylpyrrole-5-carboxamide (a compound of the formula (12) wherein R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 =
CH2CH3) To a cooled mixture of 4-amino-l-methyl~3-/.-propyTpyriOle-5-carboxamide (3. 00 g, 16. 55 mmol), DMAP (101 mg, 0. 83 mmol) and triethylamine (4. 6 mL, 33. 00 mmol) in CH2C1, (50 mL) in an ice bath was added dropwise 2-ethoxybenzoyl chloride in CH2C12 (30 mL) over a period of 10 minutes, and the reaction mixture was stirred in an ice bath for 1 h. The reaction was quenched with 1 N HCl solution (100 mL), and was extracted with 3% MeOH in CHCL, (3 x 100 mL). The combined organic layer was washed with saturated aqueous NaHCO3 (50 mL), dried (MgSO4), and filtered. The filtrate was evaporated to dryness in vacuo to afford an off-white solid, and the crude product was purified by MPLC on silica gel (2% MeOH in CHC13) to afford the titled compound (5. 01 g, 92%) as a white solid. Analytically pure compound was obtained by crystallization from ethyl acetate/hexanes. mp 166-167 °C;
IR (neat) 3334, 3149 (NH), 1668, 1641 (C=O) cm'1;
Η NMR (CDC13/TMS) δ 0. 92 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 47-1. 59 (m, 2 Ii, CΗ2CH2CΗ3), 1. 52 (t, J = 6. 6 Hz, 3 H, OCH2CH3), 2. 34 (t, J = 7. 5 Ηz, 2 Η, CH2CΗ2CΗ3), 3. 85 (s, 3 H, NCH3), 4. 29 (q, J= 6. 6 Hz, 2 H, OCH2CH3), 6. 52 (s, 1 H, H-2), 7. 04 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 09-7. 15 (m, 1 H, H-5'), 7. 51 (ddd, J= 8. 4 Hz, 7. 2 Hz, 1. 8 Hz, 1 H, H-4'), 8. 29 (dd, J= 8. 1 Hz, 1. 8 Hz, 1 H, H-6'), 9. 37 (br s, 1 H, NH); MS (FAB) m/z 330 (MH+).
Preparative Example 20
Preparation of 1 -methyl-4-(2-/7-propoxybenzamido)-3-..-propylpyrrole-5-carboxamide (a compound of the formula (12) wherein R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 = CH,CH2CH3)
The titled compound was prepared as described in Preparative Example 19 by
using 2-77-propoxybenzoyl chloride in place of 2-ethoxybenzoyl chloride, yield: 91% mp 136-137 °C (CHCl3/Et2O/hexanes); IR (neat) 3338, 3159 (NH), 1646 (C=O) cm'1; Η NMR (CDC13/TMS) δ 0. 91 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 06 (t, J= 7. 5 Iiz, 3 Η, OCΗ2CΗ2CH3), 1. 47-1. 57 (m, 2 Η, CΗ,CH2CΗ3), 1. 85-1. 95 (m, 2 Ii, OCH2CH2CH3), 2. 33 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 85 (s, 3 H, NCH3), 4. 18 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 52 (s, 1 H, H-2), 7. 04 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 12 (td, J= 8. 1 Hz, 0. 9 Hz, 1 H, H-5'), 7. 48-7. 54 (m, 1 H, H-4'), 8. 29 (dd, J= 8. 1 Hz, 2. 1 Hz, 1 H, H-6'), 9. 36 (br s, 1 H, NH); MS (FAB) m/z 344 (MH+).
Preparative Example 21
Preparation of
4-(2-ethoxy-5-(4-(3-fluoiOpropyl)piperazinylsulfonyl)benzamido)-3-ethyl-l-methylpy rrole-5-carboxamide (a compound of the formula (25) wherein R1 = CH3, R2 = H, R3 = CH2CH,CH3, R4 = CH,CH3, R16 = 4-(3-fluoropropyl)piperazinylsulfonyl)
To a mixture of 4-amino~3-ethyI-l-methylpyrrole-5-carboxamide (125 mg, 0.74 mmol), 2~ethoxy-5-(4-(3-fluoiOpropyl)pipe_azinylsulfonyl)benzoic acid (279 mg, 0.74 mmol), HOBT (151 mg, 1.12 mmol), and DMAP (18 mg, 0. 15 mmol) in anliydrous pyridine (5 mL) at room temperature under nitrogen atmosphere was slowly added EDC (214 mg, 1.12 mmol) over a period of 5 minutes, and the reaction mixture was stirred for 2 h. Pyridine was removed under vacuum and the resulting residue was diluted with brine (100 L). Extraction with 5% MeOH in CHC13 (2 x 100 mL) was performed and the combined organic layer was dried (MgSO4), and filtered. The filtrate was evaporated to dryness in vacuo to afford a brown solid, and the crude product was purified by MPLC on silica gel (gradient elution: 2% MeOH in CHC13 followed by 3% MeOH in CHC13) to afford the titled compound (310 mg, 80%) as a yellowish solid. Analytically pure compound was obtained by crystallization from CH,CI,/MeOH/hexanes.
mp 182.5-183 °C;
IR (neat) 3353 (NH), 1648 (CO), 1 170 (SO,) cm'1;
Η NMR (CDCl TMS) δ 1.16 (t, J= 7. 5 Hz, 3 H, CH2CH3), 1 .58 (t, J= 7. 2 Ηz, 3 Η,
OCΗ2CH3), 1. 72-1. 90 (m, 2 H, CH2CH2F), 2. 39 (q, J= 7. 5 Hz, 2 H, CHCH3), 2.
47 (t, J= 7. 2 Hz, 2 Ii, NCHCFI,), 2.53 (dd, J= 4.8 Hz, 4.5 Hz, 4 Ii, 2 NCFI,), 3.05
(dd, J- 4.8 Hz, 4.5 Hz, 4 Ii, 2 SO,NCH2), 3. 85 (s, 3 H, NCH3), 4. 37 (q, J= 7.2 Hz, 2
H, OCH2CH3), 4.42 (dt, J= 47.4 Hz, 6.0 Hz, 2 H, CH,CH2F), 6. 54 (s, 1 Ii, H-2), 7. 16
(d, J= 8. 7 Hz, I H, H-3'), 7. 89 (dd, J= 8. 7 Hz, 2.7 Hz, 1 H, H-4'), 8. 64 (d, J- 2.7
Hz, I H, H-6'), 9. 19 (br s, 1 H, NH); MS (FAB) m/z 524 (MH+).
Preparative Example 22
Preparation of
4-(2-ethoxy-5-(4-(3-fluoiOpiOpyl)piperazinylsulfonyl)benzamido)-3-(3-fluoropiOpyl)- l-methylpyrroIe-5-carboxamide (a compound of the formula (25) wherein R' = CH3, R2 = H, R3 = CH2CIi2CH,F, R4 = CH2CH3, R16
4-(3-πuoiOpropyl)piperazinylsurfonyl)
The titled compound was prepared as described in Preparative Example 21 by using 4-amino-:3-(3-_luoiOpropyl)-l-methylpyrroIe-5-carboxamide in place of
4-amino-3-ethyI- 1 -methylpyrrole-5-carboxamide. yield: 86% mp 169-171 °C (CH,Cl,/hexanes);
IR (neat) 3352 (NH), 1647 (CO), 1 170 (SO,) cm'1;
Η NMR (CDCL/TMS) δ 1.57 (t, J= 7. 2 Hz, 3 H, OCH,CH3), 1. 72-1 . 98 (m, 4 H, 2
CH,CH2F), 2. 47 (t, J = 7. 5 Hz, 2 li, NCH2CH,), 2.46-2.60 (m, 6 Ii, CH2CH2CIi,F and 2 NCH2), 3.06 (br s, 4 H. 2 S02NCH2), 3. 86 (s, 3 li, NCH3), 4. 37 (q, J= 7.2 Hz,
2 H, OCH,CH3), 4.42 (dt, J= 47.4 Hz, 5.1 Hz, 4 H, 2 CH,CH2F), 6. 56 (s, 1 H, H-2), 7.
16 (d, J = 9.0 Hz, 1 Ii, H-3'), 7. 89 (dd, J= 9.0 Hz, 2.4 Hz, 1 Ii, FI-41), 8. 62 (cl, J= 2.4
Hz, 1 H, H-6'), 9. 20 (br s, 1 H, NH); MS (FAB) m/z 556 (MH+).
Preparative Example 23
Preparation of
3-cyclopiOpylmethyl-4-(2-ethoxy-5-(4-(3-fluoiOpiOpyl)piperazinyIsulfonyl)benzamid o)-l-methyIpyrrole-5-carboxamide (a compound of the formula (25) wherein R1 = CH,, R2 = H, R3 = cyclopropylmethyl, R4 = CH2CH3, R16 = 4-(3-fluoiOpropyl)piperazinylsulfonyl)
The titled compound was prepared as described in Preparative Example 21 by using 4-amino-3-cyclopropylmethyl- l-methylpyrrole-5-carboxamide in place of 4-amino-3-ethyl-l-metl ylpyrrole-5-carboxamide. yield: 91 % mp 198-199 °C (CH,Cl2/ether);
IR (neat) 3359, 3288 (NH), 1642 (CO), 1 170 (S02) cm"1;
'H NMR (CDCl/TMS) δ 0.09-0.14 (m, 2 H, c-C3H5), 0.45-0.51 (m, 2 Ii, c-C,H5),
0.83-0.97 (m, 1 H, c-C H5), 1.57 (t, J= 6.9 Hz, 3 H, OCH2CH3), 1. 73-1. 90 (m, 2 H, CHCF F), 2.29 (d, J= 6.9 Hz, 2 Ii, CHCH), 2. 47 (t, J= 7. 5 Hz, 2 H, NCH H,), 2.54 (dd, J = 4.8 Hz, 4.5 Hz, 4 Ii, 2 NCH,), 3.07 (dd, J = 4.8 Hz, 4.5 Hz, 4 H, 2 SO,NCH2), 3. 87 (s, 3 H, NCH3), 4. 37 (q, J = 6.9 Hz, 2 H, OCH,CH3), 4.44 (dt. J = 47.4 Hz, 6.0 Hz, 2 H, CH,CH,F), 6. 66 (s, I Ii, H-2), 7. 16 (d, J= 8.7 Hz, 1 Ii, H-3'), 7. 90 (dd, J= 8.7 Hz, 2.4 Hz, I H, H-4'), 8. 64 (cl, J= 2.4 Hz, 1 H, H-6*), 9. 18 (br s, 1 Ii, NH); MS (FAB) m/z 550 (Ml-f).
Preparative Example 24
Preparation of
5-(2-ethoxyphenyl)-l-methyl-3-?7-propyl-l,6-dihydiO-7H-pyrrolo[4,3-(fJpyrimidin-7-o ne (a compound of the formula (9) wherein R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3)
A suspension of
4-(2-ethoxybenzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide (5. 01 g, 15. 21 mmol) and NaOH (3. 04 g, 76. 05 mmol) in a mixture of water (50 mL) and MeOH
(100 mL) was heated at 80 °C under nitrogen atmosphere for 5 h. The reaction mixture was cooled to room temperature, and MeOH was removed under vacuum. The resulting aqueous layer was acidified to about pH 9-10 with 1 N aqueous HCl solution, and was extracted with 2% MeOH in CHC13 (2 x 300 mL). Combined organic layer was dried (MgSO4), filtered, and evaporated to dryness in vacuo to afford a yellow solid. The crude product was purified by MPLC on silica gel (gradient elution: 1% MeOH in CHC13 followed by 2% MeOH in CHC13) to afford the titled compound (3. 62 g, 77%) as a white solid. Analytically pure compound was obtained by crystallization from CHCl3/Et2O/hexanes. mp 128. 5-129 °C;
IR (neat) 3319 (NH), 1675 (CO) cm'1;
Η NMR (CDCl TMS) δ 1. 01 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 59 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 68-1. 81 (m, 2 Η, CΗ2CH2CΗ3), 2. 72 (t, J = 7. 5 Hz, 2 Ii, CH2CH2CH3), 4. 08 (s, 3 H, NCH3), 4. 27 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 86 (s, 1 H, H-2), 7. 02 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 09-7. 15 (ra, 1 H, H-5'), 7. 41 (ddd, J= 8.
4 Hz, 7. 2 Hz, 1. 8 Hz, 1 H, H-4'), 8. 49 (dd, J= 8. 1 Hz, 1. 8 Hz, 1 H, H-6'), 10. 91 (br s, 1 H, NH); MS (FAB) m/z 312 (MH+).
Preparative Example 25 Preparation of l-methyl-5-(2-77-propoxyphenyl)-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-
7-one (a compound of the formula (9) wherein R1 = CΗ3, R2 = H, R3 = CH,CH2CH3,
R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 12 by using l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of 4-(2-ethoxybenzamido)- 1 -methyl-3 -/7-propy lpyrrole-5 -carboxamide. yield: 94% mp 108-108. 5 °C (CHCl3/Et2O/hexanes);
IR (neat) 3326 (NH), 1684 (CO) cm'1;
Η NMR (CDC13/TMS) δ 1. 01 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 16 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 70-1. 82 (m, 2 Η, CΗ,_CH2CΗ3), 1. 94-2. 05 (m, 2 H, OCH,CH2CH3), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 08 (s, 3 H, NCH3), 4. 16 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 86 (s, 1 H, H-2), 7. 02 (d, J= 8. 1 Hz, 1 H, H-3'), 7. 12 (t, J= 7. 2 Hz, 1 H, H-5'), 7. 41 (ddd, J= 8. 1 Hz, 7. 2 Hz, 1. 8 Hz, 1 H, H-4'), 8. 50 (dd, J= 8. 1 Hz, I. 8 Hz, 1 H, H-6'), 10. 94 (br s, 1 H, NH); MS (FAB) m/z 326 (MH+).
Preparative Example 26 Preparation of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-/7-propyl-l,6-dihydro-7H-pyrrolo[4, 3-_ ]pyrimidin-7-one (a compound of the formula (2) wherein Y = Cl, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3)
To a stirred and cooled chlorosulfonic acid (6 mL) in an ice bath under nitrogen atmosphere was added portionwise
5-(2-ethoxyphenyl)-l-methyl-3-7 -propyl-l ,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-o ne (1. 51 g, 4. 85 mmol), and the reaction mixture was stirred in an ice bath for 1 h. Then, the mixture was warmed to room temperature gradually and stirring was continued for additional over 1 h at room temperature. Resulting mixture was transferred dropwise to the well-stirred mixture of CΗC13 (50 mL) and ice (50 g), and was extracted with 5% MeOH in CHC13 (2 x 100 mL). Combined extracts were dried (Na2SO4), filtered, and evaporated to dryness under reduced pressure to give the desired sulfonyl chloride as a yellow solid. The crude product was solidified by dissolving in CHC13 (20 mL), followed by diluting with diethyl ether (30 mL) and hexanes (100 mL) to afford the titled compound (1. 90 g, 96%) as a pale yellow solid. Analytically pure compound was obtained by crystallization from CHCl3/Et2O/hexanes. mp 164. 5-166 °C dec; IR (neat) 3341 (NH), 1693 (CO), 1174 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 1. 02 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 66 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 68-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 2. 75 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 4. 09 (s, 3 H, NCH3), 4. 42 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 92 (s, 1" H, H-2), 7. 20 (d, J= 9. 0 Hz, 1 H, H-3'), 8. 08 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 9. 13 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 61 (br s, 1 H, NH); MS (FAB) m/z 392 (MH+-H2O).
Preparative Example 27
Preparation of
5-(5-chlorosulfonyl-2-77-propoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,3-cdpyrimidin-7-one (a compound of the formula (2) wherein Y = Cl, R1 = CΗ3, R2
= H, R — CH CH2CH3, R = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 14 by using l-methyl-5-(2-77-propoxyphenyl)-3-77-propyl-l,6-dihydiO-7H-pyrrolo[4,3-c]pyrimidin- 7-one in place of 5-(2-ethoxyphenyl)-
1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3--/Jpyrimidin-7-one. yield: 94% mp 136 °C dec (CΗCl3/Et2O);
IR (neat) 3330 (NH), 1665 (CO) , 1174 (SO2) cm'1; Η NMR (CDC13/TMS) δ 1. 02 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 18 (t, J- 7. 2 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 68-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 12 (m, 2 H,
OCH,CH2CH3), 2. 76 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 4. 09 (s, 3 H, NCH3), 4. 30 (t,
J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 93 (s, 1 H, H-2), 7. 21 (d, J= 9. 0 Hz, 1 H, H-3'),
8. 07 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 9. 11 (d, J= 2. 4 Hz, 1 H, H-6'); MS (FAB) m/z 424 (MH+).
Preparative Example 28
Preparation of
4-(2-(2-fluoroethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide (a
compound of the formula (12) wherein R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2F)
The titled compound was prepared as described in Preparative Example 10 by using 2-(2-fluoroethoxy)benzoyl chloride in place of 2-ethoxybenzoyl chloride. yield: 67% mp 132-132. 5 °C (ethyl acetate/hexanes); IR (neat) 3344, 3164 (NH), 1664, 1640 (CO) cm'1;
Η NMR (CDC13/TMS) δ 0. 91 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 49-1. 62 (m, 2 Η, CΗ2CH2CΗ3), 2. 33 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 85 (s, 3 H, NCH3), 4. 38-4. 51 (m, 2 H, OCH2CH2F), 4. 72-4. 91 (m, 2 H, OCH2CH2F), 6. 52 (s, 1 Η, Η-2), 7. 03 (d, J= 8. 1 Hz, 1 H, H-3'), 7. 17 (td, J= 8. 1 Hz, 1. 2 Hz, 1 H, H-5'), 7. 50-7.56 (m, 1 H, H-4'), 8. 28 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 Ii, H-6'), 9. 11 (br s, 1 H, NH); MS (FAB)
Preparative Example 29
Preparation of
5-(2-(2-fluoroethoxy)phenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyriOlo[4,3-f/]pyri midin-7-one (a compound of the formula (9) wherein R1 = CΗ3, R2 = H, R3 =
CH2CH2CH3, R4 = CH2CH2F)
A suspension of
4-(2-(2-fluoroethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide (1. 60 g, 4. 60 mmol) and potassium tert-butoxide (1. 03 g, 9. 21 mmol) in tert-BuOH (25 mL) was heated at 60 °C under nitrogen atmosphere for 5 h. The reaction mixture was cooled to room temperature, diluted with water (25 mL) and tert-BuOH was removed under vacuum. The resulting aqueous layer was acidified to about pH 5-6 with 1 N aqueous HCl solution, and was extracted with 5% MeOH in CHC13 (2 x 100 mL). Combined organic layer was dried (MgSO4), filtered, and evaporated to dryness in vacuo to afford a yellow solid. The crude product was purified by MPLC on silica
gel (1%) MeOH in CHC13) to afford the titled compound (1. 24 g, 82%) as a pale yellow solid. Analytically pure compound was obtained by crystallization from ethyl acetate/hexanes. mp 116-117 °C; IR (neat) 3348 (NH), 1676 (CO) cm'1 ;
'H NMR (CDCyTMS) δ l. Ol (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 70-1. 78 (m, 2 Η, CΗ2CH2CΗ3), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 07 (s, 3 H, NCH3), 4. 36-4. 48 (m, 2 H, OCH2CH2F), 4. 77-4. 96 (m, 2 H, OCH2CH2F), 6. 86 (s, 1 Η, Η-2), 7. 02 (d, J= 8. 1 Hz, 1 H, H-3'), 7. 17 (td, J= 8. 1 Hz, 0. 9 Hz, 1 H, H-5'), 7. 39-7.46 (m, 1 H, H-4'), 8. 44 (dd, J= 8. 1 Hz, 1. 8 Hz, 1 H, H-6'), 10. 60 (br s, 1 H, NH); MS (FAB)
Preparative Example 30
Preparation of 5-(5-chlorosulfonyl-2-(2-fluoroethoxy)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H- pyrrolo[4,3-tt]pyrimidin-7-one (a compound of the formula (2) wherein Y = Cl, R' =
CΗ3, R2 = H, R3 = CH,CH2CH3, R4 = CH2CH2F)
The titled compound was prepared as described in Preparative Example 14 by using 5-(2-(2-fluoiOethoxy)phenyl)-l-methyl-3-77-propyl-l,6-dihydiO-7H-pyrrolo[4,3-(i]pyri midin-7-one in place of
5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydiO-7H-pyriOlo[4,3-6]pyrimidin-7-o ne. yield: 85% mp 156. 5-157. 5 °C (ethyl acetate/hexanes);
IR (neat) 3344 (NΗ), 1680 (CO), 1174 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 1. 02 (t, J= 7. 5 Ηz, 3 Η, CΗ,CΗ2CH3), 1. 70-1. 78 (m, 2 Η,
CΗ2CH2CΗ3), 2. 75 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 4. 09 (s, 3 H, NCH3), 4. 51-4.
63 (m, 2 H, OCH2CH2F), 4. 84-5. 02 (m, 2 H, OCH2CH2F), 6. 92 (s, 1 Η, Η-2), 7. 23
(d, J= 9. 0 Hz, 1 H, H-3'), 8. 10 (dd, J= 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 9. 09 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 46 (br s, 1 H, NH); MS (FAB) /z 428 (MIL).
Preparative Example 31 Preparation of N-(2-cyano-l-methyl-2-77-propylvinyl)-N-methylglycine ethyl ester (a compound of the formula (20) wherein R1 = R2 = CH3, R3 = 77-propyl)
The titled compound was prepared as described in Preparative Example 7 by using
3-cyano-2-hexanone in place of 2-cyanopropionaldehyde. yield: 55% IR (neat) 2181 (CΝ), 1743 (CO) cm'1 ;
Η ΝMR (CDC13/TMS) δ 0. 93 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 30 (t, J= 7. 2 Ηz,
3 Η, OCΗ2CH3), 1. 46-1. 58 (m, 2 Η, CΗ2CH2CΗ3), 1. 90 (s, 3 H, CH3), 2. 14 (t, J= 7.
5 Hz, 2 H, CH2CH2CH3), 3. 1 1 (s, 3 H, ΝCH3), 4. 05 (s, 2 H, NCH2CO), 4. 22 (q, J= 7.
2 Hz, 2 H, OCH2CH3) - Z isomer and 0. 94 (t, J- 7. 5 Hz, 3 H, CH2CH2CH3), 1. 29 (t, J= 7. 2 Hz, 3 H, OCH2CH3), 1. 52-1. 65 (m, 2 Η, CΗ2CH2CΗ3), 2. 11 (d, J= 7. 5 Hz,
2 H, CH2CH2CH3), 2. 19 (s, 3 H, CH3), 2. 90 (s, 3 H, NCH3), 3. 80 (s, 2 H, NCH2CO),
4. 21 (q, J= 7. 2 Hz, 2 H, OCH2CH3) - E isomer; MS (FAB) m/z 225 (MH+).
Preparative Example 32 Preparation of N-(2 -cyano- l-methyl-2-77-propylvinyl)-N-methylgly cine amide (a compound of the formula (19) wherein R1 = R2 = CH3, R3 = 77-propyl)
A suspension of N-(2-cyano-l -methyl -2 -77-propylvinyl)-N-methylglycine ethyl ester (2. 03 g, 9. 05 mmol in 29% aqueous ammonia solution (13 mL) and MeOH (7 mL) was stirred overnight at room temperature. The reaction mixture was concentrated z'77 vacuo, and the aqueous layer was extracted with CHC13 (40 mL x 3). Combined organic layer was dried (ΝajSO,,), filtered and the filtrate was evaporated to dryness under reduced pressure. Resulting residue was purified by MPLC on silica gel (gradient elution: 1: 1 ethyl acetate/hexanes containing 1% Et3Ν followed by 5% MeOH in CHC13) to afford the titled compound (1. 03 g, 56%) as a yellowish oil.
IR (neat) 3323, 3208 (NH), 2180 (CN), 1670 (CO) cm'1;
Η NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 48-1. 61 (m, 2 Η, CΗ2CH2CΗ3), 1. 84 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 1. 93 (s, 3 H, CH3), 3. 04 (s, 3 H, NCH3), 3. 79 (s, 2 H, NCH2CO), 5. 67 (br s, 1 H, NH), 6. 34 (br s, 1 H, NH) - Z isomer and 0. 95 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 45-1. 58 (m, 2 Η, CΗ2CH,CΗ3), 2. 15 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 20 (s, 3 H, CH3), 2. 86 (s, 3 H, NCH3), 3. 66 (s, 2 H, NCH2CO), 5. 76 (br s, 1 H, NH), 6. 19 (br s, 1 H, NH) - E isomer; MS
Preparative Example 33
Preparation of 4-amino-l,2-dimethyl-3-77-propylpyrrole-5-carboxamide (a compound of the formula (15) wherein R1 = R2 = CH3, R3 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 9 by using
N-(2-cyano-l-methyl-2-77-propylvinyl)-N-methylglycine amide in place of N-(2-cyano-2-77-propylvinyl)-N-methyl glycine amide. yield: 34% mp 135 °C dec (CHCl3/hexanes);
IR (neat) 3357, 3171 (ΝH2), 1639 (CO) cm'1;
'H NMR (CDC13/TMS) δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 39-1. 51 (m, 2 Ii, CΗ2CH2CΗ3), 2. 11 (s, 3 H, CH3), 2. 31 (t, J- 7. 5 Hz, 2 H, CH2CH2CH3), 3. 23 (br s,
2 H, NH2), 3. 78 (s, 3 H, NCH3), 6. 16 (br s, 2 H, CONH2); MS (FAB) m/z 196 (MH+).
Preparative Example 34
Preparation of 1 ,2-dimethyl-4-(2-ethoxybenzamido)-3-77-propylpyrrole-5-carboxamide (a compound of the formula (12) wherein R1 = R2 = CH3, R3 = CH2CH2CH3, R4 = CH2CH3)
The titled compound was prepared as described in Preparative Example 10 by using 4-amino-l,2-dimethyl-3-77-propylpyrrole-5-carboxamide in place of 4-amino-2-methyl-3-77-propylpyrrole-5-carboxamide.
yield: 73% mp 171. 5 °C dec (CHCl3/Et2O/hexanes);
IR (neat) 3348, 3148 (NH), 1649 (CO) cm'1;
Η NMR (CDC13/TMS) δ 0. 87 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 38-1. 49 (m, 2 Η,
CΗ2CH2CΗ3), 1. 51 (t, J= 6. 9 Hz, 3 H, OCH2CH3), 2. 17 (s, 3 Η, CΗ3), 2. 33 (t, J= 7.
5 Hz, 2 H, CH2CH2CH3), 3. 77 (s, 3 H, NCH3), 4. 29 (q, J= 6. 9 Hz, 2 H, OCH2CH3),
7. 04 (d, J= 8. 4 Ηz, 1 Η, Η-3'), 7. 09-7. 14 (m, 1 H, H-5'), 7. 47-7. 53 (m, 1 H, H-4'),
8. 29 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 9. 37 (br s, 1 H, NH); MS (FAB) m/z 344 (MH+).
Preparative Example 35
Preparation of l,2-dimethyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide (a compound of the formula (12) wherein R1 = R2 = CH3, R3 = CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 10 by using 4-amino-l ,2-dimethyl-3-77-propylpyrrole-5-carboxamide and
2- 7-propoxybenzoyl chloride in place of
4-amino-2-methyl-3-77-propylpyrrole-5-carboxamide and 2-ethoxybenzoyl chloride. yield: 69% mp 188-189 °C (CHCl3/Et2O);
IR (neat) 3344, 3155 (NH), 1643 (CO) cm'1;
Η NMR (CDCyTMS) δ 0. 85 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 05 (t, J= 7. 5 Ηz,
3 Η, OCΗ,CΗ2CH3), 1. 36-1. 49 (m, 2 Η, CΗ2CH2CΗ3), 1. 84-1. 95 (m, 2 Ii, OCH2CH2CH3), 2. 17 (s, 3 H, CH3), 2. 32 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 77 (s, 3 H, NCH3), 4. 17 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 04 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 11 (td, J= 7. 8 Hz, 1. 2 Hz, 1 H, H-5'), 7. 50 (ddd, J= 8. 4 Hz, 7. 8 Hz, 1. 8 Hz, 1 H, H-4'), 8. 29 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 9. 35 (br s, 1 H, NH); MS (FAB) m/z 358 (MH+).
Preparative Example 36
Preparation of
1 ,2-dimethyl-5-(2-ethoxyphenyl)-3-77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-<f]pyrimidin -7-one (a compound of the formula (9) wherein R1 = R2 = CΗ3, R3 = CH2CH2CH3, R4
= CH CH3)
The titled compound was prepared as described in Preparative Example 17 by using l,2-dimethyl-4-(2-ethoxybenzamido)-3-77-propylpyriOle-5-carboxamide in place of 4-(2-(2-fluoroethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 94% mp 130 °C dec (CHCyE^O/hexanes);
IR (neat) 3175 (NH), 1653 (CO) cm'1;
Η NMR (CDCl TMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 59 (t, J= 6. 9 Ηz,
3 Η, OCΗ,CH3), 1. 62-1. 73 (m, 2 Η, CΗ2CH2CΗ3), 2. 30 (s, 3 H, CH3), 2. 69 (t, J= 7. 5 Hz, 2 H, CH,CH,CH3), 4. 03 (s, 3 H, NCH3), 4. 27 (q, J= 6. 9 Hz, 2 H, OCH2CH3),
7. 01 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 12 (td, J= 7. 8 Hz, 0. 9 Hz, 1 H, H-5'), 7. 37-7. 43
(m, 1 H, H-4'), 8. 49 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 10. 85 (br s, 1 H, NH); MS
(FAB) m/z 326 (MH+).
Preparative Example 37
Preparation of l ,2-dimethyl-5-(2-77-propoxyphenyl)-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-<i]pyrimi din-7-one (a compound of the formula (9) wherein R1 = R2 = CΗ3, R3 = CH2CH,CH3, R4 = CH2CH2CH3) The titled compound was prepared as described in Preparative Example 17 by using 1 ,2-dimethyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of
4-(2-(2-fluoroethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 97%
mp 112-112. 5 °C (CHCl3/Et2O/hexanes); IR (neat) 3334 (NH), 1683 (CO) cm'1 ;
Η NMR (CDCl/TMS) δ 0. 97 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 16 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 63-1. 75 (m, 2 Η, CΗ2CH2CΗ3), 1. 94-2. 06 (m, 2 Ii, OCH,CH2CH3), 2. 30 (s, 3 H, CH3), 2. 70 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 4. 03 (s, 3 H, NCH3), 4. 16 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 02 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 12 (td, J= 7. 8 Hz, 1. 2 Hz, 1 H, H-5'), 7. 40 (ddd, J= 8. 4 Hz, 7. 8 Hz, 1. 8 Hz, 1 H, H-4'), 8. 50 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 10. 89 (br s, 1 H, NH); MS (FAB)
Preparative Example 38
Preparation of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l,2-dimethyl-3-77-propyl-l,6-dihydro-7H-pyrrol o[4,3-_ ]pyrimidin-7-one (a compound of the formula (2) wherein Y = Cl, R1 = R2 = CΗ3, R3 = CH2CH2CH3, R4 = CH2CH3) The titled compound was prepared as described in Preparative Example 14 by using l,2-dimethyl-5-(2-ethoxyphenyl)-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-_/]pyrimidin -7-one in place of 5-(2-ethoxyphenyl)- l-methyl-3-77-propyl-l,6-dihydro-7H-pyriOlo[4,3-_/]pyrimidin-7-one. yield: 98% (crude)
'Η NMR (CDC13/TMS) δ 0. 97 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 66 (t, J= 6. 9 Ηz, 3 Ii, OCΗ2CH3), 1. 64-1. 71 (m, 2 Η, CΗ2CH,CΗ3), 2. 32 (s, 3 H, CH3), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 04 (s, 3 H, NCH3), 4. 41 (q, J- 6. 9 Hz, 2 H, OCH2CH3), 7. 19 (d, J= 9. 0 Hz, 1 H, H-3'), 8. 06 (dd, J- 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 9. 15 (d, J = 2. 7 Hz, 1 H, H-6'), 10. 50 (br s, 1 H, NH); MS (FAB) m/z 424 (MH+).
Preparative Example 39
Preparation of
5-(5-chlorosulfony-2-77-propoxylphenyl)-l,2-dimethyl-3-77-propyl-l,6-dihydro-7H-pyr
rolo[4,3-^pyrimidin-7-one (a compound of the formula (2) wherein Y = Cl, R1 = R2 = CH3, R3 = CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared in a slightly impure form as described in Preparative Example 14 by using 1 ,2-dimethyl-5-(2-77-propoxyphenyl)-3-77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-αT]pyrimi din-7-one in place of
5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-o ne. yield: 100% (crude) 'Ii NMR (CDCl TMS) δ 0. 97 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 18 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 64-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 2. 00-2. 10 (m, 2 H, OCH2CH,CH3), 2. 33 (s, 3 H, CH3), 2. 73 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 04 (s, 3 Ii, NCH3), 4. 30 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 20 (d, J= 8. 7 Hz, 1 Ii, H-3'), 8. 07 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 9. 12 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 67 (br s, 1 H, NH).
Preparative Example 40
Preparation of
2-chloro-4-(2-ethoxybenzamido)-l-methyl-3-77-piOpylpyrrole-5-carboxamide (a compound of the formula (12) wherein R1 = CH3, R2 = Cl, R3 = CH2CH2CH3, R4 = CH,CH )
To a stirred solution of
4-(2-ethoxybenzamido)-l-methyl-3-77-propylpyriOle-5-carboxamide (1. 02 g, 3. 09 mmol) in CH2C12 (35 mL) at -20 °C was added N-chlorosuccinimide (0. 54 g, 4. 04 mmol) and the mixture was stirred at -10 °C for 1 h. After standing overnight in a refrigerator (ca. -12 °C), the reaction mixture was stirred at 0 °C for additional 7 h. The reaction was quenched by the addition of dilute Νa^^ aqueous solution (3 mL) and water (40 mL), and then the resulting mixture was extracted with CHC13 (20 mL x 4). Combined organic layer was dried (MgSO4), filtered and the filtrate was
evaporated to dryness under vacuum to give an oily yellow residue. The crude product was purified by MPLC on silica gel (gradient elution: 1:3 ethyl acetate/CHCl3 followed by 1 :2 ethyl acetate/CHCl3) to afford the titled compound (0. 72 g, 64%) as a white solid. Analytically pure compound was obtained by crystallization from ethyl acetate/hexanes. mp 136. 5 - 137 °C;
IR (neat) 3451, 3333 (NH), 1672, 1657 (CO) cm'1;
'Ii NMR (CDC13/TMS) δ 0. 88 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 43-1. 55 (m, 2 Ii, CΗ2CH2CΗ3), 1. 52 (t, J = 6. 9 Hz, 3 H, OCH2CH3), 2. 38 (t, J = 7. 5 Ηz, 2 Η, CH2CΗ2CΗ3), 3. 83 (s, 3 H, NCH3), 4. 30 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 05 (d, J = 8. 4 Hz, 1 H, H-3'), 7. 10-7. 15 (m, 1 H, H-5'), 7. 49-7. 55 (m, 1 H, H-4'), 8. 29 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 9. 40 (br s, 1 H, NH); MS (FAB) m/z 364 (MH+).
Preparative Example 41 Preparation of
2-chloro-l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide (a compound of the formula (12) wherein R1 = CH3, R2 = Cl, R3 = CH2CH2CH3, R4 = CH,CH CH3)
The titled compound was prepared as described in Preparative Example 28 by using l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of4-(2-ethoxybenzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 82% mp 139-140 °C (CHCl3/Et2O/hexanes); IR (neat) 3333, 3155 (NH), 1650 (CO) cm'1; Η NMR (CDCl TMS) δ 0. 87 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 05 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 42-1. 54 (m, 2 Η, CΗ2CH2CΗ3), 1. 85-1. 96 (m, 2 H, OCH,CH2CH3), 2. 37 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 3. 84 (s, 3 H, NCH3), 4. 18 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 05 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 13 (t, J= 7. 8 Hz, 1 H, H-5'), 7. 49-7. 55 (m, 1 H, H-4'), 8. 29 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 9. 39
(br s, 1 H, NH); MS (FAB) m/z 378 (MH+).
Preparative Example 42
Preparation of 2-chloro-5-(2-ethoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-_f]pyri midin-7-one (a compound of the formula (9) wherein R1 = CΗ3, R2 = Cl, R3 =
CH2CH,CH3, R = CH2CH3)
The titled compound was prepared as described in Preparative Example 17 by using 2-chloro-4-(2-ethoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide in place of 4-(2-(2-fluoroethoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide. yield: 70% mp 145. 5—146 °C (ethyl acetate/hexanes);
IR (neat) 3309 (NH), 1678 (CO) cm'1;
Η NMR (CDCyTMS) δ 0. 98 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 59 (t, J= 6. 9 Iiz, 3 Η, OCΗ2CH3), 1. 68-1. 81 (m, 2 Η, CΗ2CH2CΗ3), 2. 72 (t, J = 7. 5 Hz, 2 H,
CH2CH,CH3), 4. 07 (s, 3 H, NCH3), 4. 27 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 02 (d, J
= 8. 1 Hz, 1 H, H-3'), 7. 10-7. 15 (m, 1 H, H-5'), 7. 39-7. 45 (m, 1 H, H-4'), 8. 49 (dd,
J= 8. 1 Hz, 1. 8 Hz, 1 H, H-6'), 1 1. 00 (br s, 1 H, NH); MS (FAB) 777/z 346 (MH+).
Preparative Example 43
Preparation of
2-chloro-l-methyl-5-(2-77-propoxyphenyl)-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3- ]p yrimidin-7-one (a compound of the formula (9) wherein R1 = CΗ3, R2 = Cl, R3 = CH2CH2CH3, R — CH2CH2CH3) The titled compound was prepared as described in Preparative Example 17 by using
2-chloro- 1 -methyl-4-(2-77-propoxybenzamido)-3-77-propylpyriOle-5-carboxamide in place of 4-(2-(2-fluoroethoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide. yield: 91%
mp 1 17-1 17. 5 °C (Et2O/hexanes); IR (neat) 3315 (NH), 1687 (CO) cm'1;
Η NMR (CDC13/TMS) δ 0. 98 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 17 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 68-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 1. 95-2. 06 (m, 2 H, OCH,CH2CH3), 2. 73 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 07 (s, 3 H, NCH3), 4. 17 (t, J= 6. 6 Hz, 2 Ii, OCH2CH2CH3), 7. 03 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 13 (td, J = 8. 1 Hz, 1. 2 Hz, 1 H, H-5'), 7. 40-7. 46 (m, 1 H, H-4'), 8. 50 (dd, J= 8. 1 Hz, 1. 8 Hz, 1 H, H-6'), 11. 03 (br s, 1 H, NH); MS (FAB) m/z 360 (MH+).
Preparative Example 44
Preparation of
2-chloiO-5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydiO-7H-p yrrolo[4,3-_ Jpyrimidin-7-one (a compound of the formula (2) wherein R' = CΗ3, R2 = Y = Cl, R3 = CH2CH2CH3, R4 = CH2CH3) The titled compound was prepared as described in Preparative Example 14 by using
2-chloro-5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-(i]pyri midin-7-one in place of
5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-o ne. yield: 96% mp 164 °C dec (Et,O/hexanes);
IR (neat) 3343 (NΗ), 1691 (CO), 1175 (SO2) cm'1;
Η NMR (CDCl/TMS) δ 0. 98 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 66 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 75 (t, J = 7. 5 Hz, 2 H, CH2CH,CH3), 4. 08 (s, 3 H, NCH3), 4. 42 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 21(d, J = 9. 0 Hz, 1 H, H-3'), 8. 08 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 9. 12 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 65 (br s, 1 H, NH); MS (FAB) m/z 426 (M+- H2O).
Preparative Example 45
Preparation of
2-chloro-5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7 H-pyrrolo[4,3-< )pyrimidm-7-one (a compound of the formula (2) wherein R1 = CΗ3, R2 = Y - Cl, R3 = CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 14 by using
2-chloro- 1 -methyl-5-(2-77-propoxyphenyI)-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-_/]p yrimidin-7-one in place of 5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-_ |pyrimidin-7-o ne. yield: 78% mp 172. 5 °C dec (CΗCl3/Et2O/hexanes); IR (neat) 3330 (NH), 1703 (CO), 1182 (SO2) cm'1; Η NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz, 3 Η, OCΗ,CΗ2CH3), 1. 67-1. 82 (m, 2 Η, CΗ2CH2CΗ3), 1. 99-2. 13 (m, 2 H, OCH2CH2CH3), 2. 75 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 4. 08 (s, 3 H, NCH3), 4. 31 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 22 (d, J= 8. 7 Hz, 1 H, H-3'), 8. 09 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 9. 13 (d, J= 2. 4 Hz, 1 H H-6'), 11. 40 (br s, 1 H, NH); MS (FAB) m/z 440 (M+ - H2O).
Preparative Example 46
Preparation of
2-bromo-4-(2-ethoxybenzamido)-l-methyl-3-77-propylpyriOle-5-carboxamide (a compound of the formula (12) wherein R1 = CH3, R2 = Br, R3 = CH2CH2CH3, R4 = CH2CH3)
To a stirred solution of
4-(2-ethoxybenzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide (636 mg, 1. 93 mmol) and sodium acetate (238 mg, 2. 90 mmol) in acetic acid (13 mL) at room
temperature was added dropwise bromine (119 μL, 2. 32 mmol) in acetic acid (6. 5 mL) over a period of 10 minutes, and the mixture was stirred for 10 minutes. The reaction mixture was diluted with water (10 mL), and was extracted with Et2O (10 mL x 4). Combined organic layer was dried (Na^O^, filtered and the filtrate was evaporated to dryness under vacuum. The crude residue was purified by MPLC on silica gel (gradient elution: 1% MeOH in CHC13 followed by 3% MeOH in CHC13) to afford the titled compound (544 g, 69%) as a white solid. Analytically pure compound was obtained by crystallization from CHC13/ Et2O/hexanes. mp 152. 5 - 153. 5 °C; IR (neat) 3453, 3192 (NH), 1663, 1644 (CO) cm4;
Η NMR (CDCl/TMS) δ 0. 88 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 43-1. 58 (m, 2 Η, CΗ2CH,CΗ3), 1. 51 (t, J = 6. 9 Hz, 3 H, OCH2CH3), 2. 38 (t, J = 7. 5 Iiz, 2 Η, CH2CΗ2CΗ3), 3. 86 (s, 3 H, NCH3), 4. 30 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 04 (d, J = 8. 1 Hz, 1 H, H-3'), 7. 09-7. 14 (m, 1 Ii, H-5'), 7. 48-7. 54 (m, 1 H, H-4'), 8. 28 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 9. 37 (br s, 1 H, NH); MS (FAB) m/z 408 (M+).
" Preparative Example 47
Preparation of
2-bromo- 1 -methyl-4-(2-77-propoxybenzamido)-3-?7-propylpyrrole-5-carboxamide (a compoimd of the formula (12) wherein R1 = CH3, R2 = Br, R3 = CH2CH2CH3, R4 =
CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 34 by using l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of 4-(2-ethoxybenzamido)-l-methyl-3-77-piOpylpyrrole-5-carboxamide. yield: 85% mp 142-143 °C (CHCl3/Et2O/hexanes);
IR (neat) 3332, 3149 (NH), 1648 (CO) cm'1;
'H NMR (CDC13/TMS) δ 0. 87 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 05 (t, J= 7. 2 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 42-1. 58 (m, 2 Η, CΗ2CH,CΗ3), 1. 84-1. 96 (m, 2 H,
OCH,CH2CH3), 2. 37 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 86 (s, 3 H, NCH3), 4. 18 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 05 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 12 (td, J= 8. 1 Hz, 0. 9 Hz, 1 H, H-5'), 7. 49-7. 55 (m, 1 H, H-4'), 8. 29 (dd, J= 8. 1 Hz, 1. 8 Hz, 1 H, H-6'), 9. 41 (br s, 1 H, NH); MS (FAB) 777/z 422 (M+).
Preparative Example 48
Preparation of
2-bromo-5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_/|pyri midin-7-one (a compound of the formula (9) wherein R1 = CΗ3, R2 = Br, R3 = CH2CH,CH3, R4 = CH2CH3)
The titled compound was prepared as described in Preparative Example 17 by using 2-bromo-4-(2-ethoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide in place of 4-(2-(2-fluoiOethoxybenzamido)- 1 -methyl-3-/7-propylpyrrole-5-carboxamide. yield: 100% mp 152. 5-153 °C (ethyl acetate/hexanes); IR (neat) 3311 (NH), 1679 (CO) cm'1;
Η NMR (CDC13/TMS) δ 0. 98 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 59 (t, J= 6. 9 Ηz, 3 Ii, OCΗ2CH3), 1. 69-1. 81 (m, 2 Ii, CΗ2CH,CΗ3), 2. 72 (t, J = 7. 5 Hz, 2 H, CH2CH,CH3), 4. 09 (s, 3 H, NCH3), 4. 28 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 02 (d, J = 8. 4 Hz, 1 H, H-3'), 7. 09-7. 15 (m, 1 H, H-5'), 7. 39-7. 45 (m, 1 H, H-4'), 8. 49 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 10. 96 (br s, 1 H, NH); MS (FAB) m/z 311 (MH+ - Br).
Preparative Example 49 Preparation of
2-bromo- 1 -methyl-5-(2-77-propoxyphenyl)-3-77-propy 1- 1 ,6-dihydro-7H-pyrrolo [4,3-_f]p yrimidin-7-one (a compound of the formula (9) wherein R1 = CΗ3, R2 = Br, R3 = CH,CH,CH3, R = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 17 by
using
2-bromo- 1 -methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of
4-(2-(2-fluoiOethoxy)benzamido)-l-methyl-3-/7-propylpyrrole-5-carboxamide. yield: 90% mp 110-1 12 °C (Et2O/hexanes); IR (neat) 3195 (NH), 1665 (CO) cm'1;
Η NMR (CDCl TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 17 (t, J= 7. 2 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 68-1. 81 (m, 2 Η, CΗ2CH2CΗ3), 1. 94-2. 06 (m, 2 H, OCH2CH2CH3), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 09 (s, 3 H, NCH3), 4. 17 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 03 (d, J = 8. 1 Hz, 1 H, H-3'), 7. 13 (td, J = 8. 1 Hz, 0. 9 Hz, 1 H, H-5'), 7. 40-7. 46 (m, 1 H, H-4'), 8. 50 (dd, J= 8. 1 Hz, 1. 8 Hz, 1 H, H-6*), 1 1. 02 (br s, 1 H, NH); MS (FAB) m/z 404 (M÷).
Preparative Example 50
Preparation of
2-bromo-5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-τ7-propyl-l,6-dihydro-7H-p yrrolo[4,3-_/]pyrimidin-7-one (a compound of the formula (2) wherein Y = Cl, R1 = CΗ3, R2 = Br, R3 = CH2CH2CH3, R4 = CH2CH3) The titled compound was prepared as described in Preparative Example 14 by using
2-bromo-5-(2-ethoxyphenyl)- 1 -methyl-3 -77-propy 1- 1 ,6-dihydro-7H-pyrrolo [4,3-ct] py ri midin-7-one in place of
5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-(fJpyrimidin-7-o ne. yield: 91% mp 191-192 °C (Et2O/hexanes);
IR (neat) 3331 (NΗ), 1696 (CO), 1178 (SO2) cm'1;
Η NMR (CDCl TMS) δ 0. 99 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 66 (t, J= 6. 9 Ηz,
3 H, OCH2CH3), 1. 67-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 2. 75 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 4. 10 (s, 3 H, NCH3), 4. 42 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 21(d, J= 8. 7 Hz, 1 H, H-3'), 8. 08 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 ,H, H-4'), 9. 12 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 66 (br s, 1 H, NH); MS (FAB) 777/z 470, 472 (M+- H2O).
Preparative Example 51
Preparation of
2-bromo-5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7
H-pyrrolo[4,3-d]pyrimidin-7-one (a compound of the formula (2) wherein Y = Cl, R1 = CΗ3, R2 = Br, R3 = CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 14 by using
2-bromo- 1 -methyl-5-(2-77-propoxypheny I)-3-/7-propyl- 1 ,6-dihydro-7H-pyrrolo [4,3-c/]p yrimidin-7-one in place of 5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyπOlo[4,3-β ]pyrimidm-7-o ne. yield: 84% mp 178 °C dec (CΗCl3/hexanes); IR (neat) 3325 (NΗ), 1691 (CO), 1178 (SO2) cm'1; Η NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 19 (t, J= 7. 5 Iiz, 3 Η, OCΗ2CΗ2CH3), 1. 67-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 2. 00-2. 12 (m, 2 H, OCH,CH2CH3), 2. 75 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 10 (s, 3 H, NCH3), 4. 30 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 22 (d, J= 9. 0 Hz, 1 H, H-3'), 8. 08 (dd, J= 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 9. 14 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 66 (br s, 1 H, NH); MS (FAB) /z 484, 486 (M+ - H2O).
Preparative Example 52
Preparation of
4-(2-ethoxybenzamido)-2-iodo- 1 -methyl-3-77-propylpyrrole-5-carboxamide (a
compound of the formula (12) wherein R1 = CH3, R2 = I, R3 = CH2CH2CH3, R4 = CH,CH3)
To a stirred solution of
4-(2-ethoxybenzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide (1. 10 g, 3. 34 mmol) in benzene (30 mL) at 0 CC was added portionwise iodine (0. 93 g, 3. 67 mmol) and mercury oxide (0. 62 g, 2. 84 mmol) alternately, and the mixture was stirred for 2 h at 0 °C. The reaction mixture was diluted with ethyl acetate (100 mL), washed once with dilute Na^O;, aqueous solution (100 mL), and the aqueous layer was further extracted with ethyl acetate (100 mL). The combined organic layer was dried (MgSO4), filtered and the filtrate was evaporated to dryness under vacuum. The crude residue was purified by MPLC on silica gel (20% ethyl acetate in CHC13) to afford the titled compound (1. 51 g, 99%>) as a white solid. Analytically pure compound was obtained by crystallization from ethyl acetate/hexanes. mp 157. 5 - 158 °C; IR (neat) 3338, 3186 (NH), 1660 (CO) cm'1;
'H NMR (CDC13/TMS) δ 0. 90 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 42-1. 54 (m, 2 Η, CΗ,CH2CΗ3), 1. 52 (t, J = 6. 9 Hz, 3 H, OCH2CH3), 2. 37 (t, J = 7. 5 Ηz, 2 Η, CH2CΗ2CΗ3), 3. 87 (s, 3 H, NCH3), 4. 30 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 05 (d, J = 8. 1 Hz, 1 H, H-3'), 7. 10-7. 15 (m, 1 H, H-5'), 7. 49-7. 55 (m, 1 H, H-4'), 8. 29 (dd, J= 7. 8 Hz, 2. 1 Hz, 1 H, H-6'), 9. 43 (br s, 1 H, NH); MS (FAB) m/z 456 (MIL).
Preparative Example 53
Preparation of
2-iodo-l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide (a compound of the formula (12) wherein R1 - CH3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH,CH3)
The titled compound was prepared as described in Preparative Example 34 by using l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of 4-(2-ethoxybenzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide.
yield: 82% mp 169. 5-170 °C (ethyl acetate/hexanes);
IR (neat) 3340, 3146 (NH), 1642 (CO) cm'1;
Η NMR (CDC13/TMS) δ 0. 88 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 05 (t, J= 7. 5 Ηz,
3 Ii, OCΗ2CΗ2CH3), 1. 40-1 . 53 (m, 2 Η, CΗ2CH2CΗ3), 1. 84-1. 96 (m, 2 H,
OCH2CH,CH3), 2. 36 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 86 (s, 3 H, NCH3), 4. 18 (t,
J= 6. 9 Hz, 2 H, OCH2CH2CH3), 7. 05 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 09-7. 15 (m, 1 H,
H-5'), 7. 52 (ddd, J= 8. 4 Hz, 7. 5 Hz, 1. 8 Hz, 1 H, H-4'), 8. 28 (dd, J= 8. 0 Hz, 1. 8
Hz, 1 H, H-6'), 9. 42 (br s, 1 H, NH); MS (FAB) m/z 470 (MH+).
Preparative Example 54
Preparation of
5-(2-ethoxyphenyl)-2-iodo-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-(i]pyrimi din-7-one (a compound of the formula (9) wherein R1 = CΗ3, R2 = I, R3 = CH2CH,CH3, R4 = CH2CH3)
The titled compound was prepared as described in Preparative Example 17 by using 4-(2-ethoxybenzamido)-2-iodo-l -methyl-3-77-propylpyrrole-5-carboxamide in place of
4-(2-(2-fluoroethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 81% mp 178-178. 5 °C (Et2O/hexanes);
IR (neat) 3309 (NH), 1667 (CO) cm'1;
Η NMR (CDCl TMS) δ 0. 99 (t, J= 7. 2 Hz, 3 H, CH2CH,CH3), 1. 60 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH,CΗ3), 2. 72 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 4. 10 (s, 3 H, NCH3), 4. 28 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 02 (d, J = 8. 4 Hz, 1 H, H-3'), 7. 13 (td, J= 8. 4 Hz, 1. 2 Hz, 1 H, H-5'), 7. 39-7. 45 (m, 1 H, H-4'), 8. 49 (dd, J = 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 10. 96 (br s, 1 H, NH); MS (FAB)
Preparative Example 55
Preparation of
2-iodo-l-methyl-5-(2-77-propoxyphenyl)-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-_/]pyr imidin-7-one (a compound of the formula (9) wherein R' = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 17 by using 2-iodo-l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of
4-(2-(2-fluoroethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 98% mp 141-142 °C (CHCl hexanes);
IR (neat) 3320 (NH), 1678 (CO) cm'1;
'H NMR (CDCl TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 17 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 1. 94-2. 06 (m, 2 Ii, OCH,CH2CH3), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 10 (s, 3 H, NCH3), 4. 17 (t, J= 6. 6 Hz, 2 H, OCH,CH2CH3), 7. 03 (d, J= 8. 4 Hz, 1 H, H-3'), 7. 10- 7. 15 (m, 1 H, H-5'), 7. 40-7. 45 (m, 1 H, H-4'), 8. 50 (dd, J= 7. 8 Hz, 1. 8 Hz, 1 H, H-6'), 10. 98 (br s, 1 Ii, NH); MS (FAB) m/z 452 (MH+).
Preparative Example 56
Preparation of
5-(5-chlorosulfonyl-2-etlιoxyphenyl)-2-iodo-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyr rolo[4,3-fiT[pyrimidin-7-one (a compound of the formula (2) wherein Y = Cl, R' = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 - CH2CH3) The titled compound was prepared as described in Preparative Example 14 by using
5-(2-ethoxyphenyl)-2-iodo-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-<f]pyrimi din-7-one in place of
5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-( |pyrimidin-7-o
ne. yield: 75% mp 197 °C dec (CHCl3/hexanes); IR (neat) 3327 (NH), 1670(00), 1174 (SO2) cm'1; ' H NMR (CDC13/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 66 (t, J = 6. 9 Ηz, 3 Ii, OCΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 74 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 4. 11 (s, 3 H, NCH3), 4. 42 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 21 (d, J = 8. 7 Hz, 1 H, H-3'), 8. 08 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 9. 13 (d, J= 2. 7 FIz, 1 H, H-6'), 10. 58 (br s, 1 H, NH); MS (FAB) m/z 518 (MH+- H2O).
Preparative Example 57
Preparation of
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-2-iodo- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H- pyrrolo[4,3-_ ]pyrimidin-7-one (a compound of the formula (2) wherein Y = Cl, R1 = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 14 by using
2-iodo-l-methyl-5-(2-77-propoxyphenyl)-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-(/Jpyr imidin-7-one in place of 5-(2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-o ne. yield: 93% mp 177 °C dec (CΗCl3/Et2O); IR (neat) 3323 (NH), 1679 (CO), 1 175 (SO2) cm'1; Η NMR (CDCl/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Iiz, 3 Η, OCΗ2CΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 00-2. 12 (m, 2 H, OCH2CH2CH3), 2. 74 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 11 (s, 3 H, NCH3), 4. 30 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 21 (d, J= 9. 0 Hz, 1 H, H-3'), 8. 08 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 9. 14 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 61 (br s, 1 H, NH); MS
(FAB) m/z 532 (MH+- H2O).
Preparative Example 58
Preparation of 5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)- 1 -methyl -3-77-propy 1- 1 ,6- dihydro-7H-pyrrolo[4,3-<JJpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH,CH,CH3, R4 = CH2CH3; NR6R7 is 4-(cyanomethyl)piperidinyl)
To a mixture of 5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro-7H-pyrolo [4,3 -ct]pyrimidm-7-one (200 mg, 0. 49 mmol) and 4-(cyanomethyl)piperidine trifluoroacetic acid (139 m g, 0. 59 mmol) in anliydrous dichloromethane (15 mL) in an ice bath was added triethylamine (0. 20 mL, 1. 46 mmol), and the mixture was stirred at 0 °C under nitrogen atmosphere for 2 h. The reaction mixture was evaporated to dryness under reduced pressure, and the resulting oily residue was purified by MPLC on silica gel (gradient elution: 4:1 ethyl acetate/hexanes followed by 2% MeOΗ in CΗC13) to afford the titled compound (217 mg, 89%) as a yellow solid. Analytically pure compound was obtained by crystallization from EtOH/CHCy mp 217. 5-218 °C;
IR (neat) 3325 (NH), 2246 (CN), 1691 (CO), 1 164 (SO.) cm'1; 'H NMR (CDCl TMS) δ 1. 00 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 42-1. 68 (m, 3 Η, CΗ and 2 CΗJ, 1. 61 (t, J = 7. 2 Hz, 3 H, OCH2CH3), 1. 68-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 1. 84-1. 93 (m, 2 H, 2 CHeq), 2. 29 (d, J= 6. 6 Hz, 2 H, CH2CN), 2. 40 (td, J= 1 1. 7 Hz, 2. 1 Hz, 2 H, 2 NCHJ, 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 91 (br d, J= 11. 7 Hz, 2 H, 2 NCHJ, 4. 08 (s, 3 H, NCH3), 4. 36 (q, J= 7. 2 Hz, 2 H, OCH2CH3), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 85 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 62 (br s, 1 H, NH); MS (FAB) m/z 498 (MH+).
Preparative Example 59
Preparation of
5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyl- l,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH,CH3; NRδR7 is 4-(cyanomethyl)piperidinyl)
The titled compound was prepared as described in Preparative Example 46 by using 5-(5-chlorosιιlfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyiOlo[ 4,3-_/|pyrimidin-7-one in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrolo[4,3 --/ pyrimidin-7-one. yield: 96% mp 194-194. 5 °C (EtOAc/hexanes);
IR (neat) 3304 (NΗ), 2245 (CN), 1691 (CO), 1166 (SO2) cm'1; Η NMR (CDCyTMS) δ 1. 00 (t, J- 7. 5 Hz, 3 H, CH2CH2CH3), 1. 18 (t, J= 7. 5 Iiz, 3 Η, OCΗ2CΗ2CH3), 1. 41-1. 59 (m, 2 Η, 2 CΗJ, 1. 60-1. 80 (m, 3 Η, CΗ and CΗ,CH2CΗ3), 1. 89 (br d, J = 1 1. 4 Hz, 2 H, 2 CHJ, 1. 98-2. 10 (m, 2 H, OCH2CH2CH3), 2. 29 (d, J= 6. 6 Hz, 2 H, CH2CN), 2. 40 (td, J= 12. 0 Hz, 2. 4 Hz, 2 H, 2 NCHJ, 2. 71 (t, J= 7. 5 Hz, 2 H, CH,CH,CH3), 3. 91 (br d, J= 12. 0 Hz, 2 Ii, 2 NCHJ, 4. 08 (s, 3 H, NCH3), 4. 25 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 89 (s, 1 H, H-2), 7. 14 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 65 (br s, 1 H, NH); MS (FAB) m/z 512 (MH+).
Preparative Example 60
Preparation of
5-(5-(4-(2-cyanoethyl)piperidinylsulfonyl)-2-ethoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6- dihydro-7H-pyrrolo[4,3-d]pyrimidin-7-one (a compound of the formula (1) wherein
R5 = SO2NR6R7, R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is
4-(2-cyanoethyl)piperidinyl)
The titled compound was prepared as described in Preparative Example 46 by using 4-(2-cyanoethyl)piperidine trifluoroacetic acid in place of 4-(cyanomethyl)piperidine trifluoroacetic acid. yield: 76% mp 225-225. 5 °C (EtOH/ CHC13);
IR (neat) 3325 (NH), 2243 (CN), 1692 (CO), 1162 (SO2) cm'1;
'Ii NMR (CDC13/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 28-1. 46 (m, 3 Η, CΗ and 2 CΗJ, 1. 57-1. 79 (m, 6 Η, CΗ2CH,CΗ3, CH2CH2CN and 2 CHJ, 1. 64 (t,
J= 6. 9 Hz, 3 H, OCH2CH3), 2. 33-2. 39 (m, 4 Η, CΗ2CH2CN and 2 NCΗJ, 2. 71 (t,
J= 7. 5 Ηz, 2 Η, CH2CΗ2CΗ3), 3. 87 (br d, J= 1 1. 7 Hz, 2 H, 2 NCHJ, 4. 08 (s, 3 H,
NCH3), 4. 36 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 9. 0 Hz,
1 H, H-3'), 7. 81 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 64 (br s, 1 H, NH); MS (FAB) m/z 512 (MH+).
Preparative Example 61
Preparation of
5-(5-(4-(2-cyanoethyl)piperidinylsulfonyl)-2-w-propoxyphenyl)-l-methyl-3-«-propyl- l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidm-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-(2-cyanoethyl)piperidinyl)
The titled compound was prepared as described in Preparative Example 46 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrolo[
4,3-c/]pyrimidin-7-one and 4-(2-cyanoethyl)piperidine trifluoroacetic acid in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-proρyl-l,6-dihydro-7H-pyrolo[4,3
-d]pyrimidin-7-one and 4-(cyanomethyl)piperidine trifluoroacetic acid. yield: 96%
mp 179-179. 5 °C (EtOAc/hexanes);
IR (neat) 3330 (NH), 2243 (CN), 1692 (CO), 1165 (SO.) cm'1; 'H NMR (CDCl/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 30-1. 42 (m, 2 Η, 2 CΗJ, 1. 57-1. 79 (m, 7 Η, CΗ, CH2CΗ,CN, CH2CH2CH3 and 2 CHJ, 1. 98-2. 10 (m, 2 H, OCH2CH2CH3), 2. 33-2. 39 (m, 2 Ii, 2 NCHJ, 2. 35 (t, J= 7. 2 Hz, 2 H, CH2CH,CN), 2. 71 (t, J- 7. 5 Ηz, 2 Η, CH2CΗ2CΗ3), 3. 87 (br d, J= 11. 7 Hz, 2 H, 2 NCHJ, 4. 08 (s, 3 H, NCH3), 4. 25 (t, J = 6. 3 Hz, 2 H, OCH2CH2CH3), 6. 89 (s, 1 H, H-2), 7. 14 (d, J = 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 69 (br s, 1 H, NH); MS (FAB) m/z 526 (MH+).
Preparative Example 62
Preparation of
5-(2-ethoxy-5-(4-(ethoxycarbonylmethyl)piperidinylsulfonyl)phenyl)-l-methyl-3-77-pr opyl-l,6-dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(ethoxycarbonylmethyl)piperidinyl)
The titled compound was prepared as described in Preparative Example 46 by using 4-(ethoxycarbonylmethyl)piperidine in place of 4-(cyanomethyl)piperidine trifluoroacetic acid. yield: 74% mp 146-147 °C (EtOAc/hexanes);
IR (neat) 3316 (NH), 1738, 1695 (CO), 1 161 (SO.) cm'1;
'H NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 22 (t, J= 7. 5 Ηz, 3 Η, CO2CΗ,CH3), 1. 31-1. 46 (m, 2 Η, 2 CΗJ, 1. 63 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3),
1. 67-1. 80 (m, 5 Η, CΗ, CΗ2CH2CΗ3 and 2 CHJ, 2. 21 (d, J = 6. 6 Hz, 2 H,
CH2CO2), 2. 39 (td, J= 1 1. 7 Hz, 2. 1 Hz, 2 H, 2 NCHJ, 2. 71 (t, J- 7. 5 Hz, 2 H,
CH2CH2CH3), 3. 83 (br d, J= 11. 7 Hz, 2 H, 2 NCHJ, 4. 08 (s, 3 H, NCH3), 4. 09 (q,
J= 7. 2 Hz, 2 H, CO,CH,CH3), 4. 36 (q, J= 6. 9 Hz, 2 H, OCH,CH3), 6. 89 (s, 1 H,
H-2), 7. 12 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 81 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 85 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 65 (br s, 1 H, NH); MS (FAB) 777/z 545 (MH+).
Preparative Example 63 Preparation of
5-(5-(4-(ethoxycarbonylmethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-
77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-<JJpyrimidin-7-one (a compound of the formula
(1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 - H, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NRδR7 is 4-(ethoxycarbonyhnethyl)piperidinyl) The titled compound was prepared as described in Preparative Example 46 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyI)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrolo[
4,3-_ |pyrimidin-7-one and 4-(ethoxycarbonylmethyl)piperidine in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrolo[4,3 - ]pyrimidin-7-one and 4-(cyanomethyl)piperidine trifluoroacetic acid. yield: 93% mp 147. 5-148 °C (EtOAc/CΗCl3);
IR (neat) 3335 (NH), 1732, 1669 (CO), 1 163 (SO2) cm'1;
1H NMR (CDCl3/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Iiz, 3 Η, OCΗ2CΗ2CH3), 1. 22 (t, J= 6. 9 Ηz, 3 Η, CO2CΗ2CH3), 1. 25-1. 46 (m, 2 Ii, 2
CΗJ, 1. 66-1. 85 (m, 5 Η, CΗ, CΗ2CH2CΗ3 and 2 CHJ, 1. 98-2. 10 (m, 2 Ii,
OCH,CH,CH3), 2. 21 (d, J= 6. 6 Hz, 2 H, CH,CO2), 2. 33-2. 45 (m, 2 H, 2 NCH , 2.
71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 83 (br d, J= 1 1. 7 Hz, 2 H, 2 NCHJ, 4. 08 (s,
3 H, NCH3), 4. 09 (q, J = 6. 9 Hz, 2 H, CO2CH2CH3), 4. 25 (t, J = 6. 6 Hz, 2 H, OCH,CH2CH3), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7
Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 67 (br s, 1 H, NH); MS
(FAB) m/z 559 (MH+).
Preparative Example 64
Preparation of
5-(2-ethoxy-5-(4-(2-ethoxycarbonylethyl)piperidinylsulfonyl)phenyl)-l-methyl-3-77-pr opyl-l,6-dihydro-7H-pyrrolo[4,3-^pyr_midin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-ethoxycarbonylethyl)piperidinyl)
The titled compound was prepared as described in Preparative Example 46 by using 4-(2-ethoxycarbonylethyl)piperidine in place of 4-(cyanomethyl)piperidine trifluoroacetic acid, yield: 77% mp 139. 5-140 °C (EtOAc/hexanes);
IR (neat) 3322 (NH), 1734, 1694 (CO), 1 162 (SO2) cm'1;
Η NMR (CDCyTMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 17-1. 44 (m, 3 Η, CΗ and 2 CΗJ, 1. 22 (t, J = 7. 2 Ηz, 3 Η, CO,CΗ,CH3), 1. 52-1. 68 (m, 2 Η, CH2CΗ2CO2), 1. 63 (t, J= 7. 2 Hz, 3 H, OCH2CH3), 1. 69-1. 80 (m, 4 Η, CΗ,CH2CΗ3 and 2 CHJ, 2. 27 (t, J= 7. 5 Hz, 2 H, CH2CH2CO2), 2. 33 (br t, J = 11. 4 Ηz, 2 Ii, 2 NCΗJ, 2. 71 (t, J = 7. 5 Ηz, 2 Η, CH2CΗ2CΗ3), 3. 83 (br d, J = 11. 4 Hz, 2 Ii, 2 NCHJ, 4. 08 (s, 3 H, NCH3), 4. 09 (q, J= 7. 2 Hz, 2 H, CO,CH2CH3), 4. 35 (q, J= 7. 2 Hz, 2 H, OCH2CH3), 6. 89 (s, 1 H, H-2), 7. 12 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 85 (d, J= 2. 4 Hz, ϊ H, H-6'), 10. 64 (br s, 1 H, NH); MS (FAB) m/z 559 (MH+).
Preparative Example 65
Preparation of
5-(5-(4-(2-ethoxycarbonylethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3- 77-propyl- l,6-dihydro-7H-pyrrolo[4,3-tt pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NRδR7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH,CH3; NR6R7 is 4-(2-ethoxycarbonylethyl)piperidinyl)
The titled compound was prepared as described in Preparative Example 46 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrolo[ 4,3-_ ]pyrimidin-7-one and 4-(2-ethoxycarbonylethyl)piperidine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrolo[4,3 -ct]pyrimidin-7-one and 4-(cyanomethyl)piperidine trifluoroacetic acid. yield: 80% mp 134-135 °C (EtOAc/CΗCl3);
IR (neat) 3335, 3300 (NH), 1735, 1688 (CO), 1 163 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 1. 00 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ,CH3), 1. 22 (t, J= 7. 2 Ηz, 3 Η, CO2CΗ2CH3), 1. 21-1. 40 (m, 3 Η, CΗ and 2 CΗJ, 1. 49-1. 62 (m, 2 Η, CH2CΗ2CO2), 1. 67-1. 80 (m, 4 H, CH2CH2CH3 and 2 CHJ, 1. 98-2. 08 (m, 2 H, OCH2CH2CH3), 2. 27 (t, J= 7. 5 Hz, 2 H, CH2CH2CO2), 2. 29-2. 38 (m, 2 Η, 2 NCΗJ, 2. 71 (t, J= 7. 5 Ηz, 2 Η, CH2CΗ,CΗ3), 3. 83 (br d, J = 12. 6 Hz, 2 H, 2 NCHJ, 4. 082 (q, J= 7. 2 Hz, 2 H, CO2CH2CH3), 4. 083 (s, 3 H, NCH3), 4. 24 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 66 (br s, 1 H, NH); MS (FAB) /z 573 (MH+).
Preparative Example 66
Preparation of 5-(5-((S)-l-benzyloxycarbonyl-2-methylpropyl)aminosulfonyl-2-ethoxyphenyl)-l-met hyl-3-;7-propyl-l,6-dihydiO-7H-pyrrolo[4,3-_/]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 =
CH2CH3; NR6R7 is ((S)-l-benzyloxycarbonyl-2-methylpropyl)amino)
The titled compound was prepared as described in Preparative Example 46 by using L-valine benzyl ester hydrochloride in place of 4-(cyanomethyl)piperidine trifluoiOacetic acid. yield: 79% mp 103-104 °C (EtOAc/Et2O/hexanes);
IR (neat) 3327 (NH), 1741, 1674 (CO), 1 164 (SO2) cm'1;
'H NMR (CDC13/TMS) δ 0. 86 (d, J= 6. 9 Hz, 3 H, CHCH3), 0. 97 (d, J= 6. 9 Ηz, 3 Η, CΗCH3), 1. 00 (t, J = 7. 2 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 61 (t, J = 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 68-1. 76 (m, 2 Η, CΗ2CH2CΗ3), 2. 05-2. 21 (m, 1 H, CH(CH3)2), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 87 (dd, J= 9. 9 Hz, 5. 1 Hz, 1 H, NCHCO,), 4. 08 (s, 3 H, NCH3), 4. 29 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 89 (s, 2 H, OCH2Ph), 5. 27 (d, J= 9. 9 Hz, 1 H, SO2NH), 6. 89 (s, 1 H, H-2), 7. 00 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 10-7. 26 (m, 5 H, ArH), 7. 84 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 92 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 64 (br s, 1 H, NH); MS (FAB) m/z 581 (MIL).
Preparative Example 67
Preparation of
5-(5-((S)- 1 -benzyloxycarbonyl-2-methylpropyl)aminosulfonyl-2-77-propoxypheny 1)- 1 - methyI-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-(i]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is ((S)-l-benzyloxycarbonyl-2-methylpropyl)amino)
The titled compound was prepared as described in Preparative Example 46 by using
5-(5-chloiOsulfonyl-2-77-propoxyphenyl)- 1 -methyl-3 -77-propy 1-1 ,6-dihydro-7H-pyrolo[ 4,3-c/]pyrimidin-7-one and L-valine benzyl ester hydrochloride in place of 5-(5-chloiOSiιlfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrolo[4,3 -<3jpyrimidin-7-one and 4-(cyanomethyl)piperidine trifluoroacetic acid, yield: 82% mp 126-127 °C (EtOAc/Et2O/hexanes); IR (neat) 3330 (NΗ), 1741, 1675 (CO), 1 165 (SO2) cm'1; Η NMR (CDC13/TMS) δ 0. 86 (d, J= 6. 9 Ηz, 3 Η, CΗCH3), 0. 97 (d, J= 6. 9 Ηz, 3 Η, CΗCH3), 1. 01 (t, J = 7. 5 Ηz, 3 Η, CΗ,CΗ2CH3), 1. 18 (t, J = 7. 5 Ηz, 3 Η, OCΗ,CΗ2CH3), 1. 69-1. 78 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 14 (m, 3 H, OCH,CH2CH3 and CH(CH3)2), 2. 73 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 88 (dd, J = 9. 9 Hz, 5. 1 Hz, 1 H, NCHCO2), 4. 09 (s, 3 H, NCH3), 4. 19 (t, J = 6. 6 Hz, 2 H,
OCH2CH2CH3), 4. 89 (s, 2 H, OCH2Ph), 5. 19 (d, J= 9. 9 Hz, 1 H, SO2NH), 6. 89 (s, 1 H, H-2), 7. 02 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 11-7. 33 (m, 5 H, ArH), 7. 85 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 95 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 67 (br s, 1 H, NH); MS (FAB) m/z 595 (MH+).
Preparative Example 68
Preparation of
4-(2-ethoxy-5-nitrobenzamido)-l-methyl-3-?7-propylpyrrole-5-carboxamide (a compound of the formula (13) wherein R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 - CH2CH3)
The titled compoimd was prepared as described in Preparative Example 10 by using 2-ethoxy-5-nitrobenzoyl chloride in place of 2-ethoxybenzoyl chloride, yield: 96% mp 227-227. 5 °C (CHCl3/Et2O); IR (neat) 3447, 3299 (NH), 1657, 1639 (CO), 1341, 1288 (NO2) cm'1;
Η NMR (CDC13/TMS) δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH2CH,CH3), 1. 46-1. 57 (m, 2 Η, CΗ2CH,CΗ3), 1. 60 (t, J = 6. 9 Hz, 3 H, OCH2CH3), 2. 33 (t, J = 7. 5 Hz, 2 Ii, CH2CH2CH3), 3. 85 (s, 3 H, NCH3), 4. 42 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 54 (s, 1 H, H-2), 7. 16 (d, J= 9. 0 Hz, 1 H, H-3'), 8. 39 (dd, J= 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 9. 13 (br s, 1 H, NH), 9. 16 (d, J= 2. 7 Hz, 1 H, H-6'); MS (FAB) m/z 375 (MH+).
Preparative Example 69
Preparation of
4-(5-nitro-2-77-pι-opoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide (a compound of the formula (13) wherein R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 10 by using 5-nitro-2-77-propoxybenzoyl chloride in place of 2-ethoxybenzoyl chloride, yield: 94%
mp 224-224. 5 °C (CHCl3/Et,O);
IR (neat) 3388, 3186 (NH), 1659, 1639 (CO), 1341, 1277 (NO2) cm'1; 'H NMR (CDCyTMS) δ 0. 91 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 09 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 47-1. 59 (m, 2 Η, CΗ2CH2CΗ3), 1. 91-2. 03 (m, 2 H, OCH2CH2CH3), 2. 32 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 85 (s, 3 H, NCH3), 4. 30 (t, J= 6. 9 Hz, 2 H, OCH2CH2CH3), 6. 54 (s, 1 H, H-2), 7. 16 (d, J= 8. 7 Hz, 1 H, H-3'), 8. 39 (dd, J- 8. 7 Hz, 3. 0 Hz, 1 H, H-4'), 9. 12 (br s, 1 H, NH), 9. 16 (d, J= 3. 0 Hz, 1 H, H-6'); MS (FAB) m/z 389 (MH+).
Preparative Example 70
Preparation of
5-(2-ethoxy-5-nitiOphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-6 ]pyrimi din-7-one (a compound of the formula (10) wherein R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3) The titled compound was prepared as described in Preparative Example 17 by using 4-(2-ethoxy-5-nitrobenzamido)-l -methyl-3-77-propylpyrrole-5-carboxamide in place of
4-(2-(2-fluoiOethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 77% mp 211-211. 5 °C (CHCl3/Et2O);
IR (neat) 3327 (NH), 1684 (CO), 1341, 1268 (NO2) cm'1;
'H NMR (DMSO- ) δ 0. 93 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 37 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 58-1. 70 (m, 2 Η, CΗ2CH2CΗ3), 2. 59 (t, J = 7. 5 Hz, 2 Ii, CH2CH2CH3), 3. 99 (s, 3 H, NCH3), 4. 27 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 23 (s, 1 H, H-2), 7. 36 (d, J== 9. 3 Hz, 1 H, H-3'), 8. 35 (dd, J= 9. 3 Hz, 3. 0 Hz, 1 H, H-4'), 8. 43 (d, J= 3. 0 Hz, 1 H, H-6'), 11. 75 (br s, 1 H, NH); MS (FAB) 777/z 357 (MH+).
Preparative Example 71
Preparation of
l-methyl-5-(5-nitro-2-77-propoxyphenyl)-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-£Jpy rimidin-7-one (a compound of the formula (10) wherein R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 17 by using 1 -methyl-4-(5-nitro-2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of
4-(2-(2-fluoroethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 95% mp 181. 5 °C dec (CHCl3/Et2O); IR (neat) 3324 (NH), 1689 (CO), 1345, 1273 (NO2) cm'1;
'H NMR (CDCyTMS) δ 1. 02 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J = 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 68-1. 82 (m, 2 Η, CΗ2CH2CΗ3), 1. 91-2. 12 (m, 2 Ii, OCH,CH2CH3), 2. 75 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 4. 09 (s, 3 H, NCH3), 4. 28 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 6. 91 (s, 1 H, H-2), 7. 12 (d, J= 9. 3 Hz, 1 H, H-3'), 8. 30 (dd, J= 9. 3 Hz, 3. 0 Hz, 1 H, H-4'), 9. 36 (d, J= 3. 0 Hz, 1 H, H-6'), 10. 61 (br s, 1 H, NH); MS (FAB) m/z 371 (MH+).
Preparative Example 72 Preparation of 5-(5-amino-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydiO-7H-pyrrolo[4,3- ]pyri midin-7-one (a compound of the formula (3) wherein R1 = CΗ3, R2 = H, R3 = CH,CH2CH3, R4 = CH2CH3)
A mixture of
5-(2-ethoxy-5-nitiOphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrrolo[4,3-t/]pyrimi din-7-one (443 mg, 1. 21 mmol) and 5% Pd/C (43 mg) in TΗF (10 mL) and EtOΗ (10 mL) was purged with hydrogen gas three times and stirred vigorously under hydrogen atmosphere (1 atm; a balloon) at room temperature for 5 h. The mixture was filtered tlirough a Celite pad, and the filtrate was evaporated to dryness under reduced pressure. The resulting yellow residue was purified by MPLC on silica gel (1 %
MeOH in CHC13) to afford the titled compound (388 mg, 98%) as a pale yellow solid.
Analytically pure compound was obtained by crystallization from EtOAc/hexanes. mp 165. 5-166 °C;
IR (neat) 3542, 3329, 3297 (NH), 1647 (CO) cm'1;
Η NMR (CDC13/TMS) δ 1. 01 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 53 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 68-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 2. 72 (t, J - 7. 5 Hz, 2 H,
CH2CH,CH3), 4. 07 (s, 3 H, NCH3), 4. 16 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 76 (dd, J
= 9. 0 Hz, 3. 0 Hz, 1 Ii, H-4'), 6. 85 (s, 1 H, H-2), 6. 87 (d, J= 9. 0 Hz, 1 H, H-3'), 7.
85(d, J= 3. 0 Hz, 1 H, H-6'); MS (FAB) 777/z 327 (MH+).
Preparative Example 73 Preparation of
5-(5 -amino-2-77-propoxypheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,3 -d] p yrimidin-7-one (a compound of the formula (3) wherein R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 60 by using l-methyl-4-(5-nitiO-2-77-propoxybenzamido)-3-77-piOpylpyrrole-5-carboxamide in place of
5-(2-ethoxy-5-nitrophenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-<i]pyrimi din-7-one. yield: 63% mp 94-96. 5 °C (CΗ2Cl,/MeOΗ/Et2O);
IR (neat) 3505, 3439, 3312 (NH), 1676 (CO) cm'1;
Η NMR (DMSO- ) δ 1. 19 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 23 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 84-2. 03 (m, 4 Η, CΗ2CH2CΗ3 and OCH2CH2CH3), 2. 84 (t, J =
7. 5 Hz, 2 H, CH2CH2CH3), 4. 20 (t, J = 6. 3 Hz, 2 H, OCH,CH2CH3), 4. 22 (s, 3 H, NCH3), 5. 13 (br s, 2 H, NH,_), 6. 94 (dd, J= 8. 7 Hz, 3. 0 Hz, 1 H, H-4'), 7. 15 (d, J =
8. 7 Hz, 1 H, H-3'), 7. 44 (s, 1 H, H-2), 7. 45 (d, J= 3. 0 Hz, 1 H, H-6'), 11. 57 (br s, 1 H, NH); MS (FAB) 777/z 341 (MH+).
Preparative Example 74
Preparation of
4-(5-bromo-2-ethoxybenzamido)-l-methyl-3-77-piOpylpyrrole-5-carboxamide (a compound of the formula (14) wherein R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 =
CH2CH3)
The titled compound was prepared as described in Preparative Example 10 by using 5-bromo-2-ethoxybenzoyl chloride in place of 2-ethoxybenzoyl chloride. yield: 98% mp 158-159 °C (EtOAc/Et2O/hexanes);
IR (neat) 3445, 3174 (NH), 1656 (CO) cm'1;
'Ii NMR (CDC13/TMS) δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 47-1. 59 (m, 2 Ii,
CΗ,CH2CΗ3), 1. 52 (t, J = 6. 9 Hz, 3 H, OCH2CH3), 2. 32 (t, J = 7. 5 Ηz, 2 Η,
CH2CΗ2CΗ3), 3. 85 (s, 3 H, NCH3), 4. 27 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 52 (s, 1 H, H-2), 6. 93 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 59 (dd, J- 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 8.
40 (d, J= 2. 7 Hz, 1 H, H-6'), 9. 28 (br s, 1 H, NH); MS (FAB) m/z 391 (MH+- H2O).
Preparative Example 75
Preparation of 4-(5-bromo-2-77-propxybenzamido)-l -methyl-3-77-propylpyrrole-5-carboxamide (a compoimd of the formula (14) wherein R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 =
CH2CH,CH3)
The titled compound was prepared as described in Preparative Example 10 by using 5-bromo-2-77-propoxybenzoyl chloride in place of 2-ethoxybenzoyl chloride. yield: 89% mp 148-150 °C (CHCl3/hexanes);
IR (neat) 3315, 3174 (NH), 1659, 1642 (CO) cm'1;
Η NMR (CDCl TMS) δ 0. 91 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 05 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 46-1. 56 (m, 2 Η, CΗ2CH2CΗ3), 1. 85-1. 97 (m, 2 H,
OCH2CH2CH3), 2. 31 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 3. 84 (s, 3 H, NCH3), 4. 16 (t, J- 6. 9 Hz, 2 H, OCH2CH2CH3), 6. 53 (s, 1 H, H-2), 6. 94 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 59 (dd, J= 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 8. 40 (d, J= 2. 7 Hz, 1 H, H-6'), 9. 28 (br s, 1 H, NH); MS (FAB) 777/ 405 (MH+- H2O).
Preparative Example 76
Preparation of
5-(5-bromo-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-(i]pyri midin-7-one (a compound of the formula (11) wherein R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3)
The titled compound was prepared as described in Preparative Example 17 by using 4-(5-bromo-2-ethoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide in place of
4-(2-(2-liuoroethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 80% mp 151. 5-152 °C (EtOAc/Et2O/hexanes);
IR (neat) 3318 (NH), 1690 (CO) cm'1;
"H NMR (CDCyTMS) δ 1. 02 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 59 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 67-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 2. 73 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 4. 08 (s, 3 H, NCH3), 4. 25 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 87 (s, 1 H, H-2), 6. 90 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 49 (dd, J= 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 8. 59 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 79 (br s, 1 H, NH); MS (FAB) 777/z 390 (M+).
Preparative Example 77 Preparation of
5-(5-bromo-2-77-piOpoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrrolo[4,3-ct]p yrimidin-7-one (a compound of the formula (11) wherein R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH,CH2CH3)
The titled compound was prepared as described in Preparative Example 17 by
using
4-(5-bromo-2-77-propoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide in place of
4-(2-(2-fluoroethoxy)benzamido)-l-methyl-3-77-propylpyriOle-5-carboxamide. yield: 76% mp 118-119 °C (EtOAc/hexanes); IR (neat) 3324 (NH), 1696 (CO) cm"1;
'HNMR (CDCl TMS) δ 1. 02 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 15 (t, J= 7. 2 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 68-1. 80 (m, 2 H, CH2CH2CH3), 1. 93-2. 05 (m, 2 H, OCH2CH2CH3), 2. 73 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 08 (s, 3 H, NCH3), 4. 14 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 88 (s, 1 H, H-2), 6. 91 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 50 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 60 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 82 (br s, 1 H, NH); MS (FAB) m/z 404 (M+).
Preparative Example 78
Preparation of
5-(5-cyano-2-ethoxyphenyl)- 1 -methyl-3-π-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-<i]py ri midin-7-one (a compound of the formula (4) wherein R1 = CΗ3, R2 = H, R3 = CH2CH,CH3, R — CH2CH3) A mixture of
5-(5-bromo-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-c ]pyri midin-7-one (560 mg, 1. 43 mmol) and copper(I) cyanide (2. 57 g, 28. 7 mmol) in 1 -methyl -2 -pyrrolidinone (10 mL) was heated at 190 °C for 5 h, and then cooled to room temperature. The reaction mixture was poured into a cooled mixture of 29% aqueous ammonia solution (70 mL) and water (140 mL) in an ice bath, and the resulting deep blue suspension was stirred for 1 h in an ice bath. The mixture was extracted with CΗC13 (80 mL x 3), the combined organic layer was dried (MgSO4), filtered and the filtrate was evaporated to dryness under reduced pressure. The crude residue was solidified from Et2O/hexanes, and the resulting solid was purified by
MPLC on silica gel (1% MeOH in CHCI3) to afford the titled compound (376 mg, 78%) as a pale yellow solid. Analytically pure compound was obtained by crystallization from CHCl3/Et,O. mp 232. 5-233 °C; IR (neat) 3329 (NH), 2228 (CN), 1692 (CO) cm'1 ;
Η NMR (CDCl/TMS) δ 1. 02 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 63 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 68-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 73 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 4. 08 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 90 (s, 1 H, H-2), 7. 09 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 69 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 82 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 62 (br s, 1 H, NH); MS (FAB) m/z 337 (MH+).
Preparative Example 79 Preparation of
5-(5-cyano-2-77-p1Opoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ ]p yrimidin-7-one (a compound of the formula (4) wherein R1 = CΗ3, R2 = H, R3 =
CH2CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Preparative Example 66 by using 4-(5-cyano-2-77-propoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide in place of 5-(5-cyano-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-<j/]pyri midin-7-one. yield: 84% mp 179-180. 5 °C (CΗCl3/hexanes);
IR (neat) 3333 (NH), 2225 (CN), 1689 (CO) cm'1; Η NMR (CDCl TMS) δ 1. 02 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 18 (t, J= 7. 2 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 68-1. 80 (m, 2 Η, CΗ,CH2CΗ3), 1. 98-2. 09 (m, 2 H,
OCH2CH2CH3), 2. 73 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 4. 08 (s, 3 H, NCH3), 4. 24 (t,
J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 90 (s, 1 H, H-2), 7. 10 (d, J= 9. 0 Hz, 1 H, H-3'),
7. 69 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 83 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 66 (br s,
1 H, NH); MS (FAB) m/z 351 (MH+).
Example 1
Preparation of 5-(2-ethoxy-5-(4-methylpiperazinylsulfony l)phenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro -7H-pyrrolo[4,3-£/jpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NR6R7, R1 = CΗ3, R2 = H, R3 = CH,CH2CH3, R4 - CH2CH3; NR6R7 is 4-methylpiperazinyl)
To a mixture of 5-(5 -chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4, 3-/|pyrimidin-7-one (170 mg, 0. 41 mmol) and 1 -methylpiperazine (69 μL, 0. 62 mmol) in anliydrous CΗ,C12 (10 mL) or EtOH (10 mL) was added triethylamine (1 15 μL, 0. 83 mmol), and the mixture was stirred at room temperature under nitrogen atmosphere for 1-12 h. The reaction mixture was evaporated to dryness under reduced pressure, and the resulting yellow residue was purified by MPLC on silica gel (gradient elution: 2% MeOH in CHC13 followed by 3% MeOH in CHC13) to afford the titled compound (161 mg, 82%) as a yellowish solid. Analytically pure compound was obtained by crystallization from EtOAc/hexanes. mp 220. 5-221 °C; IR (neat) 3334 (NH), 1678 (CO), 1172 (SO2) cm'1;
Η NMR (CDCl TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 63 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 27 (s, 3 H, NCH3), 2. 49 (dd, J = 5. 1 Hz, 4. 8 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 11 (dd, J = 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 88 (s, 1 H, H-2), 7. 12 (d, J= 8. 7 Hz, 1 H, H-3"), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 60 (br s, 1 H, NH); MS (FAB) m/z 474 (MU4).
Example 2
Preparation of
5-(2-ethoxy-5 -(4-methylpiperazinylsulfony l)pheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro -7H-pyrrolo[4,3-(JJpyriιτιidm-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-methylpiperazinyl)
To a solution of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro -7H-pyrrolo[4,3-_ jpyrimidin-7-one (77 mg, 0. 16 mmol) in anhydrous CΗ2C12 (2 mL) was added 1 M HCl ether solution (180 μL, 0. 18 mmol) at room temperature under nitrogen atmosphere, and the solution was stirred for about 10 minutes. The reaction mixture was poured slowly into anhydrous ether (50 mL), and the resulting white precipitates were collected by filtration. The filtered solid was dissolved in H2O (20 mL), filtered tlirough a membrane filter (0. 45 μm), and the filtrate was freeze-dried to afford the titled compound (79 mg, 95%) as an off-white floppy solid. mp l31. 5 °C dec;
IR (neat) 3334 (NH), 1686 (CO), 1163 (SO2) cm'1;
'H NMR (DMSO- ) δ 0. 93 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 36 (t, J= 6. 9 Iiz, 3 Η, OCΗ,CH3), 1. 58-1. 70 (m, 2 Η, CΗ,_CH2CΗ3), 2. 58 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 66-2. 83 (br s, 5 H, NCH3 and 2 SO2NCHJ, 3. 05-3. 22 (m, 2 Ii, 2 SO2NCHJ, 3. 35-3. 54 (m, 2 H, 2 +HNCHJ, 3. 72-3. 88 (m, 2 Η, 2 ÷ΗNCHJ, 3. 99 (s, 3 Ii, NCΗ3), 4. 24 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 23 (s, 1 H, H-2), 7. 41 (d, J = 9. 0 Hz, 1 H, H-3'), 7. 86 (dd, J= 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 7. 97 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 58 (br s, 1 Ii, NH+), 1 1. 75 (br s, 1 H, NH).
Example 3
Preparation of
5-(5-(4-methylpiperazinylsulfonyl)-2-77-propoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-d ih ydro-7H-pyrrolo[4,3-_f]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R' = CH3, R2 - H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NRδR7 is
4-methylpiperazinyl)
The titled compoimd was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,3-t/]pyrimidin-7-one in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-_/Jpyrimidin-7-one. yield: 81% mp 183-183. 5 °C (EtOAc/hexanes); IR (neat) 3297 (NH), 1695 (CO), 1171 (SO2) cm'1; Η NMR (CDCl/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 18 (t, J= 7. 5 Iiz,
3 Η, OCΗ2CΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 07 (m, 2 H, OCH2CH2CH3), 2. 27 (s, 3 H, NCH3), 2. 49 (dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 1 1 (dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO,NCH2), 4. 08 (s, 3 H, NCH3), 4. 24 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 88 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 88 (d, J= 2.
4 Hz, 1 H, H-6'), 10. 67 (br s, 1 H, NH); MS (FAB) 777/z 488 (MH+).
Example 4
Preparation of 5-(5-(4-methylpiperazinylsιxlfonyl)-2-77-piOpoxyphenyl)-l-methyl-3-77-propyl-l,6-dih ydro-7H-pyrrolo[4,3-d]pyrimidin-7-one hydrochloride (a compound of the formula
(1) wherein R5 = SO,NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-methylpiperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(5-(4-methylpiperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dih ydro-7H-pyrrolo[4,3-<fJpyrimidin-7-one in place of
'5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydro
-7H-pyrrolo[4,3-t ]pyrimidin-7-one. yield: 93%
mp 124. 5 °C dec;
IR (neat) 3348 (NH), 1680 (CO), 1167 (SO,) cm'1;
'H NMR (DMSO- 6) δ 0. 93 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 0. 97 (t, J= 7. 2 Ηz, 3 Η, OCΗ,CΗ,CH3), 1. 57-1. 70 (m, 2 Η, CΗ,CH2CΗ3), 1. 70-1. 81 (m, 2 H, OCH2CH2CH3), 2. 58 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 75 (s, 3 H, NCH3), 2. 76-2. 80 (m, 2 H, 2 SO2NCHJ, 3. 08-3. 22 (m, 2 H, 2 SO2NCHJ, 3. 35-3. 50 (m, 2 Ii, 2 +HNCHJ, 3. 81 (br d, J= 12. 3 Hz, 2 H, 2 +HNCHJ, 3. 99 (s, 3 Η, NCΗ3), 4. 14 (t, J = 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 24 (s, 1 H, H-2), 7. 42 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 87 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 7. 98 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 93 (br s, 1 H, NIL), 11. 76 (br s, 1 H, NH).
Example 5
Preparation of
5-(2-ethoxy-5-(4-ethylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydiO-7 H-pyrrolo[4,3-d]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Ii, R3 = CH,CH2CH3, R4 = CH2CH3; NR6R7 is 4-ethylpiperazinyl)
The titled compound was prepared as described in Example 1 by using 1-ethylpiperazine in place of 1-methylpiperazine. yield: 89% mp 200-200. 5 °C (CHCl3/EtOAc/hexanes);
IR (neat) 3332 (NH), 1680 (CO), 1172 (SO,) cm'1;
Η NMR (CDCyTMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 02 (t, J= 7. 2 Ηz,
3 Η, NCΗ,CH3), 1. 63 (t, J = 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 67-1. 77 (m, 2 Η, CΗ,CH2CΗ3), 2. 40 (q, J= 7. 2 Hz, 2 H, NCH2CH3), 2. 53 (dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 NCH,), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 11 (dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 88 (s, 1 H, H-2), 7. 12 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 80 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 62 (br s, 1 H, NH); MS (FAB) m/z 488 (MH+).
Example 6
Preparation of
5-(2-ethoxy-5-(4-77-propylpiperazinylsulfonyl)phenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihyd ro-7H-pyrrolo[4,3-(f]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is -4-77-propylpiperazinyl)
The titled compound was prepared as described in Example 1 by using 1-77-piOpylpiperazine in place of 1-methylpiperazine. yield: 76% mp 202. 5 °C dec (CHCl3/Et2O/hexanes);
IR (neat) 3332 (NH), 1677 (CO), 1170 (SO2) cm'1;
'H NMR (CDCl TMS) δ 0. 90 (t, J= 7. 5 Hz, 3 H, NCH,CH2CH3), 0. 99 (t, J= 7. 5
Ηz, 3 Ii, CΗ2CΗ2CH3), 1. 37-1. 50 (m, 2 Η, NCΗ2CH2CΗ3), 1. 63 (t, J= 6. 9 Hz, 3 H, OCH2CH3), 1. 64-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 2. 28 (dd, J= 7. 8 Hz, 7. 5 Hz, 2 H, NCH2CH2CH3), 2. 52 (dd, J= 4. 8 Hz, 3. 9 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 3. 10 (dd, J = 4. 8 Hz, 3. 9 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 88 (s, 1 H, H-2), 7. 12 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 63 (br s, 1 Ii, NH); MS (FAB) m/z 502 (MH+).
Example 7
Preparation of
5-(2-ethoxy-5-(4-77-piOpylpiperazinylsιxlfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihyd ro-7H-pyrrolo[4,3- ]pyrimidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-77-propylpiperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-77-piOpylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6-dihyd
ro-7H-pyrrolo[4,3-<^]pyrimidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro -7H-pyrrolo[4,3-_/]pyrimidin-7-one. yield: 98% mp 232. 5 °C dec;
IR (neat) 3334 (NΗ), 1686 (CO), 1163 (SO2) cm'1;
Η NMR (DMSO- ) δ 0. 87 (t, J= 7. 5 Ηz, 3 Η, NCΗ2CΗ2CH3), 0. 93 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 36 (t, J = 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 56-1. 72 (m, 4 Η, CΗ2CH2CΗ3 and NCH2CH2CH3), 2. 58 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 82 (br dd, J = 12. 3 Hz, 11. 7 Hz, 2 H, 2 SO2NCHJ, 2. 94-3. 07 (m, 2 H, NCH2CH2CFI3), 3. 05-3. 17 (m, 2 H, 2 SO2NCH j, 3. 47-3. 58 (m, 2 H, 2 +HNCHJ, 3. 79 (br d, J= 1 1. 7 Ηz, 2 Η, 2 +ΗNCHJ, 3. 99 (s, 3 Η, NCΗ3), 4. 24 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 25 (s, 1 H, H-2), 7. 42 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 87 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 7. 98 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 69 (br s, 1 H, NH+), 11. 82 (br s, 1 H, NH).
Example 8
Preparation of
5-(2-ethoxy-5-(4-isopropylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihy dro-7H-pyrrolo[4,3-_ |pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-isopropylpiperazinyl)
The titled compound was prepared as described in Example 1 by using 1-isopropylpiperazine in place of 1 -methylpiperazine. yield: 87% mp 241. 5 °C dec (CHCl3/Et2O);
IR (neat) 3333 (NH), 1680, 1672 (CO), 1177 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 0. 990 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 0. 993 (t, J= 6. 6 Ηz, 6 Η, CΗ(CH3)2), 1. 63 (t, J = 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 67-1. 77 (m, 2 Ii, CΗ2CH2CΗ3), 2. 60(dd, J = 4. 8 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 61-2. 68 (m, 1 H,
CH(CH3)2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 3. 09 (dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 88 (s, 1 H, H-2), 7. 1 1 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 62 (br s, 1 H, NH); MS (FAB) m/z 502 (MH+).
Example 9
Preparation of
5-(2-ethoxy-5-(4-isopropylpiperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihy dro-7H-pyrrolo[4,3- Jpyrimidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-isopropylpiperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-isopropylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6-dihy dro-7H-pyrrolo[4,3-d]pyrimidin-7-one in place of 5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l -methyl-3-77-propyl-l,6-dihydro -7H-pyrrolo[4,3-_f]pyrimidin-7-one. yield: 98% mp 244. 5 °C dec; IR (neat) 3336(NΗ), 1684 (CO), 1 166 (SO2) cm'1; Η NMR (DMSO-_ 6) δ 0. 93 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 23 (t, J= 6. 6 Ηz, 6 Η, CΗ(CH3)2), 1. 37 (t, J = 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 57-1. 72 (m, 2 Η, CΗ2CH2CΗ3), 2. 58 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 76-2. 88 (m, 2 H, 2 SO,NCHJ, 3. 07-3. 19 (m, 2 H, 2 SO,NCHeq), 3. 30-3. 56 (m, 3 H, CH(CH3), and 2 ÷HNCHJ, 3. 82 (br d, J= 12. 3 Ηz, 2 Η, 2 ÷ΗNCHJ, 3. 99 (s, 3 Η, NCΗ3), 4. 24 (q, J = 6. 9 Hz, 2 H, OCH2CH3), 7. 24 (s, 1 H, H-2), 7. 42 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 88 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 7. 99 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 38 (br s, 1 H, NH+), 1 1. 78 (br s, 1 H, NH).
Example 10
Preparation of
5-(2-ethoxy-5-(4-(2-fluoroethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6- dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one (a compound of the formula (1) wherein R5 - SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-(2-fluoroethyl)piperazine hydrochloride in place of 1-methylpiperazine. yield: 92% mp 204. 5-205 °C (EtOAc/hexanes); IR (neat) 3335 (NH), 1678 (CO), 1 169 (SO2) cm 1;
Η NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 66-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 62-2. 75 (m, 8 H, NCH2CH,F,
2 NCH, and CH2CH2CH3), 3. 13 (dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 08 (s,
3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 49 (ddd, J= 47. 4 Hz, 5. 1 Hz, 4. 5 Hz, 2 H, NCH,CH2F), 6. 89 (s, 1 Η, Η-2), 7. 12 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 80 (dd,
J = 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J = 2. 4 Hz, 1 H, H-6'), 10. 63 (br s, 1 H, NH); MS (FAB) 777/z 506 (MH+).
Example 1 1 Preparation of
5-(2-ethoxy-5-(4-(2-fluoroethyl)piperazinylsulfonyl)phenyl)- 1 -methyl-3-77-propyl- 1 ,6- dihydro-7H-pyrrolo[4,3-d]pyrimidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 - H, R3 = CH,CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-fluoroethyl)piperazinyl) The titled compound was prepared as described in Example 2 by using
5-(2-ethoxy-5-(4-(2-fluoroethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6- dihydro-7H-pyrrolo[4,3-_f]pyrimidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydro -7H-pyrrolo[4,3-_f]pyrimidin-7-one.
yield: 99% mp 76 °C dec;
IR (neat) 3333 (NH), 1684 (CO), 1164 (SO2) cm'1;
'H NMR (DMSO-fiQ δ 0. 93 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 36 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 58-1. 70 (m, 2 Η, CΗ2CH2CΗ3), 2. 58 (t, J = 7. 5 Hz, 2 H,
CH2CH2CH3), 2. 74-2. 91 (m, 2 H, 2 SO.NCHJ, 3. 18-3. 33 (m, 2 H, 2 SO2NCHJ,
3. 47-3. 68 (m, 4 H, NCH2CH2F and 2 +HNCHJ, 3. 73-3. 87 (m, 2 Η, 2 +ΗNCHJ, 3.
99 (s, 3 Η, NCΗ3), 4. 24 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 85 (br d, J= 47. 1 Hz, 2 H,
NCH,CH2F), 7. 25 (s, 1 Η, Η-2), 7. 42 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 87 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 98 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 14 (br s, 1 H, NH+), 11.
87 (br s, 1 H, NH).
Example 12
Preparation of 5-(5-(4-(2-fluoroethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyl- l,6-dihydro-7H-pyrrolo[4,3-_/|pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-(2-flιxoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo
[4,3-_/|pyrimidin-7-one and 1 -(2-fluoroethyl)piperazine hydrochloride in place of
5-(5 -chlorosulfony 1-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrro lo [4,
3- ]pyrimidin-7-one and 1-methylpiperazine. yield: 82% mp 158-159 °C (EtOAc/hexanes);
IR (neat) 3339 (NΗ), 1673 (CO), 1168 (SO2) cm'1;
Η NMR (CDCl TMS) δ 0. 99 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 19 (t, J= 7. 5 Ηz,
3 Η, OCΗ,CΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 10 (m, 2 H,
OCH,CH2CH3), 2. 62-2. 75 (m, 8 H, NCH2CH,F, 2 NCH2 and CH2CH2CH3), 3. 13
(dd, J= 5. 1 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 24 (t, J= 6. 5 Hz, 2 H, OCH2CH2CH3), 4. 49 (ddd, J- 47. 7 Hz, 5. 1 Hz, 4. 5 Hz, 2 H, NCH2CH,F), 6. 89 (s, 1 Η, Η-2), 7. 13 (d, J= 9. 0 Ηz, 1 Η, Η-3'), 7. 80 (dd, J- 9. 0 Hz, 2. 7 Hz, 1 Ii, H-4'), 8. 88 (d, J = 2. 7 Hz, 1 H, H-6'), 10. 66 (br s, 1 H, NH); MS (FAB) m/z 520 (MH+).
Example 13
Preparation of
5-(5-(4-(2-fluoroethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyl- l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one hydrocliloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(5-(4-(2-fluoroethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyl- l,6-dihydiO-7H-pyrrolo[4,3-<^pyrimidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro -7H-pyrrolo[4,3-_/)pyrimidin-7-one. yield: 99% mp 107 °C dec; IR (neat) 3351 (NΗ), 1677 (CO), 1168 (SO2) cm'1;
Η NMR (DMSO- ) δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 0. 97 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 58-1. 70 (m, 2 Η, CΗ2CH2CΗ3), 1. 70-1. 80 (m, 2 H, OCH2CH2CH3), 2. 58 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 74-2. 88 (m, 2 H, 2 SO2NCHJ, 3. 17-3. 34 (m, 2 H, 2 SO2NCHJ, 3. 46-3. 68 (m, 4 H, NCH2CH2F and 2 +HNCHJ, 3. 73-3. 87 (m, 2 Η, 2 +ΗNCHJ, 3. 99 (s, 3 Η, NCΗ3), 4. 15 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 4. 84 (br d, J = 48. 0 Hz, 2 Ii, NCH2CH2F), 7. 24 (s, 1 Η, Η-2), 7. 43 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 87 (dd, J- 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 7. 98 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 03 (br s, 1 Ii, NH+), 11. 80 (br s, 1 H, NH).
Example 14
Preparation of
5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l, 6~dihydro~7H-pyrrolo[4,3-<fJpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3~f_uoropropy_)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-(3-fluoropropyl)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 85% mp 217. 5-218 °C (EtOAc/CHCl3/hexanes);
IR (neat) 3333 (NH), 1676 (CO), 1 169 (SO2) cm'1;
Η NMR (CDCl TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 69-1. 89 (m, 4 Η, CΗ,CH2CΗ2F and CH2CH2CH3), 2. 47 (t, J= 7. 5 Hz, 2 H, NCH2CH2), 2. 54 (dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 3. 10 (dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 43 (dt, J= 46. 8 Hz, 6. 0 Hz, 2 H, CH,CH2F), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 63 (br s, 1 H, NH); MS (FAB)
Example 15
Preparation of
5-(2-ethoxy-5-(4-(3-fluoiOpropyπpiperazinylsulfonyl)phenyI)-3-ethyl-l-methyl- l,6-cli hydro-7H-pyπOlo[4,3-(/Jpyrimidin-7-one (a compound of the formula (1) wherein 1 = SO,NR('R7, R1 = CH„ R2 = Ii, R1 - CH,CH , R4 - CH2CH,; NR6R7 is 4-(3-fluoiOpiOpyl)piperazinyl)
A mixture of
4-(2-cthoxy-5-(4-(3-IluoropiOpyl)piperazinylsulfonyl)benzamido)-3-ethyl-l-meLhylpy ιτolc-5-carboxamide (270 mg, 0.52 mmol) and 1-BuOK (244 mg, 2.16 mmol ) in
anhydrous t-BuOH (10 mL) was heated at 80 °C under nitrogen atmosphere for 5 h. The reaction mixture was cooled to room temperature, and was evaporated to dryness under vacuum. The resulting residue was diluted with water (20 mL), acidified to about pH 8 with 1 N aqueous HCl solution, and was extracted with CH2CI2 (2 v. 50 mL). Combined organic layer was dried (MgS04), filtered, and evaporated to dryness in vacuo to afford a white solid. The crude product was purified by MPLC on silica gel (3% MeOH in CHCl,) to afford the titled compound (247 mg, 95%) as a white solid. Analytically pure compound was obtained by crystallization from CH ,C 1,/EtO Ac/hexanes . mp l 93-l 94 °C;
IR (neat) 3328 (NH), 1670 (CO), 1 165 (SO,) cm'1;
'H NK R (CDCI3/TMS) δ 1.32 (t, J= 7. 5 Hz, 3 H, CH,CH3), 1.64 (t, J= 7. 2 Hz, 3 H, OCH,CH3), 1. 71-1. 89 (m, 2 H, CHCILF), 2. 47 (t, J = 7. 5 Hz, 2 H, NCHCH,), 2.54 (dd, J= 5.1 Hz, 4.8 Hz, 4 H, 2 NCH,), 2. 77 (q, J= 7. 5 Hz, 2 H, CH,CH ), 3.10 (dd, J= 5.1 Hz, 4.8 Hz, 4 H, 2 SO,NCH,), 4.08 (s, 3 H, NCH3), 4. 36 (q, J= 7.2 Hz, 2 H, OCH,CH3), 4.43 (dt, J= 47.1 Hz, 6.0 Hz, 2 H, CH,CH,F), 6. 90 (s, 1 H, H-2), 7. 13 (d, J= 9.0 Hz, I Ii, H-3'), 7. 80 (dd, J= 9.0 Hz, 2.4 Hz, 1 Ii, H-4'), 8. 87 (d, J = 2.4 Hz, 1 H, H-6'), 10.64 (br s, 1 H, NH); MS (FAB) m/z 506 (MH+).
Example 16
Preparation of
5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-3-(3-_luoropropyl)- l-m ethyl- l ,6-dihydro-7H-pyrroIo[4,3-_/|pyrimidin-7-one (a compound of the formula (1) wherein R5 - SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH,CH,CH,F, R4 = CH,CH3; NRftR7 is 4-(3-fluoropiOpyl)piperazinyI)
The titled compound was prepared as described in Example 15 by using 4-(2-ethoxy-5-(4-(3-fluoropiOpyl)piperazinylsulfonyl)benzamido)-3-(3-flιιoropjOpyl)- l-methylpyrrole-5-carboxamide in place of
4-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfony l)benzamido)-3-ethyl- 1 -methy I py
rrole-5-carboxamide. yield: 87% mp 225 UC dec (CH,Cl,/ether); IR (neat) 3330 (NH), 1680 (CO), 1 171 (SO,) cm'1; ' Ii NMR (CDCl/TMS) δ 1.64 (t, J = 7. 2 Hz, 3 Ii, OCH2CH3), 1. 71-1 . 88 (m, 2 Ii, NCH,CH,CH2F), 2.03-2.23 (m, 2 Ii, CH,CH,CH2F), 2. 47 (t, J = 7. 2 Hz, 2 H, NCH ii,), 2.54 (dd, J = 5.1 Hz, 4.5 Hz, 4 Ii, 2 NCH,), 2. 86 (t, J = 7. 5 Hz, 2 Ii, CH,CH,CH2F), 3.10 (dd, J= 5.1 Hz, 4.5 Hz, 4 H, 2 S02NCH2), 4.09 (s, 3 H, NCH.,), 4. 36 (q, J = 7.2 Hz, 2 Ii, OCH2CH3), 4.41 (dt, J = 47.1 Hz, 6.0 Hz, 2 H, NCH,CH,CH,F), 4.52 (dt, J = 47.4 Ηz, 6.0 Hz, 2 H, CH,CH2CH2F), 6. 92 (s, I H, H-2), 7. 13 (d, J= 9.0 Hz, 1 Ii, H-3'), 7. 82 (dd, J= 9.0 Hz, 2.4 Hz, 1 H, H-4'), 8. 86 (d, J= 2.4 Hz, 1 Ii, H-6'), 10.67 (br s, 1 H, NH); MS (FAB) m/z 538 (MH+).
Example 17 Preparation of
3-cyclopiOpylmethyl-5-(2-ethoxy-5-(4-(3-fluoiOpropyl)piperazinylsuIfonyl)phenyl )-l - methyl- l,6-dihydiO-7H-pyrrolo[4,3-_/Jpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NRύR7, R1 - CH3, R2 = H, R3 - cyclopropylmethyl, R4 - CFI,CH3; NR6R7 is 4-(3-£_uoropropyI)piperazinyl) The titled compound was prepared as described in Example 15 by using
3-cycIopropylmethyl-4-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)benzamid o)-l-methylpyrrole-5-carboxamide in place of
4-(2-ethoxy-5-(4-(3-fluoropiOpyl)piperazinylsuIfonyl)benzamido)-3-ethyl-l -methylpy rrole-5-carboxamide. yield: 92% mp 223-224.5 °C (CIi,Cl,/EtO Ac/hexanes);
IR (neat) 3328 (NH), 1685 (CO), 1 171 (SO,) cm'1;
'H NMR (CDCl/TMS) δ 0.27-0.32 (m, 2 Ii, c-C,H5), 0.49-0.55 ( , 2 H, c-C,I-I5),
0.98-1.12 (m, 1 H, c-C3H5), 1 .64 (t, J= 6.9 Hz, 3 H, OCH,CH3), 1. 70-1. 89 (m, 2 H,
CH,CH2F), 2. 47 (1, J= 7. 5 Hz, 2 H, NC 2CH,), 2.54 (dd, J= 4.8 Hz, 4.5 Hz, 4 H, 2 NCH,), 2.65 (d, J = 6.9 Hz, 2 Ii, CHCH,), 3.10 (dd, J = 4.8 Ηz, 4.5 Ηz, 4 Η, 2 S02NCΗ2), 4.10 (s, 3 H, NCH3), 4. 36 (q, J = 6.9 Hz, 2 H, OCH,CH3), 4.43 (dt, J = 47.1 Hz, 6.0 Hz, 2 H, CH,C/J,F), 7.00 (s, 1 H, H-2), 7. 13 (d, J= 8.7 Hz, 1 H, H-3').. 7. 80 (dd, J= 8.7 Hz, 2.4 Hz, 1 H, H-4'), 8. 87 (d, J= 2.4 Hz, I H, H-6'), 10.65 (br s, 1 H, NH); MS (FAB) m/z 532 (MH+).
Example 18
Preparation of 5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l, 6-dihydro-7H-pyrrolo[4,3-< |pyrimidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH„ R4 = CH,CH3; NR6R7 is 4-(3-fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5 -(4-(3 -fluoropropy l)piperazinylsulfony l)pheny 1)- 1 -methyl-3 -77-propy 1- 1 , 6-dihydro-7H-pyrrolo[4,3-_f]pyrimid_n-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydro -7H-pyrrolo[4,3-_ ]pyrimidin-7-one. yield: 99% mp l23 °C dec;
IR (neat) 3318 (NΗ), 1682 (CO), 1169 (SO,) cm'1;
Η NMR (DMSO- ) δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 36 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 58-1. 70 (m, 2 Η, CΗ2CH2CΗ3), 2. 01-2. 15 (m, 2 li, CH2CH2CH2F), 2. 58 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 81 (br t, J= 13. 2 Hz, 2 H, 2 SO2NCHJ, 3. 08-3. 24 (m, 4 H, NCH2CH2 and 2 SO2NCH j, 3. 49-3. 67 ( , 2 H, 2 ÷HNCHJ, 3. 81 (br d, J= 12. 6 Ηz, 2 Η, 2 +ΗNCHJ, 3. 99 (s, 3 Η, NCΗ3), 4. 24 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 51 (dt, J= 46. 8 Hz, 5. 7 Hz, 2 H, CH2CH2F), 7. 25 (s, 1 Η, Η-2), 7. 42 (d, J= 9. 0 Ηz, 1 Η, Η-3'), 7. 88 (dd, J= 9. 0 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 7. 99 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 92 (br s, 1 H, NH+), 11. 83 (br s, 1 H, NH).
Example 19
Preparation of
5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propy 1- 1 , 6-dihydro-7H-pyrrolo[4,3-(i]pyrimidin-7-one sulfuric acid (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH,CH3; NR6R7 is 4-(3-fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyI-l, 6-dihydiO-7H-pyrrolo[4,3-tt]pyrimidin-7-one and 10% ethanolic H2SO4 solution in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro -7H-pyrrolo[4,3-c |pyrimidin-7-one and 1 NΗC1 etheral solution, yield: 90% mp 82 °C dec;
IR (neat) 3314 (ΝΗ), 1717 (CO), 1 166 (SO2) cm'1;
Η ΝMR (DMSO- ) δ 0. 93 (t, J= 7. 2 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 36 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 58-1. 70 (m, 2 Ii, CΗ2CH,CΗ3), 1. 93-2. 11 (m, 2 H, CH,_CH2CH,F), 2. 58 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 56-2. 74 (m, 2 Ii, 2 SO2ΝCHJ, 3. 15-3. 30 (m, 4 H, NCH2CH2 and 2 SO2NCHJ, 3. 53-3. 65 (m, 2 H, 2 +HNCHJ, 3. 75-3. 88 (m, 2 Η, 2 ÷ΗNCHJ, 4. 00 (s, 3 Η, NCΗ3), 4. 25 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 51 (dt, J= 47. 4 Hz, 5. 6 Hz, 2 H, CH2CH2F), 7. 27 (s, 1 Η, Η-2), 7. 44 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 89 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 7. 98 (d, J= 2. 4 Hz, 1 H, H-6'), 9. 30 (br s, 1 H, NH+).
Example 20
Preparation of
5-(2-ethoxy-5 -(4-(3 -fluoropropyl)piperazinylsulfony l)phenyl)- 1 -methyl-3 -77-propy 1- 1 , 6-dihydro-7H-pyrrolo[4,3--/Jpyrimidin-7-one phosphonic acid (a compound of the
formula (1) wherein R5 = SO2NRδR7, R1 = CH3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3-fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l , 6-dihydiO-7H-pyrrolo[4,3-_/]pyrimidin-7-one and 10%) ethanolic Η3PO4 solution in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro -7H-pyrrolo[4,3-ct]pyrimidin-7-one and 1 NΗC1 etheral solution, yield: 91% mp 83 °C dec;
IR (neat) 3311 (ΝΗ), 1662 (CO), 1166 (SO2) cm'1;
"Η ΝMR (DMSO- ) δ 0. 92 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 35 (t, J= 6. 9 Ηz, 3 Η, OCΗ,CH3), 1. 57-1. 70 (m, 2 Η, CΗ2CH,CΗ3), 1. 67-1. 84 (m, 2 Ii, CH,CH2CH2F), 2. 41 (t, J= 7. 2 Hz, 2 H, ΝCH,CH2), 2. 50 (br s, 4 H, 2 NCH2), 2. 57 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 93 (br s, 4 H, 2 SO2NCH2), 3. 99 (s, 3 H, NCH3), 4. 22 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 41 (dt, J= 47. 4 Hz, 5. 7 Hz, 2 H, CH2CH,F), 7. 22 (s, 1 H, H-2), 7. 37 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 Ii, H-4'), 7. 88 (d, J= 2. 4 Hz, 1 H, H-6'), 1 1. 72 (br s, 1 H, NH).
Example 21
Preparation of
5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l, 6-dihydro-7H-pyrrolo[4,3-d]pyrimidin-7-one methanesulfonic acid (a compound of the formula (1) wherein R5 = SO2NR6R7, R' = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3-fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-(3-fluoropropyI)piperazinylsuIfonyI)phenyl)-l-methyl-3-77-propyl-l, 6-dihydro-7H-pyriOlo[4,3-<fJpyrimidin-7-one and 10% CΗ3SO3Η/CΗ,Cl2 solution in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydro -7H-pyrrolo[4,3-_/]pyrimid_n-7-one and 1 NΗC1 etheral solution, yield: 90% mp 74 °C dec; IR (neat) 3321 (ΝΗ), 1683 (CO), 1173 (SO2) cm'1 ;
'Ii ΝMR (DMSO- ) δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 36 (t, J= 6. 9 FTz, 3 Η, OCΗ2CH3), 1. 58-1. 70 (m, 2 Η, CΗ2CH2CΗ3), 1. 93-2. 11 (m, 2 H, CH2CH2CH2F), 2. 33 (s, 3 H, CH3SO3), 2. 58 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 65 (br t, J = 1 1. 4 Hz, 2 H, 2 SO2ΝCHJ, 3. 15-3. 30 (m, 4 H, NCH2CH, and 2 SO2NCHJ, 3. 59 (br d, J= 12. 9 Hz, 2 H, 2 +HNCHJ, ), 3. 81 (br d, J- 12. 9 Ηz, 2 Η, 2 +ΗNCHJ, 4. 00 (s, 3 Η, NCΗ3), 4. 24 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 51 (dt, J= 47. 4 Hz, 5. 7 Hz, 2 H, CH2CH2F), 7. 26 (s, 1 Η, Η-2), 7. 43 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 89 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 7. 98 (d, J= 2. 4 Hz, 1 H, H-6'), 9. 34 (br s, 1 Ii, NH+).
Example 22
Preparation of
5-(5-(4-(3-fluoropropyl)piperazinylsιxlfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-piOpy l-l ,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(3-fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo [4,3-_f]pyrimidin-7-one and 1 -(3-fluoropiOpyl)piperazine hydrochloride in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3- ]pyrimidin-7-one and 1-methylpiperazine. yield: 90% mp 154-154. 5 °C (EtOAc/Et2O/hexanes); IR (neat) 3337 (NΗ), 1684 (CO), 1 168 (SO2) cm'1;
'H NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH,CH3), 1. 19 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 67-1. 87 (m, 4 Η, CΗ2CH2CΗ2F and CH2CH2CH3), 2. 03-2. 10 (m, 2 H, OCH2CH2CH3), 2. 47 (t, J= 7. 2 Hz, 2 H, NCH2CH2), 2. 54 (dd, j = 5. 1 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 11 (br dd, J= 5. 1 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 24 (t, J = 6. 6 Hz, 2 H, OCH2CH2CH3), 4. 43 (dt, J= 47. 1 Hz, 6. 0 Hz, 2 H, CH2CH2F), 6. 89 (s, 1 Η, Η-2), 7. 13 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 81 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 88 (d, J= 2.
4 Hz, 1 H, H-6'), 10. 66 (br s, 1 H, NH); MS (FAB) m/z 534 (MH+).
Example 23
Preparation of
5-(5-(4-(3-fiuoropropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propy l-l,6-dihydro-7H-pyrrolo[4,3-< |pyrimidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH,CH2CH3, R4 - CH2CH2CH3; NR6R7 is 4-(3-fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(5-(4-(3-fluoropropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-piOpy l-l,6-dihydro-7H-pyrrolo[4,3-_/Jpyrimidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro -7H-pyrrolo[4,3-c ]pyrimidin-7-one. yield: 88% mp 105 °C dec;
IR (neat) 3318 (NΗ), 1685 (CO), 1168 (SO2) cm'1; "Η NMR (DMSO-c δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 0. 97 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 58-1. 70 (m, 2 Η, CΗ2CH2CΗ3), 1. 70-1. 80 (m, 2 H, OCH2CH2CH3), 2. 00-2. 17 (m, 2 H, CH2CH2CH2F), 2. 58 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 81 (br t, J = 10. 8 Hz, 2 H, 2 SO2NCHJ, 3. 10-3. 24 (m, 4 H, NCH,CH2 and 2 SO2NCHJ, 3. 56 (br d, J= 12. 0 Hz, 2 H, 2 +HNCHJ, 3. 80 (br d, J = 12. 0 Ηz, 2 Η, 2 +ΗNCHJ, 3. 99 (s, 3 H, NCH3), 4. 14 (t, J = 6. 3 Hz, 2 H,
OCH2CH2CH3), 4. 51 (dt, J= 47. 1 Hz, 5. 7 Hz, 2 H, NCH2CH2F), 7. 24 (s, 1 Η, Η-2), 7. 43 (d, J= 9. 0 Ηz, 1 Η, Η-3'), 7. 87 (dd, J= 9. 0 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 7. 99 (d, J = 2. 4 Hz, 1 H, H-6'), 10. 85 (br s, 1 H, NH+), 11. 75 (br s, 1 H, NH).
Example 24
Preparation of
5-(2-ethoxy-5-(4-((R)-3-fluoro-2-methylpiOpyl)piperazinylsulfonyl)phenyl)-l -methyl- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ |pyrimidin-7-one (a compound of the formula (1) wherein R5 - SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-((R)-3-fluoro-2-methylpropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-((R)-3-fluoro-2-methylpropyl)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 90% mp 212. 5-213 °C (CHCl3/Et2O); [α]D 16 = - 5. 2 ° (c = 2. 0 , CHC13); IR (neat) 3332 (NH), 1676 (CO), 1169 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 0. 92 (d, J= 6. 6 Hz, 3 H, CHCH3), 0. 99 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 64 (t, J = 7. 2 Ηz, 3 Η, OCΗ,CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH,CΗ3), 1. 82-2. 03 (m, 1 H, CHCH3), 2. 16 (ddd, J= 12. 6 Hz, 6. 6 Hz, 1. 8 Hz,
1 Ii, NCH2CH), 2. 33 (dd, J= 12. 6 Hz, 8. 4 Hz, 1 H, NCH2CH), 2. 45-2. 58 (m, 4 Ii,
2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 07-3. 10 (m, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 27 (ddd, J= 47. 4 Hz, 5. 4 Hz, 2. 7 Hz, 2 H, CHCH.F), 4. 36 (q, J= 7. 2 Ηz, 2 Η, OCH2CΗ3), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 1 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 1 Hz, 1 H, H-6'), 10. 63 (br s, 1 H, NH); MS (FAB) 777/z 534 (MH+).
Example 25
Preparation of
5-(2-ethoxy-5-(4-((S)-3-fluoro-2-methylpropyl)piperazinylsulfonyl)phenyl)-l-methyl- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH,CH3, R4 = CH2CH3; NR6R7 is 4-((S)-3-fluoro-2~methylpropyl)piperazinyl) The titled compound was prepared as described in Example 1 by using l-((S)-3-fluoro-2-methylp1Opyl)piperazine hydrochloride in place of
1 -methylpiperazine. yield: 90% mp 212. 5-213 °C (CHCl3/Et2O); [ ]D l6 = + 5. 2 ° (c = 2. 0 , CHC13);
IR (neat) 3332 (NH), 1676 (CO), 1169 (SO2) cm'1;
Η NMR (CDCyTMS) δ 0. 92 (d, J= 6. 6 Hz, 3 H, CHCH3), 0. 99 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 64 (t, J = 7. 2 Ηz, 3 Η, OCΗ2CH3), 1. 67-1. 79 (m, 2 Ii, CΗ2CH2CΗ3), 1. 82-2. 03 (m, 1 H, CHCH,), 2. 16 (ddd, J= 12. 6 Hz, 6. 6 Hz, 1. 8 Hz, 1 H, NCH2CH), 2. 33 (dd, J= 12. 6 Hz, 8. 4 Hz, 1 H, NCH2CH), 2. 45-2. 58 (m, 4 H,
2 NCH,), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 07-3. 10 (m, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 27 (ddd, J= 47. 4 Hz, 5. 4 Hz, 2. 7 Hz, 2 H, CHCH2F), 4. 36 (q, J= 7. 2 Ηz, 2 Η, OCH2CΗ3), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 1 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 1 Hz, 1 H, H-6'), 10. 63 (br s, 1 H, NH); MS (FAB) m/z 534 (MH+).
Example 26
Preparation of
5-(5-(4-(l,3-difluoroisopropyl)piperazinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-pr opyl-l,6-dihydro-7H-pyrrolo[4,3-^pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(l ,3-difluoroisopropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-(l,3-difluoroisopropyl)piperazine hydrochloride in place of 1 -methylpiperazine'.
yield: 75% mp 218. 5-219 °C (CHCl EtOAc/hexanes); IR (neat) 3338 (NH), 1676 (CO), 1170 (SO,) cm'1;
"H NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 67-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 2. 71 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 82 (dd, J = 5. 1 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 87-3. 06 (m, 1 Ii, NCH), 3. 10 (br dd, J= 5. 1 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 56 (dd, J= 48. 0 Hz, 5. 1 Hz, 4 H, 2 CHCH2F), 6. 89 (s, 1 Η, Η-2), 7. 13 (d, J= 9. 0 Ηz, 1 Η, Η-3'), 7. 80 (dd, J= 9. 0 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 86 (d, J = 2. 4 Hz, 1 H, H-6'), 10. 62 (br s, 1 H, NH); MS (FAB) m/z 538 (MH+).
Example 27
Preparation of 5-(2-ethoxy-5-(4-(4-fluorobutyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6
-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one (a compound of the formula (1) wherein
R5 = SO2NR6R7, R1 = CΗ3, R2 - H, R3 = CH,CH2CH3, R4 = CH2CH3; NR6R7 is
4-(4-fluorobutyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 1 -(4-fluorobutyl)piperazine trifluoroacetic acid in place of 1 -methylpiperazine. yield: 53% mp 188-189 °C (EtOAc/CHCl3/hexanes);
IR (neat) 3326 (NH), 1678 (CO), 1167 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 50-1. 70 (m, 4 Η, CΗ2CH2CH2CΗ2F), 1. 64 (t, J = 6. 9 Hz, 3 H, OCH2CH3), 1. 67-1. 79 (m, 2 Η,
CΗ2CH2CΗ3), 2. 37 (dd, J= 7. 5 Hz,7. 2 Hz, 2 H, NCH2CH,), 2. 53 (dd, J= 5. 1 Hz, 4.
8 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 10 (br dd, J= 5. 1 Hz,
4. 8 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3),
4. 40 (dt, J= 47. 1 Hz, 6. 0 Hz, 2 H, CH,CH2F), 6. 89 (s, 1 Η, Η-2), 7. 12 (d, J= 8. 7
Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 63 (br s, 1 H, NH); MS (EI) m/z 533 (M+).
Example 28 Preparation of
5-(5-(4-(4-fluorobutyl)piperazinylsulfonyl)-2-77-propoxypheιιyl)-l-methyl-3-77-propyl- l,6-dihydro-7H-pyrrolo[4,3-_f]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH,CH2CH3; NR6R7 is 4-(4-fluorobutyl)piperazinyl) The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,3-_/jpyrimidin-7-one and l-(4-fluorobutyl)piperazine trifluoroacetic acid in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-< ]pyrinιidin-7-one and 1 -methylpiperazine. yield: 74% mp 162-163 °C (EtOAc/Et,O/hexanes);
IR (neat) 3335 (NΗ), 1683 (CO), 1170 (SO,) cm'1;
'H NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 18 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 50-1. 94 (m, 6 Η, CΗ2CH,CH,CΗ2F and CH2CH,CH3), 1. 98-2. 09 (m, 2 H, OCH2CH2CH3), 2. 40 (t, J= 7. 2 Hz, 2 H, NCH,CH2), 2. 56 (dd, J = 5. 1 Hz, 4. 8 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 12 (br dd, J = 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO,NCH2), 4. 08 (s, 3 H, NCH3), 4. 24 (t, J= 6. 6 Hz, 2 H, OCH,CH2CH3), 4. 40 (dt, J= 47. 4 Hz, 6. 0 Hz, 2 H, CH2CH,F), 6. 89 (s, 1 Η, Η-2), 7. 13 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 81 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 85 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 69 (br s, 1 H, NH); MS (FAB) 777/z 548 (MH+).
Example 29
Preparation of
5-(2-ethoxy-5-(4-(2,2,2-trifluoroethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-piOp
yl-l,6-dihydro-7H-pyrrolo[4,3-_7 pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2,2,2-trifluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-(2,2,2-trifluoroethyl)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 80% mp 243-243. 5 °C (EtOAc/hexanes);
IR (neat) 3337 (NH), 1676 (CO), 1170 (SO2) cm'1;
'H NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 7. 2 Ηz, 3 Η, OCΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 71 (t, J = 7. 5 Hz, 2 H,
CH2CH2CH3), 2. 77 (dd, J= 5. 1 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 96 (q, j = 9. 6 Hz, 2 H,
CH2CF3), 3. 13 (dd, J= 5. 1 Ηz, 4. 5 Ηz, 4 Ii, 2 SO2NCΗ2), 4. 08 (s, 3 H, NCH3), 4.
36 (q, J= 7. 2 Hz, 2 H, OCH2CH3), 6. 89 (s, 1 H, H-2), 7. 13 (d, J = 8. 7 Hz, 1 H,
H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 64 (br s, 1 H, NH); MS (FAB) m/z 542 (MH+).
Example 30
Preparation of
5-(2-77-piOpoxy-5-(4-(2,2,2-trifluoiOethyl)piperazinylsulfony phenyl)- 1 -methyl-3 -77-p ropyl-l,6-dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-(2,2,2-trifluoiOethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyriOlo [4,3-_/|pyrimidin-7-one and l-(2,2,2-triflιιoroethyl)piperazine hydrochloride in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-< ]pyrimidin-7-one and 1 -methylpiperazine. yield: 72%
mp 189. 5-190 °C (EtOAc/hexanes);
IR (neat) 3315 (NH), 1681 (CO), 1172 (SO.) cm'1;
Η NMR (CDC13/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ,CH2CΗ3), 1. 98-2. 10 (m, 2 H, OCH2CH2CH3), 2. 71 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 2. 77 (dd, J= 5. 1 Hz, 4. 8 Hz,
4 H, 2 NCH2), 2. 96 (q, j = 9. 3 Hz, 3 H, CH2CF3), 3. 13 (br dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 S02NCH2), 4. 08 (s, 3 H, NCH,), 4. 25 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 89 (s, 1 H, H-2), 7. 14 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J = 2. 4 Hz, 1 H, H-6'), 10. 67 (br s, 1 H, NH); MS (FAB) m/z 556 (MFL).
Example 31
Preparation of
5-(2-ethoxy-5-(4-(3,3,3-trifluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-pro pyl-l,6-dihydro-7H-pyrrolo[4,3-6T|pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH,CH3; NR6R7 is 4-(3,3,3-trif_ιιoropropyl)piperazinyl)
The titled, compound was prepared as described in Example 1 by using l-(3,3,3-trifluoropropy_)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 87% mp 219-220 °C (EtOAc/hexanes);
IR (neat) 3339 (NH), 1684 (CO), 1168 (SO2) cm'1;
'Ii NMR (CDCl/TMS) δ 0. 99 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 7. 2 Ηz,
3 Η, OCΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 14-2. 30 (m, 2 Ii, CH2CH2CF3), 2. 56 (dd, J= 5. 1 Ηz, 4. 8 Ηz, 4 Η, 2 NCΗ2), 2. 60 (t, J= 7. 5 Hz, 2 Ii,
NCH2CH2CF3), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 1 1 (br dd, J= 5. 1 Hz, 4. 8
Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 36 (q, J= 7. 2 Hz, 2 H, OCH2CH3), 6.
89 (s, 1 H, H-2), 7. 13 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 81 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H,
H-4'), 8. 86 (d, J = 2. 4 Hz, 1 H, H-6'), 10. 63 (br s, 1 H, NH); MS (FAB) m/z 556
(MIL).
Example 32
Preparation of 5-(2-77-propoxy-5-(4-(3,3,3-trifluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77- propyl-l,6-dihydro-7H-pyrrolo[4,3-tt]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-(3,3,3-trifluoropropyl)ρiperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyriOlo
[4,3-£t]pyrimidin-7-one and l-(3,3,3-trifluoropropyl)piperazine hydrochloride in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-< Jpyrimidin-7-one and 1 -methylpiperazine. yield: 81% mp 177-178 °C (EtOAc/Et,O);
IR (neat) 3339 (NΗ), 1676 (CO), 1 171 (SO2) cm'1;
'ΗNMR (CDCyTMS) δ 1. 00 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 19 (t, J= 7. 2 Iiz,
3 Η, OCΗ2CΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 10 (m, 2 H, OCH2CH2CH3), 2. 14-2. 30 (m, 2 H, CH2CH2CF3), 2. 56 (dd, J= 5. 1 Ηz, 4. 8 Ηz, 4 Η,
2 NCΗ,), 2. 60 (t, J = 7. 5 Ηz, 2 Η, NCH2CΗ2CF3), 2. 71 (t, J = 7. 5 Hz, 2 H,
CH,CH2CH3), 3. 1 1 (br dd, J = 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H,
NCH3), 4. 24 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 89 (s, 1 H, H-2), 7. 14 (d, J= 8. 7
Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 Ii, H-4'), 8. 88 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 66 (br s, 1 H, NH); MS (FAB) m/z 570 (MH+).
Example 33
Preparation of
5-(5-(4-(2-chloroethyl)piperazinylsulfonyl)-2-ethoxyphenyl)-l -methyl -3 -77-propyl- 1 ,6
-dihydro-7H-pyrrolo[4,3-ct]pyrimidin-7-one (a compound of the formula (1) wherein
R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is
4-(2-chloroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-(2-chloroethyl)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 87% mp 226 °C dec (CHCl3/Et2O);
IR (neat) 3335 (NH), 1678 (CO), 1172 (SO.) cm'1;
Η NMR (CDCl/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz, 3 Ii, OCΗ2CH,), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 62 (dd, J= 4. 8 Hz, 4. 5 Hz, 4
H, 2 NCH2), 2. 71 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 72 (t, J = 6. 6 Hz, 2 H,
NCH2CH2C1), 3. 12 (br dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 3. 51 (t, J= 6. 6
Hz, 2 H, CH2CH2C1), 4. 08 (s, 3 Η, NCΗ3), 4. 36 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6.
89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 86 (d, J = 2. 7 Hz, 1 H, H-6'), 10. 63 (br s, 1 H, NH); MS (FAB) m/z 522
(M+).
Example 34
Preparation of 5-(5-(4-(3-chloropropyl)piperazinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,
6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one (a compound of the formula (1) wherein
R5 = SO,NRδR7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is
4-(3-chloropropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 1 -(3 -chloropropy l)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 94% mp 203 °C dec (CHCl3/Et2O);
IR (neat) 3333 (NH), 1679 (CO), 1171 (SO.) cm'1;
Η NMR (CDCyTMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 64 (t, J= 6. 9 Ηz,
3 H, OCH2CH3), 1. 67-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 1. 83-1. 91 (m, 2 H, CH2CH2CH2C1),2. 49 (t, J= 6. 9 Hz, 2 H, NCH2CH2), 2. 54 (dd, J= 4. 8 Hz, 4. 2 Hz,
4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 10 (br dd, J= 4. 8 Hz, 4. 2 Hz, 4 H, 2 SO2NCH2), 3. 52 (t, J= 6. 6 Hz, 2 H, CH2CH2C1), 4. 08 (s, 3 Η, NCIi,), 4. 36 (q, J = 6. 9 Ηz, 2 Η, OCH2CΗ3), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 63 (br s, 1 H, NH); MS (FAB) m/z 536 (M+).
Example 35 Preparation of
5-(5-(4-(3-chloropropyl)piperazinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-propyl-l, 6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH„ R4 = CH2CH3; NR6R7 is 4-(3-chloropropyl)piperazinyl) The titled compound was prepared as described in Example 2 by using
5-(5-(4-(3-chloropropyl)piperazinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-piOpyl-l , 6-dihydro-7H-pyrrolo[4,3-_ ]pyriiuidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro -7H-pyrrolo[4,3-<f]pyrimidin-7-one. yield: 99% mp 135 °C dec;
IR (neat) 3338 (NΗ), 1682 (CO), 1166 (SO2) cm'1;
Η NMR (OMSO-d6) δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ,CΗ,CH3), 1. 36 (t, J= 6. 9 Ηz, 3
Η, OCΗ2CH3), 1. 58-1. 70 (m, 2 Η, CΗ2CH2CΗ3), 2. 10-2. 19 (m, 2 Ii, CH2CH2CH2C1), 2. 58 (t, J= 7. 2 Hz, 2 H, CH2CH2CH3), 2. 80 (br t, J= 11. 4 Hz, 2 H, 2 SO,NCHJ, 3. 10-3. 24 (m, 4 H, NCH,CH2 and 2 SO2NCHeq), 3. 54-3. 59 (m, 2 H, 2 +HNCHJ, 3. 71 (t, J= 6. 3 Ηz, 2 Η, CΗ2CH2C1), 3. 77-3. 82 (m, 2 Η, 2 +ΗNCHJ, 3. 99 (s, 3 Η, NCΗ3), 4. 24 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 25 (s, 1 H, H-2), 7. 42 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 88 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 7. 99 (d, J= 2. 7
Hz, 1 H, H-6'), 10. 83 (br s, 1 H, NH+).
Example 36
Preparation of 5-(2-ethoxy-5-(4-(2-hydroxyethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l
,6-dihydro-7H-pyrrolo[4,3-<^pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 1 -(2-hydroxyethyl)piperazine in place of 1 -methylpiperazine. yield: 99% mp 175 °C dec (EtOAc/hexanes);
TR (neat) 3429, 3323 (NH and OH), 1675 (CO), 1 167 (SO.) cm'1;
'H NMR (CDCl TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 7. 2 Iiz, 3 Η, OCΗ2CH3), 1. 68-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 2. 36 (br s, 1 H, OH), 2. 55 (t, J =
5. 4 Hz, 2 H, NCH2CH2), 2. 61 (dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7.
5 Hz, 2 H, CH2CH2CH3), 3. 12 (br dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO2NCH2), 3. 58
(br t, J= 5. 4 Hz, 2 H, CH2CH2OH), 4. 08 (s, 3 H, NCH3), 4. 39 (q, J= 7. 2 Hz, 2 H,
OCH2CH3), 6. 89 (s, 1 H, H-2), 7. 14 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 FIz, 2. 7 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 64 (br s, 1 H, NH); MS (FAB)
Example 37
Preparation of 5-(2-ethoxy-5-(4-(2-hydroxyethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6-dilwdro-7H-pyrrolo[4,3-_ ]pyrirnidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH,CH3, R4 = CH2CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using
5-(2-ethoxy-5-(4-(2-hydroxyethyl)piperazinylsulfonyl)phenyl)- 1 -methyl-3-77-propy 1- 1 ,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydro -7H-pyrrolo[4,3-_ ]pyrimidin-7-one. yield: 99% mp 96 °C dec;
IR (neat) 3327 (NΗ and OΗ), 1679 (CO), 1166 (SO,) cm'1;
Η NMR (DMSO- ) δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 36 (t, J= 7. 2 Ηz, 3 Η, OCΗ2CH3), 1. 58-1. 74 (m, 2 Η, CΗ2CH2CΗ3), 2. 59 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 91 (br t, J = 11. 7 Hz, 2 H, 2 SO2NCHJ, 3. 10-3. 27 (m, 4 Ii, NCH2CH2 and 2 SO2NCHJ, 3. 58 (br d, j = 1 1. 7 Hz, 2 H, 2 +HNCHJ, 3. 68-3. 82 (m, 4 Η, CΗ2CH2OΗ and 2 +HNCHeq), 4. 00 (s, 3 Η, NCΗ3), 4. 10 (br s, 1 H, OH), 4. 23 (q, J = 7. 2 Hz, 2 H, OCH2CH3), 7. 26 (s, 1 H, H-2), 7. 42 (d, J = 9. 0 Hz, 1 H, H-3'), 7. 88 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 00 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 60 (br s, 1 H, NH+), 11. 95 (br s, 1 H, NH).
Example 38
Preparation of
5-(5-(4-(2-hydroxyethyl)piperazinylsιxlfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-prop yl-l ,6-dihydro-7H-pyrrolo[4,3-<i]pyrimidm-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Ii, R3 = CH2CH2CH3, R4 = CH2CH,CH3;
NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compoimd was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo [4,3-< ]pyrimidin-7-one and l-(2-hydroxyethyl)piperazine in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-</]pyrimidm-7-one and 1 -methylpiperazine. yield: 98% mp 228 °C dec (EtOAc/hexanes);
IR (neat) 3539, 3338 (NH and OH), 1677 (CO), 1 167 (SO2) cm'1; Η NMR (CDCyTMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 67-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 10 (in, 2 H, OCH2CH2CH3), 2. 34 (br s, 1 H, OH), 2. 55 (t, J= 5. 4 Hz, 2 H, NCH2CH2), 2. 61 (dd, J= 5. 1 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 12 (br dd, J= 5. 1 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 3. 57 (br s, 2 H, CH2CH2OH), 4. 08 (s, 3 H, NCH,), 4. 25 (t, J= 6. 3 Hz, 2 H, OCH2CH,CH3), 6. 89 (s, 1 H, H-2), 7. 15 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 88 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 67 (br s, 1 H, NH); MS (FAB) 777/z 518 (MH+).
Example 39
Preparation of
5-(5-(4-(2-hydroxyethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-r?-prop yl-l ,6-dihydro-7H-pyrrolo[4,3-< ]pyrimidin-7-one hydrocliloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(5-(4-(2-hydroxyethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-prop yl-l,6-dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one in place of 5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydiO -7H-pyrrolo[4,3-<^pyrimidin-7-one. yield: 99% mp 66. 5 °C dec; IR (neat) 3332 (NΗ and OΗ), 1676 (CO), 1 166 (SO2) cm'1; Η NMR (DMSO- ,) δ 0. 92 (t, J= 7. 2 Ηz, 3 Η, CΗ,CΗ2CH3), 0. 96 (t, J= 7. 2 Ηz, 3 Ii, OCΗ2CΗ2CH3), 1. 56-1. 80 (m, 4 Ii, 2 CΗ,CH2CΗ3), 2. 59 (t, J = 7. 5 Hz, 2 H, CH2CH,CH3), 2. 91 (br t, J = 1 1. 7 Hz, 2 H, 2 SO2NCHJ, 3. 12-3. 27 (m, 4 H, NCH2CH2 and 2 SO2NCHJ, 3. 58 (br d, j = 11. 7 Hz, 2 H, 2 +HNCHJ, 3. 68-3. 85 (m, 4 Η, CΗ2CH2OΗ and 2 +HNCHJ, 4. 00 (s, 3 Η, NCΗ3), 4. 15 (t, J= 6. 3 Hz, 2 H,
OCH,CH2CH3), 4. 66 (br s, 1 H, OH), 7. 28 (s, 1 H, H-2), 7. 44 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 89 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 01 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 85 (br s, 1 H, NH+), 12. 01 (br s, 1 H, NH).
Example 40
Preparation of
5-(2-ethoxy-5-(4-(3-hydroxyρropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl- l,6-dihydro-7H-pyrrolo[4,3-(/Jpyrimidin-7-one (a compound of the formula (1) wherein R5 - SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3-hydroxypropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-(3-hydroxypropyl)piperazine in place of 1 -methylpiperazine. yield: 99% mp 180. 5 °C dec (EtOAc/ hexanes); IR (neat) 3460, 3331 (NH and OH), 1677 (CO), 1 168 (SO2) cm'1 ;
Η NMR (CDCl TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 65 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 67-1. 80 (m, 4 Η, CΗ2CH2CΗ2OΗ and CH2CH2CH3), 2. 58-2. 65 (m, 6 H, NCH2CH2 and 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH,CH3), 3. 09 (br s,
4 H, 2 SO,_NCH2), 3. 71 (t, J= 5. 4 Hz, 2 H, CH,CH,OH), 4. 08 (s, 3 H, NCH3), 4. 26 (br s, 1 H, OH), 4. 37 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 88 (s, 1 H, H-2), 7. 13 (d, J=
8. 7 Hz, 1 H, H-3'), 7. 77 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 65 (br s, 1 H, NH); MS (FAB) m/z 518 (MH+).
Example 41 Preparation of
5-(2-ethoxy-5-(4-(3-hydroxypropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyI- l,6-dihydiO-7H-pyrrolo[4,3-- ]pyrimidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3-hydroxypropyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-(3-hydroxypropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl- l,6~dihydro-7H-pyrrolo[4,3-_ |pyrirnidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro -7H-pyrrolo [4,3-_ ]pyrimidin-7-one. yield: 98% mp 81 °C dec;
IR (neat) 3333 (NΗ and OΗ), 1684 (CO), 1163 (SO2) cm'1; Η NMR (DMSO-O δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 35 (t, J= 7. 2 Ηz, 3 Η, OCΗ2CH3), 1. 58-1. 76 (m, 2 Η, CΗ2CH,CΗ3), 1. 78-1. 90 (m, 2 H, CH2CH2CH2OH), 2. 59 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 84 (br t, J= 11. 7 Hz, 2 H, 2 SO2NCHJ, 3. 04-3. 20 (m, 4 H, NCH2CH2 and 2 SO2NCHJ, 3. 42 (t, J = 6. 3 Hz, 2 H, CH2CH2OH), 3. 52 (br d, J= 1 1. 7 Hz, 2 H, 2 ÷HNCHJ, 3. 80 (br d, J= 1 1. 7 Ηz, 2 Η, 2 +ΗNCHJ, 4. 00 (s, 3 Η, NCΗ3), 4. 21 (br s, 1 Ii, OH), 4. 23 (q, J= 7. 2 Hz, 2 H, OCH2CH3), 7. 27 (s, 1 H, H-2), 7. 43 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 87 (dd, J = 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 00 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 05 (br s, 1 H, NH+), 1 1. 95 (br s, 1 H, NH).
Example 42 Preparation of
5-(5-(4-(3-hydroxypropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-pro pyl-l ,6-dihydro-7H-pyrrolo[4,3-< Jpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NR6R7, R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH2CH,CH3; NR6R7 is 4-(3-hydroxypropyl)piperazinyl) The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo [4,3--7]pyrimidin-7-one and l-(3-hydroxypropyl)piperazine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydiO-7H-pyrrolo[4, 3-<f]pyrimidin-7-one and 1 -methylpiperazine.
yield: 94% mp 162. 5 °C dec (EtOAc/hexanes);
IR (neat) 3484, 3302 (NH and OH), 1669 (CO), 1170 (SO2) cm'1; Η NMR (CDC13/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 20 (t, J= 7. 5 Ηz, 3 Η, OCΗ,CΗ,CH3), 1. 64-1. 80 (m, 4 Η, CΗ,CH2CΗ2OΗ and CH,CH2CH3), 1. 99-2. 1 1 (m, 2 H, OCH2CH2CH3), 2. 58-2. 64 (m, 6 H, NCH2CH2 and 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 08 (br s, 4 Ii, 2 SO2NCH2), 3. 71 (t, J= 5. 4 Hz, 2 Ii, CH2CH2OH), 4. 08 (s, 3 H, NCH3), 4. 26 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 4. 28 (br s, 1 Ii, OH), 6. 88 (s, 1 H, H-2), 7. 14 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 77(dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 69 (br s, 1 H, NH); MS (FAB) /z 532 (MH+).
Example 43
Preparation of 5-(5-(4-(3-hydroxypropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-pro pyl-l ,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH,CH3, R4 =
CH2CH2CH3; NR6R7 is 4-(3-hydroxypropyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(5-(4-(3-hydroxypropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-pro pyl-l,6-dihydro-7H-pyrrolo[4,3-t ]pyrimidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro
-7H-pyrrolo[4,3-_/]pyrimidin-7-one. yield: 99% mp 62. 5 °C dec;
IR (neat) 3347, 3321 (NΗ and OΗ), 1689 (CO), 1 168 (SO2) cm'1;
Η NMR (OMSO-d6) δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 0. 96 (t, J= 7. 5 Ηz, 3
Η, OCΗ,CΗ2CH3), 1. 57-1. 87 (m, 6 Η, CΗ2CH2CΗ2OΗ and 2 CH2CH2CH3), 2. 59 (t,
J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 89 (br t, J= 11. 7 Hz, 2 H, 2 SO2NCHJ, 3. 01-3.
19 (m, 4 H, NCH2CH2 and 2 SO2NCHJ, 3. 44 (t, J= 6. 0 Hz, 2 H, CH2CH2OH), 3. 52 (br d, J= 11. 7 Hz, 2 H, 2 +HNCHJ, 3. 79 (br d, J= 1 1. 7 Ηz, 2 Η, 2 +ΗNCHeq), 4. 00 (s, 3 Η, NCΗ3), 4. 15 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 4. 71 (br s, 1 H, OH), 7. 29 (s, 1 Ii, H-2), 7. 44 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 89 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 02 (d, J= 2. 4 Hz, 1 H, H-6'), 1 1. 13 (br s, 1 H, NH+), 12. 05 (br s, 1 H, NH).
Example 44
Preparation of
5-(2-ethoxy-5-(4-(4-hydroxybutyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-_/ pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NRδR7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(4-hydroxybutyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-(4-hydroxybutyl)piperazine in place of 1 -methylpiperazine. yield: 72% mp 196. 5 °C dec (EtOAc/hexanes);
IR (neat) 3332 (NH and OH), 1676 (CO), 1 168 (SO,) cm'1;
■ii NMR (CDCl/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Hz,
3 H, OCH2CH3), 1. 60-1. 79 (m, 6 Η, CΗ2CH2CH2CΗ2 and CH2CH2CH3), 2. 41 (br s, 2 H, NCH2CH2), 2. 60 (br t, J = 4. 8 Hz, 4 H, 2 NCH2), 2. 71 (t, J = 7. 5 Hz, 2 Ii, CH,CH2CH3), 3. 13 (br s, 4 H, 2 SO2NCH2), 3. 49 (br s, 2 H, CH2CH2OH), 4. 08 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 78 (br s, 1 H, OH), 6. 88 (s, 1 H, H-2), 7. 12 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 77 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 7 Hz, 1 Ii, H-6'), 10. 66 (br s, 1 H, NH); MS (EI) m/z 532 (MH+).
Example 45
Preparation of
5-(2-ethoxy-5-(4-(4-hydroxybutyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l
,6-dihydro-7H-pyrrolo[4,3-cf]pyrimidin-7-one hydrochloride (a compound of the
formula (1) wherein R5 = SO2NR6R7, R1 = CH3, R2 = H, R3 = CH2CH2CH„ R4 = CH2CH3; NR6R7 is 4-(4-hydroxybutyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-(3-hydroxybutyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydro -7H-py rro lo [4, 3 -d] pyrimidin-7-one . yield: 98% mp 62 °C dec; IR (neat) 3334 (NΗ and OΗ), 1680 (CO), 1167 (SO2) cm'1;
Η NMR (DMSO-O δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 36 (t, J= 7. 2 Ηz, 3 Η, OCΗ,CH3), 1. 37-1. 52 (m, 2 Η, NCΗ2CΗ,CH2CΗ2), 1. 58-1. 80 (m, 4 H, NCH2CH2CH2CH2 and CH2CH2CH3), 2. 58 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 84 (br t, J = 11. 7 Hz, 2 H, 2 SO2NCHJ, 3. 00-3. 18 (m, 4 H, NCH2CH2 and 2 SO2NCHJ, 3. 39 (t, J= 6. 3 Hz, 2 H, CH2CH2OH), 3. 48 (br d, J= 11. 7 Hz, 2 Ii, 2 +HNCHJ, 3. 79 (br d, J= 11. 7 Ηz, 2 Η, 2 +ΗNCHJ, 3. 99 (s, 3 Η, NCΗ,), 4. 22 (q, J = 7. 2 Ηz, 2 Η, OCH,CFI3), 7. 26 (s, 1 Η, Η-2), 7. 42 (d, J= 9. 0 Ηz, 1 Η, Η-3'), 7. 84 (dd, J= 9. 0 Iiz, 2. 4 Ηz, 1 Η, Η-4'), 8. 00 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 02 (br s, 1 H, NH+), 11. 84 (br s, 1 H, NH).
Example 46
Preparation of
5-(5-(4-(4-hydroxybutyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-prop yl-l,6-dihydro-7H-pyrrolo[4,3-< Jpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Ii, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(4-hydroxybutyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydiO-7H-pyrrolo [4,3-c/]pyrimidin-7-one and l-(4-hydroxybutyl)piperazine in place of
5-(5-clιlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-?7-propyl-l,6-dihydro-7H-pyπOlo[4, 3-_ ]pyrimidin-7-one and 1 -methylpiperazine. yield: 61% mp 1 19 °C dec (EtOAc/Et2O/hexanes); IR (neat) 3469, 3300 (NΗ and OΗ), 1670 (CO), 1169 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 1. 00 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 20 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 60-1. 79 (m, 6 Η, CΗ2CH2CH2CΗ2 and CH2CH2CH3), 1. 99-2. 1 1 (m, 2 H, OCH2CH2CH3), 2. 41 (br s, 2 H, NCH2CH2), 2. 61 (br t, j = 4. 8 Hz, 4 Ii, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 13 (br s, 4 H, 2 SO2NCH2), 3. 49 (br s, 2 H, CH2CH2OH), 4. 08 (s, 3 H, NCH,), 4. 25 (t, J = 6. 3 Hz, 2 H, OCH,CH2CH3), 4. 83 (br s, 1 H, OH), 6. 88 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 77 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 69 (br s, 1 H, NH); MS (FAB) m/z 546 (MH+).
Example 47
Preparation of
5-(5-(4-(4-hydroxybutyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-prop yl-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one hydrochloride (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(4-hydroxybutyl)piperazinyl)
The titled compound was prepared as described in Example 2 by using 5-(5-(4-(4-hydroxybιxtyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-prop yl-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one in place of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydro -7H-pyrrolo[4,3-fi pyrimidin-7-one. yield: 98% mp 58 °C dec;
IR (neat) 3333 (NΗ and OΗ), 1679 (CO), 1167 (SO2) cm'1; Η NMR (DMSO-d6) δ 0. 93 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 0. 96 (t, J= 7. 5 Ηz, 3
H, OCH2CH2CH3), 1. 36-1. 45 (m, 2 Η, NCΗ2CΗ2CH2CΗ2), 1. 56-1. 80 (m, 6 H, NCH2CH2CH2CH2 and 2 CH2CH2CH3), 2. 59 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 89 (br t, J = 1 1. 7 Hz, 2 H, 2 SO2NCHJ, 3. 00-3. 18 (m, 4 H, NCH2CH, and 2 SO2NCHJ, 3. 39 (t, J= 6. 3 Hz, 2 H, CH2CH2OH), 3. 51 (br d, J= 11. 4 Hz, 2 Ii, 2 +HNCHJ, 3. 80 (br d, J= 11. 4 Ηz, 2 Η, 2 +ΗNCHJ, 4. 00 (s, 3 Η, NCΗ3), 4. 15 (t, J = 6. 3 Hz, 2 H, OCH2CH2CH3), 4. 80 (br s, 1 H, OH), 7. 29 (s, 1 H, H-2), 7. 44 (d, J = 9. 0 Hz, 1 H, H-3'), 7. 89 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 02 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 14 (br s, 1 H, NH+), 12. 12 (br s, 1 H, NH).
Example 48
Preparation of
5-(2~(2-fluoroethoxy)-5-(4-(2-fluoiOethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-p ropyl-l,6-dihydro-7H-pyrrolo[4,3-< ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2F; NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-(2-fluoroethoxy)phenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H- pyrrolo[4,3-t/]pyrimidin-7-one and l-(2-fluoroethyl)piperazine hydrochloride in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methy]-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-_ ]pyrimidin-7-one and 1 -methylpiperazine. yield: 95% mp 165. 5-166 °C (EtOAc/Et2O/hexanes); IR (neat) 3357 (NΗ), 1678 (CO), 1169 (SO2) cm'1; Η NMR (CDCyTMS) δ 0. 99 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 69-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 2. 63-2. 76 (m, 6 H, NCH2CH2F and 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 14 (br dd, J = 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 40-4. 59 (m, 4 H, OCH2CH2F and NCH,CH2F), 4. 82-5. 01 (m, 2 Η, OCΗ2CH2F), 6. 88 (s, 1 Η, Η-2), 7. 15 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8. 7
Hz, 2. 4 Hz, 1 H, H-4'), 8. 82 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 40 (br s, 1 H, NH); MS (FAB) m/z 524 (MIL).
Example 49 Preparation of
5 -(2-(2 -fluoroethoxy)-5 -(4-(3 -fluoropropy piperazinylsulfony l)phenyl)- 1 -methy 1 -3 -/7- propyl- l,6-dihydro-7H-pyrrolo[4,3-_/|pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH,CH2CH3, R4 = CH2CH2F; NR6R7 is 4-(3-fluoropropyI)piperazinyl) The titled compoimd was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-(2-fluoroethoxy)phenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H- pyrrolo[4,3-fiT|pyrimidin-7-one and l-(3-fluoropropyl)piperazine hydrochloride in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyriOlo[4, 3-< Jpyrimidin-7-one and 1 -methylpiperazine. yield: 95% mp 179-180 °C (EtOAc/Et2O/hexanes); IR (neat) 3358 (NΗ), 1678 (CO), 1 171 (SO2) cm'1; Η NMR (CDCl TMS) δ 0. 99 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 65-1. 89 (m, 4 Η, CΗ,CH2CΗ2F and CH2CH,CH3), 2. 48 (t, J= 7. 2 Hz, 2 H, NCH2CH2), 2. 52-2. 58 (m, 4 H, 2 NCH2), 2. 71 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 06-3. 15 (m, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 44 (dt, J= 46. 8 Hz, 6. 0 Hz, 2 H, NCH2CH,F), 4. 45-4. 56 (m, 2 Η, OCH2CΗ,F), 4. 81-5. 00 (m, 2 H, OCH2CH2F), 6. 89 (s, 1 Η, Η-2), 7. 15 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 83 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 81 (d, J = 2. 4 Hz, 1 H, H-6'), 10. 39 (br s, 1 H, NH); MS (FAB) m/z 538 (MH+).
Example 50
Preparation of
5-(2-ethoxy-5-(4-(2-fluoroethyl)homopiperazinylsulfonyl)phenyl)-l-methyl-3-77-prop
yl-l,6-dihydro-7H-pyrrolo[4,3-_ yrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-fluoroethyl)homopiperazinyl)
The titled compound was prepared as described in Example 1 by using and 1 -(2-fluoroethyl)homopiperazine hydrochloride in place of 1 -methylpiperazine. yield: 92% mp 1 18-1 18. 5 °C (EtOAc/Et2O);
IR (neat) 3322 (NH), 1693 (CO), 1 147 (SO2) cm'1;
■H NMR (CDCyTMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 63 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 67-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 1. 79-1. 97 (m, 2 H,
NCH2CH2CH2N), 2. 71 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 80-2. 95 ( , 6 H,
NCH2CH2F and 2 NCH2), 3. 42-3. 49 (m, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4.
35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 49 (dt, J= 47. 1 Hz, 5. 4 Hz, 2 H, NCH2CH,F),
6. 89 (s, 1 Η, Η-2), 7. 10 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 85 (dd, J= 8. 7 Ηz, 2. 7 Ηz, 1 Η, Η-4'), 8. 89 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 64 (br s, 1 H, NH); MS (FAB) m/z 520
(MH+).
Example 51
Preparation of 5-(2-ethoxy-5-(4-(3-fluoropropyl)homopiperazinylsulfonyl)phenyl)-l-methyl-3-77-pro pyl-l ,6-dihydro-7H-pyrrolo[4,3--/|pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3 -fluoropropy l)homopiperaziny 1)
The titled compound was prepared as described in Example 1 by using 1 -(3-fluoiOpropyl)homopiperazine hydrochloride in place of 1 -methylpiperazine. yield: 74% mp 107-108 °C (EtOAc/Et2O);
IR (neat) 3322 (NH), 1686 (CO), 1148 (SO,) cm'1;
Η NMR (CDCl/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 63 (t, J= 6. 9 Ηz, no
3 H, OCH2CH3), 1. 72-1. 79 (m, 4 Η, CΗ2CH2CΗ2F and CH2CH2CH3), 1. 83-1. 87 (m, 2 H, NCH2CH2CH2N), 2. 61 (t, J= 6. 9 Hz, 2 H, NCH2CH2), 2. 68-2. 75 (m, 4 H, 2 NCH,), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH,CH3), 3. 43 (br dd, J= 5. 7 Hz, 5. 4 Hz, 4 H,
2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 46 (dt, J = 47. 1 Hz, 5. 7 Hz, 2 H, CH2CH2F), 6. 89 (s, 1 Η, Η-2), 7. 10 (d, J = 8. 7 Ηz, 1 Η,
Η-3'), 7. 84 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 89 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 65 (br s, 1 H, NH); MS (FAB) 777/z 534 (MH+).
Example 52 Preparation of
5-(2-ethoxy-5-(4-(2-(2-fluoroethoxy)ethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77- propyl- l,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7 -one (a compound of the formula (1) wherein R5 = SO,NR6R7, R1 - CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-(2-fluoroethoxy)ethyl)piperazinyl) The titled compound was prepared as described in Example 1 by using and l-(2-(2-fluoroethoxy)ethyl)piperazine trifluoroacetic acid in place of
1 -methylpiperazine. yield: 92% mp 167. 5-169 °C (MeOH/H2O); IR (neat) 3325 (NH), 1679 (CO), 1169 (SO2) cm'1;
Η NMR (CDCl/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 67-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 2. 59-2. 63 (m, 6 H, NCH2CH2F and 2 NCH2), 2. 71 (t, J = 7. 5 Hz, 2 H, CH2CH,CH3), 3. 09-3. 13 (m, 4 H, 2 SO2NCH2), 3. 57-3. 72 (m, 4 H, 2 OCH,CH2), 4. 09 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9 Hz, 2 Ii, OCH2CH3), 4. 42-4. 60 (m, 2 H, OCH2CH,F), 6. 89 (s, 1 Η, Η-2), 7. 12 (d, J = 8. 4 Ηz, 1 Η, Η-3'), 7. 81 (dd, J= 8. 4 Ηz, 2. 4 Ηz, 1 Η, Η-4*), 8. 87 (d, J= 2. 4 Ηz, 1 Η, Η-6'), 10. 62 (br s, 1 H, NH); MS (FAB) m/z 550 (MIL).
Example 53
i l l
Preparation of
5-(5-(4-(t-butylaminocarbonylmethyl)piperazinylsulfonyl)-2-ethoxyphenyl)-l-methyl- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-tt]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 - CH2CH3; NR6R7 is 4-(t-butylaminocarbonylmethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-(t-bιιtylaminocarbonylmethyl)piperazine trifluoroacetic acid in place of 1 -methylpiperazine. yield: 69% mp 192. 5-193 °C (EtOAc/Et2O/hexanes);
IR (neat) 3320 (NH), 1678 (CO), 1167 (SO2) cm'1;
Η NMR (CDCl TMS) δ 1. 00 (t, J = 7. 5 Hz, 3 H, CH2CH2CH3), 1. 29 (s, 9 Η, 3 CΗ,), 1. 64 (t, J = 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 64-1. 77 (m, 2 Η, CΗ,CH2CΗ3), 2. 61 (br dd, J= 5. 4 Hz, 4. 5 Hz, 4 H, 2 NCH,), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 90 (s, 2 H, CH2CO), 3. 14 (br dd, J= 5. 4 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 09 (s, 3 H, NCH3), 4. 37 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 61 (br s, 1 H, CONH), 6. 89 (s, 1 Ii, H-2), 7. 15 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 83 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 61 (br s, 1 H, NH); MS (FAB) m/z 573 (MH+).
Example 54
Preparation of
5-(5-(4-(t-butylaminocarbonylmethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-met hyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ |pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NRδR7, R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(t-butylaminocarbonylmethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo [4,3-c/]pyrimidin-7-one and l-(t-butylaminocarbonylmethyl)piperazine trifluoroacetic acid in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3-7-.-propyl- 1 ,6-dihydro-7H-pyrrolo [4, 3-_ ]pyrimidin-7-one and 1 -methylpiperazine. yield: 68% mp 164. 5-165. 5 °C (EtOAc/Et2O/hexanes); IR (neat) 3330, 3303 (NΗ), 1684 (CO), 1169 (SO2) cm'1;
'Η NMR (CDCl/TMS) δ 1. 00 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 19 (t, J= 7. 5 Ηz, 3 Η, OCΗ,CΗ2CH3), 1. 29 (s, 9 Η, 3 CΗ3), 1. 68-1. 78 (m, 2 H, CH2CH2CH3), 1. 98-2. 08 (m, 2 H, OCH2CH2CH3), 2. 58-2. 63 (m, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 91 (s, 2 H, CH2CO), 3. 12-3.17 (m, 4 H, 2 SO2NCH2), 4. 09 (s, 3 Ii, NCH,), 4. 25 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 63 (br s, 1 H, CONH), 6. 90 (s, 1 H, H-2), 7. 16 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 83 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 88 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 64 (br s, 1 H, NH); MS (FAB) m/z 587 (MH+).
Example 55 Preparation of
5-(2-ethoxy-5-(4-(4-fluorophenyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,
6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein
R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH,CH3, R4 = CH2CH3; NR6R7 is
4-(4-fluorophenyl)piperazinyl) The titled compound was prepared as described in Example 1 by using l-(4-fluorophenyl)piperazine in place of 1 -methylpiperazine. yield: 95% mp 226-227 °C (CHCl3/Et2O);
IR (neat) 3337 (NH), 1678 (CO), 1169 (SO,) cm'1; Η NMR (CDCl/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 68-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 2. 72 (t, J = 7. 5 Hz, 2 H,
CH2CH2CH3), 3. 15-3. 26 (m, 8 H, 4 NCH2), 4. 08 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9
Hz, 2 H, OCH2CH3), 6. 80-6. 84 (m, 2 H, ArH-2 and 6), 6. 89 (s, 1 H, H-2), 6. 91-6.
97 (m, 2 H, ArH-3 and 5), 7. 15 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 84 (dd, J= 8. 7 Hz, 2. 4
Hz, 1 H, H-4'), 8. 90 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 63 (br s, 1 H, NH); MS (FAB) m/z 554 (MIL).
Example 56 Preparation of
5-(2-ethoxy-5-(4-(2-pyridyl)piperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propyl- 1 ,6-d ih ydro-7H-pyrrolo[4,3-_/Jpyrimidin-7-one (a compound of the formula (1) wherein R5 =
SO,NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is
4-(2-pyridyl)piperazinyl) The titled compound was prepared as described in Example 1 by using
1 -(2-pyridyl)piperazine in place of 1 -methylpiperazine. yield: 99% mp 203-204 °C (CHCl3/Et2O/hexanes);
IR (neat) 3334 (NH), 1673 (CO), 1169 (SO,) cm'1; Η NMR (CDC13/TMS) δ 1. 01 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 62 (t, J= 6. 9 Ηz,
3 Η, OCΗ,CH3), 1. 68-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 2. 72 (t, J = 7. 5 Hz, 2 Ii, CH,CH2CH3), 3. 19 (dd, J= 5. 4 Hz, 5. 1 Hz, 4 H, 2 NCH2), 3. 66 (dd, J= 5. 4 Hz, 5. 1 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH,), 4. 34 (q, J= 6. 9 Hz, 2 H, OCH,CH3), 6. 58 (d, J= 8. 7 Hz, 1 H, PyrH-3), 6. 60-6. 64 (m, 1 H, PyrH-5), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 45 (ddd, J= 8. 7 Hz, 7. 2 Hz, 2. 1 Hz, 1 H, PyrH-4), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 12-8. 15 (m, 1 H, PyrH-6), 8. 88 (d, J= 2.
4 Hz, 1 H, H-6'), 10. 62 (br s, 1 H, NH); MS (FAB) 777/z 537 (MH+).
Example 57 Preparation of
5-(2-ethoxy-5-(4-(2-pyrimidyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-piOpyl-l,6-d ihydiO-7H-pyrrolo[4,3-£ ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-pyrimidyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using l-(2-pyrimidyl)piperazine dihydrochloride in place of 1 -methylpiperazine. yield: 94% mp 200-201 °C (CHCl3/Et2O); IR (neat) 3329 (NH), 1679 (CO), 1168 (SO2) cm'1 ;
'HNMR (CDCyTMS) δ 1. 01 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 62 (t, J= 6. 9 Ηz, 3 Η, OCΗ,CH3), 1. 68-1. 80 (m, 2 Η, CΗ,CH,CΗ3), 2. 71 (t, J = 7. 5 Hz, 2 Ii, CH2CH2CH3), 3. 14 (dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 NCH2), 3. 96 (dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 34 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 48 (d, J= 4. 8 Hz, 1 H, PyrH-5), 6. 88 (s, 1 H, H-2), 7. 12 (d, J= 8. 7 Hz, 1 H, H-3*), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 25 (d, J= 4. 8 Hz, 2 H, PyrH-4 and H-6), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 61 (br s, 1 H, NH); MS (FAB) m/z 538 (MH+).
Example 58 Preparation of l,2-dimethyl-5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-3-77-propyl-l,6-dih ydro-7H-pyrrolo[4,3-t/]pyrimidin-7-one (a compound of the formula (1) wherein R3 = SO2NR6R7, R1 = R2 = CΗ3, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-methylpiperazinyl) The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfdnyl-2-ethoxyphenyl)-l,2-dimethyl-3-77-propyl-l,6-dihydro-7H-pyπOl o[4,3-i ]pyrimidin-7-one in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3 -c |pyrimidin-7-one . yield: 84*% mp 232 °C dec (CΗCl3/Et2O/hexanes);
IR (neat) 3340 (NH), 1672 (CO), 1172 (SO2) cm'1;
Η NMR (CDCl TMS) δ 0. 94 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 63 (t, J= 7. 2 Ηz,
3 Η, OCΗ2CH3), 1. 64-1. 73 (m, 2 Η, CΗ,CH,CΗ3), 2. 28 (s, 3 H, NCH3), 2. 31 (s, 3
H, CH,), 2. 51 (br dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 68 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 12 (br dd, J = 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 04 (s, 3 H, NCH3), 4. 35 (q, J= 7. 2 Hz, 2 H, OCH2CH3), 7. 1 1 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 80 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 88 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 59 (br s, 1 H, NH); MS (FAB) m/z 488 (MH+).
Example 59
Preparation of
1 ,2-dimethyl-5-(5-(4-methylpiperazinylsulfonyl)-2-77-propoxyphenyl)-3-77-propyl- 1 ,6- dihydro-7H-pyrrolo[4,3--f]pyrimidin-7-one (a compound of the formula (1) wherein
R5 = SO2NR6R7, R1 = R2 = CΗ3, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is
4-methylpiperazinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chloiOsulfonyl-2-77-propoxyphenyl)-l,2-dimethyl-3- 7-propyl-l,6-dihydro-7H-pyr rolo[4,3-_ ]pyrimidin-7-one in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydiO-7H-pyrrolo[4,
3-d] py rimidin-7-one . yield: 82% mp 199. 5-200 °C (CΗCl3/Et2O/hexanes); IR (neat) 3311 (NH), 1677 (CO), 1175 (SO,) cm'1;
Η NMR (CDCyTMS) δ 0. 94 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 18 (t, J= 7. 5 Ηz,
3 Η, OCΗ,CΗ2CH3), 1. 61-1. 73 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 09 (m, 2 H,
OCH2CH2CH3), 2. 26 (s, 3 H, NCH3), 2. 31 (s, 3 H, CH3), 2. 49 (dd, J= 5. 1 Hz, 4. 8
Hz, 4 Ii, 2 NCH2), 2. 68 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 11 (br dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO2NCH2), 4. 04 (s, 3 H, NCH3), 4. 23 (t, J = 6. 6 Hz, 2 H,
OCH2CH2CH3), 7. 12 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H,
H-4'), 8. 89 (d, J = 2. 4 Hz, 1 H, H-6'), 10. 61 (br s, 1 H, NH); MS (FAB) m/z 502
(MH+).
Example 60
Preparation of l,2-dimethyl-5-(2-ethoxy-5-(4-(2-fluoroethyl)piperazinylsulfonyl)phenyl)-3-77-propyl- l,6-dihydro-7H-pyrrolo[4,3--dpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = R2 = CΗ3, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 ,2-dimethyl-3-77-propyl-l ,6-dihydro-7H-pyrrol o[4,3-_/Jpyrimidin-7-one and l-(2-fluoroethyl)piperazine hydrochloride in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo[4, 3-fi(]pyrimidin-7-one and 1 -methylpiperazine. yield: 80% mp 194. 5 °C (CΗCl3/Et2O/hexanes); IR (neat) 3340 (NH), 1669 (CO), 1169 (SO2) cm'1; Η NMR (CDCl TMS) δ 0. 94 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J = 6. 9 Ηz, 3 Η, OCΗ,CH3), 1. 65-1. 74 (m, 2 Η, CΗ,CH2CΗ3), 2. 31 (s, 3 H, CH3), 2. 62-2. 76 (m, 8 H, NCH2CH2F, 2 NCH2 and CH2CH,CH3), 3. 14 (br s, 4 H, 2 SO2NCH2), 4. 04 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 50 (dt, J= 47. 4 Hz, 4. 5 Hz, 2 H, NCH2CH2F), 7. 12 (d, J= 9. 0 Ηz, 1 Η, Η-3'), 7. 80 (dd, J= 9. 0 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 88 (d, J = 2. 4 Ηz, 1 Η, Η-6'), 10. 59 (br s, 1 H, NH); MS (FAB) m/z 520 (MH+).
Example 61
Preparation of l,2-dimethyl-5-(5-(4-(2-fluoroethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-3-77-pro pyl-l,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = R2 = CΗ„ R3 = CH,CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l,2-dimethyl-3-77-propyl-l,6-dihydro-7H-pyr rolo[4,3-^pyrimidin-7-one and l-(2-fluoroethyl)piperazir_e hydrochloride in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-d]pyrimidin-7-one and 1 -methylpiperazine. yield: 69% mp 191-192 °C (CΗCl3/Et2O/hexanes);
IR (neat) 3308 (NH), 1681 (CO), 1174 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 0. 94 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 61-1. 73 (m, 2 H, CH2CH2CH3), 1. 98-2. 09 (m, 2 H, OCH2CH,CH3), 2. 31 (s, 3 H, CH3), 2. 62-2. 75 (m, 8 H, NCH2CH2F, 2 NCH2 and CH,CH,CH3), 3. 11-3. 15 (m, 4 H, 2 SO2NCH2), 4. 04 (s, 3 H, NCH3), 4. 24 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 4. 49 (ddd, J = 47. 4 Hz, 4. 8 Hz, 4. 5 Hz, 2 H, NCH2CH,F), 7. 12 (d, J- 9. 0 Ηz, 1 Η, Η-3'), 7. 80 (dd, J= 9. 0 Ηz, 2. 4 Ηz, 1 Ii, Ii-4'), 8. 89 (d, J = 2. 4 Ηz, 1 Η, Η-6'), 10. 61 (br s, 1 H, NH); MS (FAB) m/z 534 (MH+).
Example 62
Preparation of l,2-dimethyl-5-(5-(2-ethoxy-4-(3-flιιoropropy])piperazinylsulfonyl)phenyl)-3-77-propy l-l,6-dihydro-7H-pyrrolo[4,3-_f]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = R2 = CΗ3, R3 - CH2CH2CH3, R4 = CH2CH3; NR6R7 is
4-(3 -fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 ,2-dimethyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrol o[4,3-c]pyrimidin-7-one and l-(3-fluoiOpiOpyl)piperazine hydrochloride in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-_ ]pyrimidin-7-one and 1 -methylpiperazine. yield: 72% mp 214. 5 °C (CΗCl3/Et2O/hexanes);
IR (neat) 3340 (NH), 1676 (CO), 1171 (SO2) cm'1;
'HNMR (CDCl/TMS) δ O. 94 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 68-1. 87 (m, 4 Η, CΗ,CH2CΗ,_F and CH2CH2CH3), 2. 31 (s, 3 H, CH,), 2. 43-2. 62 (m, 6 H, NCH2CH2 and 2 NCH2), 2. 68 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 11 (br s, 4 H, 2 SO,NCH2), 4. 04 (s, 3 H, NCH3), 4. 35 (q, J= 6. 9 Hz,
2 H, OCH2CH3), 4. 44 (dt, J- 47. 4 Hz, 6. 0 Hz, 2 H, CH,CH2F), 7. 12 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 80 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 87 (d, J= 2. 4 Ηz, 1 Η, FI-6'), 10. 59 (br s, 1 Η, NΗ); MS (FAB) m/z 534 (MΗ+).
Example 63
Preparation of l,2-dimethyl-5-(5-(4-(3-fluoropiOpyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-3-77-pr opyl-l ,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NR6R7, R1 = R2 = CΗ„ R3 = CH,CH,CH3, R4 = CH2CH2CH3; NR6R7 is 4-(3 -fluoropropy T)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l,3-dimethyl-3-77-propyl-l,6-dihydro-7H-pyr rolo[4,3-< ]pyrimidm-7-one and 1 -(3 -fluoropropy l)piperazine hydrochloride in place of 5-(5 -chlorosulfony 1-2-ethoxypheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrro lo [4, 3-_i]pyrimidin-7-one and 1 -methylpiperazine. yield: 86% mp 156-157 °C (CΗCl3/Et2O/hexanes); IR (neat) 3312 (NH), 1679 (CO), 1174 (SO,) cm'1; "H NMR (CDCl/TMS) δ 0. 94 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Iiz,
3 Η, OCΗ2CΗ2CH3), 1. 61-1. 89 (m, 4 Η, CΗ2CH2CΗ2F and CH2CH2CH3), 1. 98-2. 10 (m, 2 H, OCH2CH2CH3), 2. 31 (s, 3 H, CH3), 2. 47 (t, J= 7. 2 Hz, 2 H, NCH2CH2), 2,54 (dd, J = 5. 1 Hz, 4. 8 Hz, 4 H, 2 NCH2), 2. 68 (t, J= 7. 5 Hz, 2 H, CH2CH,CH3), 3. 1 1 (br dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO2NCH2), 4. 04 (s, 3 H, NCH3), 4. 24 (t, J =
6. 6 Hz, 2 H, OCH2CH2CH3), 4. 43 (dt, J= 47. 1 Hz, 6. 0 Hz, 2 H, CH2CH2F), 7. 13 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 80 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 88 (d, J= 2. 4 Ηz, 1 Η, Η-6'), 10. 61 (br s, 1 H, NH); MS (FAB) m/z 548 (MH+).
Example 64
Pi-eparation of l,2-dimethyl-5-(2-ethoxy-5-(4-(2 -hydroxy ethyl)piperazinylsulfonyl)phenyl)-3-77-prop yl-l,6-dihydro-7H-pyrrolo[4,3-^pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = R2 = CΗ3, R3 = CH2CH,CH3, R4 = CH2CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l,2-dimethyl-3-77-propyl-l,6-dihydro-7H-pyrrol o[4,3- ]pyrimidin-7-one and 1 -(2-hydroxyethyl)piperazine in place of 5-(5 -chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrro lo [4, 3-^pyrimidin-7-one and 1 -methylpiperazine. yield: 77% mp 130-130. 5 °C (CΗCl3/Et2O/hexanes);
IR (neat) 3555, 3323 (NH and OH), 1663 (CO), 1 168 (SO2) cm'1; 'H NMR (CDC13/TMS) δ 0. 95 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 58-1. 71 (m, 2 Η, CΗ2CH2CΗ3), 2. 31 (s, 3 H, CH3), 2. 55 (t, J= 5. 4 Hz, 2 H, NCH,CH2), 2. 61 (dd, J= 5. 1 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 68 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 13 (br dd, J= 5. 1 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 3. 57 (br t, J = 5. 4 Hz, 2 H, CH2CH2OH), 4. 04 (s, 3 H, NCH3), 4. 36 (q, J = 6. 9 Hz, 2 H, OCH,CH3), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 88 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 58 (br s, 1 H, NH); MS (FAB) m/z 518 (MH+).
Example 65
Preparation of l,2-dimethyl-5-(5-(4-(2-hydroxyethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-3-77-p
ropyl-l,6-dihydro-7H-pyrrolo[4,3-_ |pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = R2 = CΗ3, R3 = CH2CH,CH3, R4 = CH2CH2CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)- 1 ,2-dimethy 1-3 -77-propyl- 1 ,6-dihydro-7H-pyr rolo[4,3-<^pyrimidin-7-one and l-(2-hydroxyethyl)piperazine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-<fJpyrimidin-7-one and 1 -methylpiperazine. yield: 81% mp 202-202. 5 °C (CΗCl3/Et2O/hexanes);
IR (neat) 3402, 3313 (NH and OH), 1662 (CO), 1173 (SO2) cm'1; Η NMR (CDCyTMS) δ 0. 95 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Hz, 3 H, OCH,CH2CH3), 1. 60-1. 73 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 09 (m, 2 H, OCH2CH2CH3), 2. 31 (s, 3 H, CH3), 2. 56 (t, J= 5. 4 Hz, 2 H, NCH2CH2), 2. 63 (dd, J = 4. 8 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 68 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 14 (br dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 3. 58 (t, J= 5. 4 Hz, 2 H, CH2CH2OH), 4. 04 (s, 3 Ii, NCH3), 4. 25 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 14 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 88 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 62 (br s, 1 H, NH); MS (FAB) 777/z 532 (MH+).
Example 66
Preparation of l,2-dimethyl-5-(2-ethoxy-5-(4-(3-hydroxypiOpyl)piperazinylsulfonyl)phenyl)-3-77-pro pyl-l ,6-dihydro-7H-pyrrolo[4,3-<fJpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = R2 = CΗ3, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3 -hydroxypropy l)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5-(5 -chlorosulfonyl-2-ethoxyphenyl)- 1 ,2-dimethyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrol o[4,3-_ ]pyrimidin-7-one and l-(3-hydroxypropyl)piperazine in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-_i]pyriiuidin-7-one and 1 -methylpiperazine. yield: 80% mp 209-209. 5 °C (CΗCl3/Et2O/hexanes); IR (neat) 3346, 3320 (NH and OH), 1680 (CO), 1 171 (SO2) cm'1 ;
'H NMR (CDC13/TMS) δ 0. 95 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 61-1. 79 (m, 4 Η, CΗ2CH2CΗ2OΗand CH2CH2CH3), 1. 64 (t, J = 6. 9 Hz, 3 H, OCH2CH3), 2. 31 (s, 3 Η, CΗ3), 2. 65-2. 83 (m, 6 H, NCH2CH2 and 2 NCH2), 2. 68 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 22 (br s, 4 H, 2 SO,NCH2), 3. 73 (t, J= 5. 4 Hz, 2 H, CH2CH2OH), 4. 04 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 76 (dd, J= 8. 7 Hz, 2. 1 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 1 Hz, 1 H, H-6'), 10. 61 (br s, 1 H, NH); MS (FAB) m/z 532 (MH+).
Example 67 Preparation of l,2-dimethyl-5-(5-(4-(3-hydroxypropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-3-77- propyl-l,6-dihydro-7H-pyrrolo[4,3-<i]pyrimidin-7-one (a compound of the formula (1) herein R5 = SO2NR6R7, R1 = R2 = CΗ„ R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(3 -hydroxy propyl)piperaziny 1) The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l,2-dimethyl-3-77-propyl-l,6-dihydro-7H-pyr rolo[4,3-tf]pyrimidin-7-one and l-(3-hydroxypropyl)piperazine in place of 5 -(5 -chlorosulfony 1-2-ethoxypheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4, 3-β/]pyrimidin-7-one and 1 -methylpiperazine. yield: 54% mp 182-183 °C (CΗCl3/Et2O/hexanes);
IR (neat) 3490, 3310 (NH and OH), 1672 (CO), 1 172 (SO2) cm'1;
•li NMR (CDCl/TMS) δ 0. 95 (t, J= 7. 5 Hz, 3 H, CH2CH2CH,), 1. 20 (t, J= 7. 2 Iiz,
3 Η, OCΗ2CΗ2CH3), 1. 61-1. 76 (m, 4 Η, CΗ,CH2CΗ2OΗ and CH2CH2CH3), 1. 99-2.
10 (m, 2 H, OCH2CH,CH3), 2. 31 (s, 3 H, CH3), 2. 62-2. 67 (m, 6 H, NCH2CH, and 2 NCH,), 2. 69 (t, J= 7. 2 Hz, 2 H, CH2CH2CH3), 3. 07-3. 13 (m, 4 H, 2 SO2NCH2), 3. 71 (t, J= 5. 4 Hz, 2 H, CH2CH2OH), 4. 04 (s, 3 H, NCH3), 4. 25 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 77 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J = 2. 4 Hz, 1 H, H-6'), 10. 65 (br s, 1 H, NH); MS (FAB) m/z 546 (MH+).
Example 68
Preparation of 2-chloro-5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,
6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one (a compound of the formula (1) wherein
R5 = SO2NR6R7, R1 = CΗ3, R2 = Cl, R3 = CH2CH2CH3, R4 = CH,CH3; NR6R7 is
4-methylpiperazinyl)
The titled compound was prepared as described in Example 1 by using 2-chloro-5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propy 1- 1 ,6-dihydro-7H-p yrrolo[4,3-_ ]pyrimidin-7-one in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-<i]pyrimidir_-7-one. yield: 97% mp 1 15-116 °C (EtOAc/CΗCl3/hexanes);
IR (neat) 3326 (NH), 1680 (CO), 1168 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 64 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 68-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 28 (s, 3 H, NCH3), 2. 49-2. 52
(m, 4 H, 2 NCH,), 2. 72 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 11-3. 13 (m, 4 H, 2 SO,NCH2), 4. 07 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 13 (d, J= 8.
7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 85 (d, J= 2. 4 Hz, 1 H,
H-6'), 10. 72 (br s, 1 H, NH); MS (FAB) /z 508 (MH+).
Example 69
Preparation of
2-chloro-5-(5-(4-methylpiperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propy l-l,6-dihydro-7H-pyrrolo[4,3-_f]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Cl, R3 = CH2CH,CH3, R4 = CH2CH2CH3; NR6R7 is 4-methylpiperazinyl)
The titled compound was prepared as described in Example 1 by using 2-chloro-5-(5-chlorosulfonyl-2-77-propoxyphenyl)- 1 -methyl-3-77-propyl-l ,6-dihydro-7 H-pyrrolo[4,3-_/Jpyriιrιidin-7-one in place of
5-(5 -chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4, 3-< ]pyrimidin-7-one. yield: 97% mp 194-194. 5 °C (EtOAc/CΗCl3/hexanes); IR (neat) 3306 (NH), 1686 (CO), 1175 (SO2) cm'1; Η NMR (CDCl/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 1. 99-2. 10 (m, 2 H, OCH2CH2CH3), 2. 27 (s, 3 H, NCH3), 2. 49 (dd, J= 5. 1 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 72 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 11 (br dd, J = 5. 1 Hz, 4. 5 Hz, 4 li, 2 SO2NCH2), 4. 07 (s, 3 H, NCH3), 4. 25 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 13 (d, J = 8. 7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 74 (br s, 1 H, NH); MS (FAB) m/z 522 (MH+).
Example 70
Preparation of
2-chloro-5-(2-ethoxy-5-(4-(2-fluoroethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-/7-pr opyl-l,6-dihydro-7H-pyrrolo[4,3-_/jpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NRsR7, R1 = CΗ3, R2 = Cl, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-chloro-5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro-7H-p
yrrolo[4,3-_/]pyrimidin-7-one and l-(2-fluoroethyl)piperazine hydrochloride in place of
5 -(5 -chlorosulfony 1-2-ethoxypheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,
3-_/Jpyrimidin-7-one and 1 -methylpiperazine. yield: 96% mp 222-223 °C (EtOAc/CΗCl3/hexanes);
IR (neat) 3330 (NH), 1674 (CO), 1168 (SO2) cm'1;
'HNMR (CDCl/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 65 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 62-2. 75 (m, 6 H, NCH2CH2F and 2 NCH2), 2. 72 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 11-3. 14 (m, 4 H, 2
SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 37 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 50 (td, J =
47. 4 Hz, 4. 5 Hz, 2 H, NCH2CH2F), 7. 13 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8.
7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 86 (d, J= 2. 4 Ηz, 1 Η, Η-6'), 10. 70 (br s, 1 H, NH); MS
Example 71
Preparation of
2-chloro-5-(5-(4-(2-fluoroethyl)piperazinylsulfony l)-2-77-propoxyphenyl)~ 1 -methyl-3 -
77-propyl- l,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Cl, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
2-chloro-5-(5-chlorosulfonyl-2-77-propoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7
H-pyrrolo[4,3-_ ]pyrimidin-7-one and l-(2-fluoroethyl)piperazine hydrochloride in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-_ ]pyrimidin-7-one and 1 -methylpiperazine. yield: 97% mp 184-184. 5 °C (EtOAc/CΗCl3/hexanes);
IR (neat) 3313 (NH), 1687 (CO), 1173 (SO,) cm'1;
'H NMR (CDCl TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 1. 99-2. 10 (m, 2 H, OCH2CH2CH3), 2. 62-2. 75 (m, 8 H, NCH2CH2F, 2 NCH, and CH2CH2CH3), 3. 10-3. 15 (m, 4 H, 2 SO2NCH2), 4. 07 (s, 3 H, NCH,), 4. 25 (t, J = 6. 6 Hz, 2 H, OCH2CH2CH3), 4. 49 (ddd, J= 47. 7 Hz, 5. 1 Hz, 4. 5 Hz, 2 H, NCH2CH2F), 7. 14 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 87 (d, J= 2. 4 Ηz,
1 Η, Η-6'), 10. 74 (br s, 1 H, NH); MS (FAB) m/z 554 (MH+).
Example 72
Preparation of
2-chloiO-5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77- propyl- l,6-dihydro-7H-pyrrolo[4,3-d]pyriιr_idin-7-one (a compound of the foπmrla (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Cl, R3 = CH,CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3-fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-chloro-5-(5-chlorosulfony 1-2-ethoxypheny 1)- 1 -methyl-3-77-propyl- 1 ,6-dihydro-7H-p yrrolo[4,3-<^pyrimidin-7-one and l-(3-fluoropropyl)piperazine hydrochloride in place of 5-(5-chloiOsulfonyl-2-ethoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrrolo[4, 3-_τ]pyrimidin-7-one and 1 -methylpiperazine. yield: 94% mp 181-182 °C (CΗCl3/hexanes); IR (neat) 3336 (NH), 1681 (CO), 1170 (SO2) cm'1; Η NMR (CDCl/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 73-1. 84 (m, 4 Η, CΗ2CH2CΗ2F and CH2CH2CH3), 2. 47 (t, J= 7.
2 Hz, 2 H, NCH2CH,), 2. 54 (dd, J= 5. 4 Hz, 4. 2 Hz, 4 H, 2 NCH2), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 10 (br dd, J= 5. 4 Hz, 4. 2 Hz, 4 H, 2 SO2NCH2), 4. 08 (s, 3 H, NCH3), 4. 37 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 43 (dt, J= 47. 4 Hz, 6. 0 Hz, 2 Ii,
CH2CH2F), 7. 13 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 86 (d, J= 2. 4 Ηz, 1 Η, Η-6'), 10. 71 (br s, 1 H, NH); MS (FAB) 777/z 554 (MH+).
Example 73 Preparation of
2-chloro-5-(5-(4-(3-fluoropropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Cl, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR5R7 is 4-(3-fluoropropyl)piperazinyl) The titled compound was prepared as described in Example 1 by using
2-chloro-5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7 H-pyrrolo[4,3-_/|pyrimidin-7~one and l-(3-fluoropropyl)piperazine hydrochloride in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-JJpyrimidin-7-one and 1 -methylpiperazine. yield: 79% mp 179-180 °C (EtOAc/CΗCl3/hexanes); IR (neat) 3315 (NH), 1690 (CO), 1172 (SO2) cm'1; Η NMR (CDCI3/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Iiz, 3 Η, OCΗ2CΗ2CH3), 1. 67-1. 89 (m, 4 Η, CΗ2CH2CΗ2F and CH2CH2CH3), 1. 99-2. 10 (m, 2 H, OCH2CH2CH3), 2. 47 (t, J= 7. 2 Hz, 2 H, NCH2CH2), 2. 54 (dd, j = 4. 8 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 10 (br dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 07 (s, 3 H, NCH3), 4. 25 (t, J = 6. 6 Hz, 2 H, OCH2CH2CH3), 4. 43 (dt, J= 47. 1 Hz, 6. 0 Hz, 2 H, CH2CH2F), 7. 14 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 87 (d, J= 2. 4 Ηz, 1 Η, Η-6'), 10. 75 (br s, 1 Η, NΗ); MS (FAB) 777/z 568 (MΗ+).
Example 74
Preparation of
2-chloro-5-(2-ethoxy-5-(4-(2-hydroxyethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77 -propyl- l,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Cl, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl) The titled compound was prepared as described in Example 1 by using
2-chloro-5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-p yrrolo[4,3-_fJpyrimidin-7-one and 1 -(2-hydroxyethyl)piperazine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-_f|pyrimidm-7-one and 1 -methylpiperazine. yield: 96% mp 201-201. 5 °C (CΗCl3/hexanes);
IR (neat) 3553, 3327 (NH and OH), 1677 (CO), 1 168 (SO2) cm'1;
'H NMR (CDCl TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 65 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 67-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 2. 57 (t, J = 5. 4 Hz, 2 H, NCH2CH2), 2. 64 (dd, J = 4. 8 Hz, 4. 5 Hz, 4 H, 2 NCH,), 2. 72 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 14 (br dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 3. 59 (t, J = 5. 4 Hz, 2 H, CH,CH2OH), 4. 07 (s, 3 H, NCH3), 4. 37 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 15 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 71 (br s, 1 H, NH); MS (FAB) 777/2 538 (MH+).
Example 75
Preparation of
2-chloro-5-(5-(4-(2 -hydroxy ethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-(i]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Cl, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-chloiO-5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l -methyl-3-77-propyl-l,6-dihydro-7 H-pyrrolo[4,3- ]pyrimidin-7-one and l-(2-hydroxyethyl)piperazine in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-<JJpyrimidin-7-one and 1 -methylpiperazine. yield: 94% mp 194-195 °C (EtOAc/CΗCl3/hexanes); IR (neat) 3452, 3318 (NH and OH), 1687 (CO), 1173 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 1. 99-2. 11 (m, 2 H, OCH2CH2CH3), 2. 32 (br s, 1 H, OH), 2. 55 (dd, J= 5. 4 Hz, 5. 1 Hz, 2 H, NCH,CH2), 2. 61 (dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 NCH2), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 12 (br dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO2NCH2), 3. 57-3. 58 (m, 2 H, CH2CH2OH), 4. 07 (s, 3 H, NCH3), 4. 26 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 15 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 83 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 75 (br s, 1 H, NH); MS (FAB) m/z 552 (MH+).
Example 76
Preparation of
2-chloro-5-(2-ethoxy-5-(4-(3-hydroxypropyl)piperazinylsulfonyi)phenyl)-l-methyI-3- 77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Cl, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3-hydroxypropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-chloiO-5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-p yrroIo[4,3-d]pyrhnidi_i-7-one and l-(3-hydroxypropyl)piperazine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-<fJpyrimidin-7-one and 1 -methylpiperazine. yield: 98% mp 189-189. 5 °C (CΗCl3/hexanes);
IR (neat) 3331 (NH and OH), 1686 (CO), 1168 (SO2) cm'1; JH NMR (CDCl/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 65 (t, J= 6. 9 Ηz,
3 H, OCH2CH3), 1. 67-1. 79 (m, 4 Η, CΗ2CH2CΗ2OΗ and CH2CH,CH3), 2. 64 (br s, 6 H, NCH2CH2 and 2 NCH2), 2. 72 (t, J= 7. 2 Hz, 2 H, CH2CH2CH3), 3. 10 (br s, 4 H, 2 SO2NCH2), 3. 72 (t, J= 5. 4 Hz, 2 H, CH2CH2OH), 4. 08 (s, 3 H, NCH3), 4. 38 (q, J = 6. 9 Hz, 2 H, OCH2CH3), 7. 14 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 79 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 85 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 73 (br s, 1 H, NH); MS (FAB) m/z 552 (MIL).
Example 77
Preparation of 2-chloro-5-(5-(4-(3-hydroxypropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methy l-3-/7-propyl-l,6-dihydro-7H-pyπOlo[4,3-_/]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Cl, R3 = CH2CH2CH3, R4 =
CH,CH2CH3; NR6R7 is 4-(3-hydroxypropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-chloro-5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7
H-pyrrolo[4,3-_/ pyrimidin-7-one and l-(3-hydroxypiOpyl)piperazine in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,
3-_i]pyrimidin-7-one and 1 -methylpiperazine. yield: 89% mp 192-193 °C (EtOAc/CΗCl3/hexanes);
IR (neat) 3419, 3313 (NH and OH), 1688 (CO), 1173 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 20 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 64-1. 79 (m, 4 Η, CΗ2CH2CΗ,_OΗ and CH2CH2CH3), 2. 00-2.
11 (m, 2 H, OCH2CH2CH3), 2. 59-2. 62 (m, 6 H, NCH2CH2 and 2 NCH2), 2. 72 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 04-3. 12 (m, 4 H, 2 SO2NCH2), 3. 71 (t, J= 5. 4 FIz, 2
H, CH,CH2OH), 4. 08 (s, 3 H, NCH3), 4. 27 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 14
(d, J= 9. 0 Hz, 1 H, H-3'), 7. 79 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4"), 8. 86 (d, J= 2. 4
Hz, 1 H, H-6'), 10. 77 (br s, 1 H, NH); MS (FAB) m/z 566 (MIL).
Example 78
Preparation of
2-bromo-5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)- 1 -methyl-3 -77-propy 1- 1 , 6-dihydro-7H-pyrrolo[4,3-ύT]pyrimidin-7-one (a compound of the formula (1) wherein
R5 = SO2NR6R7, R1 = CΗ3, R2 = Br, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is
4-methylpiperazinyl)
The titled compound was prepared as described in Example 1 by using
2-biOmo-5-(5-chloiOSulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-p yrrolo[4,3- /]pyrimidin-7-one in place of
5-(5 -chlorosulfonyl-2-ethoxypheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,
3-<f]pyrimidm-7-one. yield: 87% mp 202. 5-203 °C dec (EtOAc/CΗCl3/hexanes); IR (neat) 3334 (NH), 1679 (CO), 1171 (SO2) cm'1;
Η NMR (CDCl/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 7. 2 Ηz,
3 Η, OCΗ2CH3), 1. 68-1. 79 (m, 2 Η, CΗ,CH2CΗ3), 2. 27 (s, 3 H, NCH3), 2. 50 (dd, J = 4. 8 Hz, 4. 2 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 09-3. 13 (m, 4 H, 2 SO2NCH2), 4. 10 (s, 3 H, NCH3), 4. 36 (q, J= 7. 2 Hz, 2 H, OCH2CH3), 7. 13 (d, J- 9. 0 Hz, 1 H, H-3'), 7. 82 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 85 (d, J= 2.
4 Hz, 1 H, H-6'), 10. 71 (br s, 1 H, NH); MS (FAB) m/z 552, 554 (MH+).
Example 79
Preparation of 2-bromo-5-(5-(4-methylpiperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propy l-l,6-dihydro-7H-pyrrolo[4,3-t ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Br, R3 = CH2CH,CH3, R4 = CH2CH,CH3; NR6R7 is 4-methylpiperazinyl)
The titled compound was prepared as described in Example 1 by using
2-bromo-5-(5-chloiOSulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydiO-7 H-pyrrolo[4,3-_ ]pyrimidin-7-one in place of
5 -(5 -chlorosulfonyl-2-ethoxypheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4, 3-fidpyrimidin-7-one. yield: 92% mp 260 °C dec (CΗCl3/hexanes);
IR (neat) 3300 (NH), 1683 (CO), 1173 (SO2) cm'1;
'H NMR (CDCl TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J- 7. 2 Iiz,
3 Η, OCΗ2CΗ2CH3), 1. 66-1. 78 (m, 2 Η, CΗ,CH2CΗ3), 1. 98-2. 10 (m, 2 H, OCH2CH2CH3), 2. 28 (s, 3 H, NCH3), 2. 51 (br s, 4 H, 2 NCH2), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 12 (br s, 4 H, 2 SO2NCH2), 4. 10 (s, 3 H, NCH3), 4. 25 (t, J= 6. 3 Hz, 2 Ii, OCH2CH2CH3), 7. 14 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 Ii, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 73 (br s, 1 H, NH); MS (FAB) /z 566, 568 ( H+).
Example 80
Preparation of
2-bromo-5-(2-ethoxy-5-(4-(2-fluoiOethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-p ropyl-l,6-dihydro-7H-pyrrolo[4,3-<f]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Br, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-biOmo-5-(5-chIorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro-7H-p yrroIo[4,3-ct pyrimidin-7-one and l-(2-fluoroethyl)piperazine hydrochloride in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-<JJpyrimidin-7-one and 1 -methylpiperazine. yield: 88% mp 208 °C dec (EtOAc/hexanes);
IR (neat) 3328 (NH), 1678 (CO), 1168 (SO,) cm'1;
Η NMR (CDC13/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz, 3 Η, OCΗ,CH3), 1. 69-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 64 (dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 NCH,), 2. 62-2. 77 (m, 4 H, NCH2CH,F and CH2CH2CH3), 3. 12 (br dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 09 (s, 3 H, NCH3), 4. 36 (q, J = 6. 9 Hz, 2 H, OCH2CH3), 4. 49 (dt, J= 47. 7 Hz, 4. 8 Hz, 2 H, NCH2CH2F), 7. 13 (d, J= 8. 7 Ηz, 1 Ii, Η-3'), 7. 81 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 85 (d, J= 2. 4 Ηz, 1 Η, Ii-6'), 10. 72 (br s, 1 Η, NΗ); MS (FAB) /z 584, 586 (MΗ+).
Example 81
Preparation of
2-bromo-5-(5-(4-(2-fluoroethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3- 77-propyl-l,6-dihydro-7H-pyrrolo[4,3-(Jjpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = Br, R3 = CH2CH2CH3, R4 = CH2CH2CH,; NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-bromo-5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7 H-pyrrolo[4,3-_/Jpyrimidin-7-one and l-(2-fluoiOethyl)piperazine hydrochloride in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrrolo[4, 3-_i]pyrimidin-7-one and 1 -methylpiperazine. yield: 84% mp 195. 5 °C dec (CΗCl3/hexanes); IR (neat) 3310 (NΗ), 1685 (CO), 1173 (SO2) cm'1; Η NMR (CDC13/TMS) δ 0. 96 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 19 (t, J= 7. 5 Ηz, 3 Ii, OCΗ,CΗ,CH3), 1. 66-1. 77 (m, 2 Η, CΗ,CH2CΗ3), 2. 00-2. 10 (m, 2 H, OCH,CH2CH3), 2. 65 (br s, 4 H, 2 NCH2), 2. 70-2. 76 (m, 2 H, NCH2CH2F), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 13 (br s, 4 H, 2 SO2NCH2), 4. 10 (s, 3 H, NCH3), 4. 25 (t, J = 6. 3 Hz, 2 H, OCH,CH2CH3), 4. 50 (dt, J = 48. 0 Hz, 6. 0 Hz, 2 H,
NCH2CH2F), 7. 14 (d, J = 9. 0 Ηz, 1 Η, Η-3'), 7. 82 (dd, J = 9. 0 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 87 (d, J= 2. 4 Ηz, 1 Η, Η-6'), 10. 73 (br s, 1 Η, NΗ); MS (FAB) m/z 598, 600 (MΗ+).
Example 82
Preparation of
2-biOmo-5-(2-ethoxy-5-(4-(3-fluoropiOpyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77- propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-d]pyrimid_n-7 -one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Br, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3 -fluoropropy l)piperazinyl)
The titled compoimd was prepared as described in Example 1 by using 2-bromo-5-(5-chlorosulfony 1-2-ethoxypheny 1)- 1 -methyl-3-/7-propy 1- 1 ,6-dihydro-7H-p yrrolo[4,3-< ]pyrimidin-7-one and l-(3-fluoropropyl)piperazine hydrochloride in place of 5 -(5 -chlorosulfony 1-2-ethoxypheny 1)- 1 -methyl-3 -77-propy 1-1 ,6-dihydro-7H-pyrrolo[4, 3-./]pyr_midin-7-one and 1 -methylpiperazine. yield: 85% mp 198 °C dec (EtOAc/hexanes); IR (neat) 3324 (NΗ), 1678 (CO), 1 169 (SO2) cm'1; Η NMR (CDC13/TMS) δ 0. 96 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 64 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 66-1. 88 (m, 4 Η, CΗ,CH2CΗ2F and CH2CH2CH3), 2. 47 (t, J= 7. 2 Hz, 2 H, NCH2CH,_), 2. 54 (dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 72 (t, J= 7. 5 Hz, 2 Ii, CH2CH2CH3), 3. 10 (br dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 10 (s, 3 H, NCH3), 4. 37 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 43 (dt, J= 47. 1 Hz, 6. 0 Hz, 2 H, CH2CH,F), 7. 13 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Ii-4'), 8. 85 (d, J = 2. 4 Ηz, 1 Η, Η-6'), 10. 71 (br s, 1 Η, NΗ); MS (FAB) m/z 598, 600 (MΗ+).
Example 83
Preparation of
2-bromo-5 -(5 -(4-(3 -fluoropropy l)piperaziny lsulfonyl)-2-77-propoxypheny 1)- 1 -methy 1- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-(/Jpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Br, R3 = CH2CH2CH3, R4 = CH,_CH2CH3; NR6R7 is 4-(3-fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-biOmo-5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7 H-pyrrolo[4,3-_/Jpyrimidin-7~one and l-(3-fluoropropyl)piperazine hydrochloride in place of 5-(5 -chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrro lo [4, 3-< ]pyrimidin-7-one and 1-methylpiperazine. yield: 88% mp 187 °C dec (CΗCl3/hexanes); IR (neat) 3314 (NH), 1687 (CO), 1171 (SO2) cm 1; Η NMR (CDC13/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ,CH3), 1. 66-1. 90 (m, 4 Η, CΗ2CH2CΗ2F and CH2CH2CH3), 1. 99-2. 1 1 (m, 2 H, OCH,CH,CH3), 2. 45-2. 65 (m, 6 H, NCH2CH2 and 2 NCH2), 2. 72 (t, J = 7. 5 Hz, 2 H, CH2CH,CH3), 3. 11 (br s, 4 H, 2 SO2NCH2), 4. 10 (s, 3 H, NCH3), 4. 25 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 4. 44 (dt, J= 47. 1 Hz, 6. 0 Hz, 2 H, CH2CH2F), 7. 14 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 87 (d, J= 2.
4 Ηz, 1 Η, Η-6'), 10. 73 (br s, 1 Η, NΗ); MS (FAB) m/z 612, 614 (MΗ+).
Example 84
Preparation of 2-biOmo-5-(2-ethoxy-5-(4-(2-hydroxyethyl)piperazinylsulfonyl)phenyI)-l-methyI-3-77 -propyl- l,6-dihydro-7H-pyrrolo[4,3- |pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = Br, R3 = CH2CH2CH3, R4 = CH,CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
2-bromo-5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-p yrrolo[4,3-c ]pyrimidin-7-one and l-(2-hydroxyethyl)piperazine in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-_ ]pyrimidin-7-one and 1 -methylpiperazine. yield: 90% mp 203. 5-205 °C dec (EtOAc/CΗCl3/hexanes);
IR (neat) 3565, 3327 (NH and OH), 1677 (CO), 1166 (SO2) cm'1;
'H MR (CDCyTMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 65 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 67-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 55 (t, J = 5. 4 Hz, 2 H, NCH2CH2), 2. 60 (dd, J= 4. 8 Hz, 4. 2 Hz, 4 H, 2 NCH2), 2. 72 (t, J= 7. 5 Hz, 2 Ii, CH2CH,CH3), 3. 12 (br dd, J= 4. 8 Hz, 4. 2 Hz, 4 H, 2 SO2NCH,), 3. 58 (t, J= 5. 4 Hz, 2 Ii, CH2CH2OH), 4. 10 (s, 3 H, NCH3), 4. 37 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 15 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 85 (d, J= 2.
4 Hz, 1 H, H-6'), 10. 72 (br s, 1 H, NH); MS (FAB) m/z 582, 584 (MH+).
Example 85
Preparation of
2-biOmo-5-(5-(4-(2-hydroxyethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l -methyl-
3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 - Br, R3 = CH2CH2CH3, R4 =
CH2CH2CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
2-bromo-5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7
H-pyrrolo[4,3-_ ]pyrimidin-7-one and 1 -(2-hydroxyethyl)piperazine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrrolo[4,
3-JJpyrimidin-7-one and 1 -methylpiperazine. yield: 87% mp 198. 5 °C dec (CΗCl3/hexanes);
IR (neat) 3453, 3312 (NH and OH), 1687 (CO), 1171 (SO2) cm'1;
]HNMR (CDC13/TMS) δ 0. 96 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Iiz,
3 Η, OCΗ2CΗ2CH3), 1. 66-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 2. 01-2. 11 (m, 2 H, OCH,CH2CH3), 2. 57 (t, J= 5. 4 Hz, 2 H, NCH,CH2), 2. 63 (dd, J= 4. 8 Hz, 4. 5 Hz,
4 H, 2 NCH2), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 13 (br dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 3. 58 (t, J= 5. 4 Hz, 2 H, CH2CH2OH), 4. 10 (s, 3 H, NCH3), 4.
26 (t, J= 6. 3 Hz, 2 Ii, OCH2CH2CH3), 7. 15 (d, J- 8. 7 Hz, 1 H, H-3'), 7. 83 (dd, J = 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 74 (br s, 1 H, NH); MS (FAB) m/z 596, 598 (MH+).
Example 86
Preparation of
2-biOmo-5-(2-ethoxy-5-(4-(3-hydroxypropyl)piperazinylsulfonyl)phenyl)-l-methyl-3- 77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_f]pyriιrιidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = Br, R3 = CH2CH2CH„ R4 = CH2CH3; NR6R7 is 4-(3-hydroxypropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-biOmo-5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-p yrrolo[4,3-d]pyrimidin-7-one and l-(3-hydroxypropyl)piperazine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrrolo[4, 3-<f]pyrimidin-7-one and 1 -methylpiperazine. yield: 90% mp 197. 5 °C dec (EtOAc/Et2O/hexanes); IR (neat) 3325 (NΗ and OΗ), 1678 (CO), 1167 (SO2) cm"1; 'Η NMR (CDC13/TMS) δ 0. 97 (t, J= 7. 5 Ηz, 3 Η, CΗ,_CΗ2CH3), 1. 57-1. 79 (m, 4 Η, CΗ2CH2CΗ2OΗand CH2CH2CH3), 1. 65 (t, J= 7. 2 Hz, 3 H, OCH2CH3), 2. 51-2. 67 (m, 6 Ii, NCH2CΗ, and 2 NCH2), 2. 72 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 08 (br s, 4 H, 2 SO2NCH2), 3. 71 (t, J= 5. 4 Hz, 2 H, CH2CH2OH), 4. 10 (s, 3 H, NCH3), 4. 38 (q, J= 7. 2 Hz, 2 H, OCH2CH3), 7. 13 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 78 (dd, J- 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 84 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 73 (br s, 1 H, NH); MS
(FAB) m/z 596, 598 (MH+).
Example 87
Preparation of 2-bromo-5-(5-(4-(3-hydroxypropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methy l-3-77-propyl-l,6-dihydiO-7H-pyrrolo[4,3-_i]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = Br, R3 = CH2CH2CH„ R4 =
CH2CH2CH3; NR6R7 is 4-(3-hydroxypropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 2-bromo-5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7
H-pyrrolo[4,3-c/]pyrimidin-7-one and l-(3-hydroxypropyl)piperazine in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,
3-£ |pyrimidin-7-one and 1 -methylpiperazine. yield: 90% mp 192 °C dec (CΗCl3/hexanes);
IR (neat) 3423, 3313 (NΗ and OΗ), 1684 (CO), 1171 (SO2) cm'1;
Η NMR (CDCl/TMS) δ 0. 97 (t, J= 7. 5 Ηz, 3 Η, CΗ,CΗ2CH3), 1. 20 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 66-1. 78 (m, 4 Η, CΗ,CH2CΗ2OΗ and CH2CH2CH3), 1. 99-2.
09 (m, 2 H, OCH2CH2CH3), 2. 55-2. 70 (m, 6 H, NCH2CH2 and 2 NCH2), 2. 72 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 10 (br s, 4 H, 2 SO,NCH2), 3. 71 (t, J= 5. 4 Hz, 2 H,
CH2CH,OH), 4. 10 (s, 3 H, NCH3), 4. 26 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 14 (d,
J= 9. 0 Hz, 1 H, H-3'), 7. 79 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz,
1 H, H-6'), 10. 76 (br s, 1 H, NH); MS (FAB) m/z 610, 612 (MH+).
Example 88
Preparation of
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-2-iodo- 1 -methyl-3 -77-propy 1- 1 ,6- dihydro-7H-pyrrolo[4,3-( ]pyrimidin-7-one (a compound of the formula (1) wherein R5 - SO2NR6R7, R1 = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is
4-methylpiperazinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-ethoxyphenyl)-2-iodo-l-methyl-3-77-propyl-l ,6-dihydiO-7H-pyr rolo[4,3-_ )pyrimidin-7-one in place of 5-(5-chloiOSiilfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyriOlo[4,
3-c lpyrimidin-7-one. yield: 97% mp 197. 5-198 °C (EtOAc/Et2O);
IR (neat) 3325 (NΗ), 1679 (CO), 1172 (SO2) cm'1; Η NMR (CDC13/TMS) δ 0. 97 (t, J= 7. 5 Iiz, 3 Η, CΗ2CΗ2CH,), 1. 64 (t, J= 6. 9 Hz,
3 H, OCH2CH3), 1. 65-1. 78 (m, 2 Η, CΗ2CH2CΗ3), 2. 28 (s, 3 H, NCH3), 2. 48-2. 53
(m, 4 Ii, 2 NCH,), 2. 71 (t, J - 7. 5 Hz, 2 H, CH,CH2CH3), 3. 07-3. 15 (m, 4 H, 2
SO2NCH2), 4. 11 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 13 (d, J= 8.
7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 67 (br s, 1 H, NH); MS (FAB) m/z 600 (MH+).
Example 89
Preparation of
2-iodo-5-(5-(4-methylpiperazinylsulfonyl)-2-77-piOpoxyphenyl)-l-methyl-3-77-propyl- l,6-dihydro-7H-pyrrolo[4,3-^pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH2CH,;
NR°R7 is 4-methylpiperazinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-2-iodo-l-methyl-3-77-propyl-l,6-dihydro-7H- pyrrolo[4,3- ]pyrimidin-7-one in place of
5 -(5-chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrro lo [4,
3-d]pyrimidin-7-one. yield: 99% mp 188-188. 5 °C (EtOAc/CΗCl3/hexanes);
IR (neat) 3300 (NH), 1680 (CO), 1173 (SO2) cm'1;
ΗNMR (CDCyTMS) δ O. 97 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 19 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ,CH3), 1. 65-1. 78 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 10 (m, 2 H, OCH2CH2CH3), 2. 27 (s, 3 H, NCH3), 2. 49 (dd, J= 5. 1 Hz, 4. 8 Hz, 4 H, 2 NCH2), 2. 71 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 3. 11 (br dd, J = 5. 1 Hz, 4. 8 Hz, 4 H, 2 SO,NCH2), 4. 11 (s, 3 H, NCH3), 4. 25 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 13 (d, J = 8. 7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J = 2. 4 Hz, 1 H, H-6'), 10. 70 (br s, 1 H, NH); MS (FAB) m/z 614 (MH+).
Example 90
Preparation of
5-(2-ethoxy-5-(4-(2-fluoroethyl)piperazinylsulfonyl)phenyl)-2-iodo-l-methyl-3-/7-pro pyl-l,6-dihydro-7H-pyrrolo[4,3-_77]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = I, R3 = CH2CH2CH„ R4 = CH2CH3; NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using 5 -(5 -chlorosulfony 1-2-ethoxypheny l)-2-iodo-l -methyl-3 -77-propy l-l,6-dihydro-7H-pyr rolo[4,3-_ ]pyr_midin-7-one and 1 -(2-flιιoroethyl)piperazine hydrochloride in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyriOlo[4, 3-_7]pyrimidin-7-one and 1 -methylpiperazine. yield: 96% mp 182. 5-183 °C (CΗCl3/hexanes); IR (neat) 3328 (NH), 1676 (CO), 1166 (SO2) cm'1; 'HNMR (CDCyTMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 65 (t, J= 6. 9 Iiz, 3 Η, OCΗ,CH3), 1. 65-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 2. 63-2. 76 (m, 8 H, NCH2CH,F, CH,CΗ2CΗ3 and 2 NCH2), 3. 1 1-3. 16 (m, 4 H, 2 SO2NCH,_), 4. 11 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9 Hz, 2 Ii, OCH2CH3), 4. 50 (dt, J= 47. 7 Hz, 4. 5 Hz, 2 H, NCH2CH,F), 7. 13 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 86 (d, J = 2. 4 Ηz, 1 Η, Η-6'), 10. 66 (br s, 1 Η, NΗ); MS (FAB) m/z 632 (MΗ+).
Example 91
Preparation of
5-(5-(4-(2-fluoroethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-2-iodo-l-methyl-3-77- propyl-1 ,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-(2-fluoroethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-2-iodo-l-methyl-3-77-propyl-l,6-dihydro-7H- pyrrolo[4,3-_ ]pyrimid_n-7-one and l-(2-fluoroethyl)piperazine hydrochloride in place of
5-(5 -chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,
3-t ]pyrimidin-7-one and 1 -methylpiperazine. yield: 96% mp 209. 5-210 °C (EtOAc/CΗCl3/hexanes);
IR (neat) 3304 (NH), 1686 (CO), 1172 (SO2) cm'1;
Η NMR (CDCl TMS) δ 0. 97 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 65-1. 78 (m, 2 Η, CΗ2CH2CΗ3), 1. 99-2. 10 (m, 2 Ii,
OCH2CH,CH3), 2. 62-2. 75 (m, 8 H, NCH2CH2F, CH2CH2CH3 and 2 NCH2), 3. 10-3. 15 (m, 4 H, 2 SO2NCH2), 4. 11 (s, 3 H, NCH3), 4. 25 (t, J = 6. 6 Hz, 2 H,
OCH,CH2CH3), 4. 49 (ddd, J= 47. 7 Hz, 5. 1 Hz, 4. 5 Hz, 2 H, NCH2CH2F), 7. 14 (d,
J= 8. 7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8. 7 Iiz, 2. 4 Ηz, 1 Η, Η-4'), 8. 87 (d, J= 2. 4 Ηz,
1 Η, Η-6'), 10. 70 (br s, 1 Η, NΗ); MS (FAB) m/z 646 (MΗ+).
Example 92
Preparation of
5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-2-iodo-l-methyl-3-77-pr opyl-l,6-dihydro-7H-pyrrolo[4,3-_f]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 - CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is
4-(3-fluoropropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-ethoxyphenyl)-2-iodo- 1 -methyl-3-77-propyl- 1 ,6-dihydro-7H-pyr rolo[4,3-<i]pyr_midin-7-one and 1 -(3 -fluoropropy l)piperazine hydrochloride in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrrolo[4,
3-flT]pyrimidin-7-one and 1 -methylpiperazine. yield: 86% mp 202. 5-203 °C (CΗCl3/hexanes); IR (neat) 3324 (NH), 1679 (CO), 1167 (SO,) cm'1;
Η NMR (CDCl/TMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 64 (t, J= 6. 9 Ηz,
3 Η, OCΗ2CH3), 1. 66-1. 88 (m, 4 Η, CΗ,CH2CΗ2F and CH2CH2CH3), 2. 50 (t, J= 7.
5 Hz, 2 H, NCH,CH2), 2. 54-2. 58 (m 4 H, 2 NCH2), 2. 71 (t, J = 7. 5 Hz, 2 Ii,
CH2CH2CH3), 3. 08-3. 14 (m, 4 H, 2 SO2NCH2), 4. 11 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 44 (dt, J= 47. 4 Hz, 5. 7 Hz, 2 H, CH2CH2F), 7. 13 (d, J= 8.
7 Ηz, 1 Η, Η-3'), 7. 82 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 84 (d, J= 2. 4 Ηz, 1 Η,
Η-6'), 10. 68 (br s, 1 Η, NΗ); MS (FAB) m/z 646 (MΗ+).
Example 93 Preparation of
5-(5-(4-(3-fluoropiOpyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-2-iodo-l-methyl-3- 77-propy I- l,6-dihydro-7H-pyrrolo[4,3-_f]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH,CH3; NR6R7 is 4-(3 -fluoropropy l)piperazinyl) The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-2-iodo-l-methyl-3-77-propyl-l ,6-dihydro-7H- pyrrolo[4,3-β]pyrimidin-7-one and l-(3-fluoropropyl)piperazine hydrochloride in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3- ]pyrimidin-7-one and 1 -methylpiperazine. yield: 89% mp 204-204. 5 °C (EtOAc/CHCl3/hexanes); IR (neat) 3310 (NH), 1685 (CO), 1 171 (SO.) cm'1; 'H NMR (CDC13/TMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 65-1. 89 (m, 4 Η, CΗ2CH2CΗ2F and CH2CH2CH3), 1. 98-2. 10 (m, 2 H, OCH,CH2CH3), ), 2. 47 (t, J= 7. 2 Hz, 2 H, NCH2CH2), 2. 54 (dd, J= 5. 4 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH,CH3), 3. 10 (br dd, J= 5.
4 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 4. 1 1 (s, 3 H, NCH3), 4. 25 (t, J = 6. 3 Hz, 2 H, OCH2CH2CH3), 4. 43 (dt, J= 47. 1 Hz, 6. 0 Hz, 2 H, CH2CH2F), 7. 14 (d, J= 9. 0 Ηz,
1 Η, Η-3'), 7. 82 (dd, J= 9. 0 Ηz, 2. 7 Ηz, 1 Ii, Η-4'), 8. 87 (d, J= 2. 7 Ηz, 1 Η, Ii-6'), 10. 70 (br s, 1 Η, NΗ); MS (FAB) 777/z 660 (MΗ+).
Example 94 Preparation of
5-(2-ethoxy-5-(4-(2-hydroxyethyl)piperazinylsulfonyl)phenyl)-2-iodo-l-methyl-3-77-p ropyl-l ,6-dihydro-7H-pyrrolo[4,3-_dpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-hydroxyethyl)piperazinyl) The titled compound was prepared as described in Example 1 by using
5-(5 -chlorosulfonyl-2-ethoxyphenyl)-2-iodo- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyr rolo[4,3-_/]pyrimidin-7-one and l-(2-hydroxyethyl)piperazine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-c/]pyrimidin-7-one and 1 -methylpiperazine. yield: 99% mp 194-195 °C (CΗCl3/hexanes);
IR (neat) 3442, 3323 (NH and OH), 1677 (CO), 1171 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 65 (t, J= 6. 9 liz,
3 Η, OCΗ2CH3), 1. 66-1. 78 (m, 2 Η, CΗ2CH2CΗ3), 2. 56 (t, J = 5. 4 Hz, 2 H,
NCH,CH2), 2. 62 (dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 H, CH,CH,CH3), 3. 12 (br dd, J= 4. 8 Hz, 4. 5 Hz, 4 H, 2 SO,NCH2), 3. 58 (t, J= 5. 4 Hz, 2 H, CH2CH2OH), 4. 11 (s, 3 H, NCH3), 4. 37 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 15 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 82 (dd, J- 8. 7 Hz, 2. 4 Hz, 1 H, H-4')5 8. 86 (d, J= 2. 4 Hz, 1 H, H-6*), 10. 68 (br s, 1 H, NH); MS (FAB) m/z 630 (MIL).
Example 95
Preparation of
5-(5-(4-(2-hydroxyethyl)piperazinylsulfonyl)-2-τ7-propoxyphenyl)-2-iodo-l-methyl-3- 77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_i]pyrimidm-7-one (a compound of the formula
(1) wherem R5 = SO2NR6R7, R1 = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-(2-hydroxyethyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-2-iodo-l-methyl-3-77-propyl-l,6-dihydro-7H- pyrrolo[4,3-_ ]pyrimidm-7-one and l-(2-hydroxyethyl)piperazine in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-<3rjpyrimidin-7-one and 1 -methylpiperazine. yield: 97% mp 183-184 °C (EtOAc/CΗCl3/hexanes); IR (neat) 3305 (NH and OH), 1686 (CO), 1172 (SO2) cm'1;
Η NMR (CDCI3/TMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH2CH,CH3), 1. 19 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 66-1. 78 (m, 2 Η, CΗ2CH2CΗ3), 1. 99-2. 11 (m, 2 H,
OCH,CH2CH3), 2. 31 (br s, 1 H, OH), 2. 55 (t, J= 5. 4 Hz, 2 H, NCH2CH2), 2. 61 (dd,
J= 5. 4 Hz, 4. 5 Hz, 4 H, 2 NCH2), 2. 71 (t, J= 7. 5 Hz, 2 Ii, CH2CH2CH3), 3. 12 (br dd, J= 5. 4 Hz, 4. 5 Hz, 4 H, 2 SO2NCH2), 3. 57 (br t, J= 5. 4 Hz, 2 H, CH2CH2OH),
4. 11 (s, 3 H, NCH3), 4. 26 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 15 (d, J= 8. 7 Hz, 1
H, H-3'), 7. 83 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'),
10. 71 (br s, 1 H, NH); MS (FAB) m/z 644 (MH+).
Example 96
Preparation of
5-(2-ethoxy-5-(4-(3-hydroxypropyl)piperazinylsulfonyl)phenyl)-2-iodo-l-methyl-3-77- propyl-1 ,6-dihydro-7H-pyrrolo[4,3-c/]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = I, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3 -hydroxypropyl)piperaziny 1)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-ethoxyphenyl)-2-iodo-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyr rolo[4,3-< ]pyrimidin-7-one and l-(3-hydroxypropyl)piperazine in place of 5-(5-chloiOsulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydiO-7H-pyrrolo[4, 3-< jpyrimidin-7-one and 1 -methylpiperazine. yield: 96% mp 120-121 °C (CΗCl3/hexanes); IR (neat) 3341 (NH and OH), 1678 (CO), 1172 (SO2) cm'1; 'H NMR (CDCl/TMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 53-1. 64 (m, 2 Η, CΗ2CH,CΗ2OΗ), 1. 63-1. 76 (m, 2 H, CH,_CH,CH3), 1. 65 (t, J = 6. 9 Hz, 3 H, OCH,CH3), 2. 62-2. 74 (m, 6 Ii, NCH2CΗ, and 2 NCH2), 2. 71 (t, J = 7. 2 Hz, 2 Ii, CH,CFI,CH3), 3. 07-3. 15 (m, 4 H, 2 SO2NCH2), 3. 71 (t, J = 5. 1 Hz, 2 H, CH,CH2OH), 4. 11 (s, 3 H, NCH3), 4. 38 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 13 (d, J = 8. 7 Hz, 1 H, H-3'), 7. 79 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 85 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 68 (br s, 1 H, NH); MS (FAB) m/z 644 (MIL).
Example 97
Preparation of 5-(5-(4-(3-hydroxypropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-2-iodo-l-methyl- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-( Jpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = I, R3 = CH2CH2CH„ R4 = CH2CH2CH3; NRδR7 is 4-(3-hydroxypropyl)piperazinyl)
The titled compound was prepared as described in Example 1 by using
5 -(5 -chlorosulfonyl-2-77-propoxyphenyI)-2-iodo- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H~ pyιτolo[4,3-_ |pyrimidin-7-one and 1 -(3-hydroxypropyl)piperazine in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,
3-c/]pyrimidin-7-one and 1 -methylpiperazine. yield: 89% mp 206-206. 5 °C (EtOAc/CΗCl3/hexanes);
IR (neat) 3423, 3310 (NH and OH), 1683 (CO), 1171 (SO2) cm'1;
'H NMR (CDCl TMS) δ 0. 97 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 20 (t, J= 7. 5 Iiz,
3 Η, OCΗ2CΗ2CH3), 1. 62-1. 78 (m, 4 Η, CΗ,_CH2CΗ2OΗ and CH2CH2CH3), 1. 99-2.
1 1 (m, 2 H, OCH2CH2CH3), 2. 58-2. 63 (m, 6 H, NCH2CH, and 2 NCH2), 2. 71 (t, J=
7. 5 Hz, 2 H, CH2CH2CH3), 3. 03-3. 12 (m, 4 H, 2 SO2NCH2), 3. 71 (t, J= 5. 4 Hz, 2
H, CH,CH2OH), 4. 11 (s, 3 H, NCH3), 4. 26 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 7. 14
(d, J= 9. 0 Hz, 1 H, H-3'), 7. 79 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4
Hz, 1 H, H-6'), 10. 72 (br s, 1 H, NH); MS (FAB) m/z 658 (MH+).
Example 98
Preparation of
5-(5-(4-(2-aminoethyl)piperidinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6- dihydro-7H-pyrrolo[4,3-<JJpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-aminoethyl)piperidinyl)
A mixture of
5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)- 1 -methyl-3-77-propy 1- 1 ,6- dihydro-7H-pyrrolo[4,3-(Jjpyrimidin-7-one (217 mg, 0. 44 mmol) and Raney Ni (1. 5 g wet; washed with Η2O and EtOH) in glacial acetic acid (20 mL) was purged with H2 tliree times, and was vigorously stirred under hydrogen atmosphere (1 atm; a balloon) at room temperature for 22 h. The reaction mixture was filtered tlirough a Celite pad, washed well with 10% MeOH in CHC13 (20 mL), and the filtrate was evaporated to dryness under vacuum to give a green oil. The resulting residue was purified by
MPLC on silica gel (gradient elution: 10% MeOH in CHC13 followed by 10% 2 N ammonia methanolic solution in CHC13) to afford the titled compound (185 mg, 84%) as a yellow oil. Analytically pure compound was obtained by crystallization from EtOH/Et2O. 5 mp 60 °C dec;
IR (neat) 3335 (ΝH), 1685 (CO), 1165 (SO-) cm'1;
'H ΝMR (DMSO- 6) δ 0. 92 (t, J = 7. 2 Hz, 3 H, CH2CH,CH3), 1. 07-1. 35 (m, 5 Η, CHCH2 and 2 CΗJ, 1. 35 (t, J = 6. 9 Ηz, 3 Η, OCΗ,_CH3), 1. 57-1. 70 (m, 4 Η, CΗ2CH2CΗ3 and 2 CHeq), 2. 23 (br t, J= 11. 4 Hz, 2 H, 2 ΝCHJ, 2. 48-2. 59 (m, 4 H, o CH2CH2ΝH2 and CH2CH2CH3), 3. 61 (br d, J = 11. 4 Hz, 2 H, 2 NCHeq), 3. 98 (s, 3 H, NCH3), 4. 22 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 22 (s, 1 H, H-2), 7. 35 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J- 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 7. 91 (d, J= 2. 7 Hz, 1 H, H-6'); MS (FAB) m/z 502 (MH4).
5 Example 99
Preparation of
5-(5-(4-(2-aminoethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-piOpyl- l,6-dihydro-7H-pyrrolo[4,3-(i]pyrimidin-7-one (a compound of the formula (1) wherein K5 = SO2NRδR7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH,CH3; 0 NR6R7 is 4-(2-aminoethyl)piperidinyl)
The titled compound was prepared as described in Example 95 by using 5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-piOpyl- l,6-dihydro-7H-pyπOlo[4,3-_f]pyrimidin-7-one in place of
5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-propyl- l ,6- 5 dihydro-7H-pyrrolo[4,3-< ]pyrimidin-7-one. yield: 90% mp 145 °C dec (EtOΗ/Et2O); IR (neat) 3304 (NH), 1673 (CO), 1152 (SO2) cm'1; Η NMR (DMSO-_f6) δ 0. 92 (t, J- 7. 5 Hz, 3 H, CH2CH2CH3), 0. 97 (t, J= 7. 2 Ηz, 3
H, OCH2CH2CH3), 1. 12-1. 28 (m, 3 Η, CHCH2), 1. 60-1. 79 (m, 8 Η, 2 CΗ2CH,CΗ3 and 2 CH2), 2. 17-2. 28 (m, 2 H, 2 NCH , 2. 44-2. 53 (m, 2 H, CH2CH,NH2), 2. 57 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 3. 63 (br d, J= 10. 5 Hz, 2 H, 2 NCHeq), 3. 99 (s, 3 H, NCH3), 4. 13 (t, J= 6. 0 Hz, 2 H, OCH2CH2CH3), 7. 22 (s, 1 H, H-2), 7. 37 (d, J = 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J- 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 92 (d, J- 2. 4 Hz, 1 H, H-6'); MS (FAB) m/z 516 (MH+).
Example 100
Preparation of 5-(5 -(4-(3-aminopropy l)piperidinylsulfonyl)-2-ethoxyphenyl)- 1 -methyl-3-77-propy 1- 1 , 6-dihydro-7H-pyrrolo[4,3-_ )pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(3 -aminopropy l)piperidinyl)
The titled compound was prepared as described in Example 95 by using 5-(5-(4-(2-cyanoethyl)piperidinylsulfonyl)-2-ethoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6- dihydro-7H-pyrrolo[4,3-c ]pyrimidin-7-one in place of
5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)- 1 -methy 1-3-77-propy 1- 1 ,6- dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one. yield: 87% mp 55 °C dec (TΗF/Et2O);
IR (neat) 3338 (NH), 1683 (CO), 1162 (SO2) cm'1;
Η NMR (DMSO- ) δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 08-1. 20 (m, 5 Η, CHCH2 and 2 CΗJ, 1. 27-1. 41 (m, 2 Η, CΗ2CH2CΗ,NΗ2), 1. 35 (t, J= 6. 9 Hz, 3 Ii, OCH2CH3), 1. 57-1. 70 (m, 4 Η, CΗ2CH,CΗ3 and 2 CHJ, 2. 16-2. 29 (m, 2 H, 2 NCHJ, 2. 47-2. 59 (m, 4 H, CH2GH,NH2 and CH2CH2CH3), 3. 62 (br d, J= 11. 2 Hz, 2 H, 2 NCHJ, 3. 99 (s, 3 H, NCH3), 4. 22 (q, J= 6. 9 Hz, 2 H, OCH,CH3), 7. 22 (s, 1 H, H-2), 7. 35 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 79 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 90 (d, J= 2. 4 Hz, 1 H, H-6'); MS (FAB) m/z 516 (MIL).
Example 101
Preparation of
5-(5 -(4-(3 -aminopropy l)piperidiny lsulfonyl)-2-77-propoxyphenyl)- 1 -methyl-3 -77-propy I-l,6-dihydiO-7H-pyrrolo[4,3-_/]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R' = CΗ3, R2 = H, R3 = CH2CH,CH3, R4 = CH2CH2CH3; NR6R7 is 4-(3 -aminopropy l)piperidinyl)
The titled compound was prepared as described in Example 95 by using 5-(5-(4-(2-cyanoethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyI- l,6-dihydro-7H-pyrrolo[4,3-(fjpyrimidin-7-one in place of 5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6- dihydro-7H-pyrrolo[4,3-<f|pyrimidin-7-one. yield: 79% mp 119-120 °C (EtOΗ/Et2O); TR (neat) 3308 (NH), 1690 (CO), 1165 (SO2) cm'1; Η NMR (DMSO- ) δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 0. 97 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 10-1. 34 (m, 7 Η, CHCH2CH2 and 2 CΗJ, 1. 58-1. 80 (m, 6 Η, 2 CΗ2CH2CΗ3 and 2 CHJ, 2. 21-2. 28 (m, 2 H, 2 NCHJ, 2. 43-2. 52 (m, 2 H, CH2CH2NH2), 2. 57 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 3. 63 (br d, J= 10. 8 Hz, 2 H, 2 NCHJ, 3. 99 (s, 3 H, NCH3), 4. 12 (t, J= 6. 3 Hz, 2 H, OCH,CH2CH3), 7. 22 (s, 1 H, Ii-2), 7. 37 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 79 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 92 (d, J= 2. 4 Hz, 1 H, H-6'); MS (FAB) 777/z 530 (MH+).
Example 102
Preparation of 5-(5-(4-(dimethylaminomethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3- 77-propyl- l,6-dihydro-7H-pyrrolo[4,3J]pyrimidin-7-one (a compound of the formula (1) wherein R5 - SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH,CH3, R4 = CH2CH2CH3; NR6R7 is 4-(dimethylaminomethyl)piperidinyl)
The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo [4,3-_ ]pyrimidin-7-one and 4-(dimethylaminomethyl)piperidine trifluoroacetic acid in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-< jpyrimidin-7-one and 1 -methylpiperazine. yield: 92% mp 123. 5 °C dec (MeOΗ/EtO Ac/hexanes); IR (neat) 3342 (NΗ), 1686 (CO), 1167 (SO2) cm'1; Η NMR (CDCl/TMS) δ 1. 00 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 18 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 23-1. 46 (m, 3 Η, CΗ and 2 CΗJ, 1. 67-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 1. 82 (br d, J = 12. 3 Hz, 2 H, 2 CHJ, 1. 97-2. 13 (m, 4 Ii, OCH2CH,CH3 and CH2N(CH3),), 2. 15 (s, 6 H, N(CH3)2), 2. 35 (br t, J= 12. 3 Hz, 2 H, 2 NCHJ, 2. 71 (t, J= 7. 5 Hz, CH2CH,CH3), 3. 85 (br d, J= 12. 3 Hz, 2 H, 2 NCH , 4. 08 (s, 3 H, NCH3), 4. 24 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 89 (s, 1 H, H-2), 7. 13 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 82 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 86 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 67 (br s, 1 H, NH); MS (FAB) m/z 530 (MH+).
Example 103
Preparation of 5-(5-(4-(2-(dimethylamino)ethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l -methyl-3 -77-propyl- l,6-dihydro-7H-pyrrolo[4,3-( lpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(2-(dimethylamino)ethyl)piperidinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l -methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo [4,3-<JJpyrimidin-7-one and 4-(2-(dimethylamino)ethyl)piperidine trifluoroacetic acid in place of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyπOlo[4, 3-_ |pyrimidin-7-one and 1 -methylpiperazine.
yield: 71% mp 160. 5 °C dec (MeOH/EtOAc/hexanes); IR (neat) 3294 (NH), 1693 (CO), 1163 (SO2) cm'1;
Η NMR (CDC13/TMS) δ 1. 00 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 19 (t, J= 7. 2 Iiz, 3 Η, OCΗ2CΗ2CH3), 1. 26-1. 41 (m, 5 Η, CHCH2 and 2 CΗJ, 1. 60-1. 78 (m, 4 Η, CΗ,CH,CΗ, and 2 CHJ, 1. 98-2. 10 (m, 2 H, OCH,CH2CH3), 2. 18 (s, 6 H, N(CH3)2), 2. 25 (t, J= 7. 5 Hz, 2 H, CH2CH2N), 2. 35 (br t, J= 11. 4 Ηz, 2 Η, 2 NCΗ j, 2. 71 (t, J= 7. 5 Ηz, 2 Η, CH2CΗ2CΗ3), 3. 81 (br d, J= 12. 0 Hz, 2 H, 2 NCHJ, 4. 08 (s, 3 H, NCH3), 4. 24 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 89 (s, 1 H, H-2), 7. 12 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 87 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 67 (br s, 1 H, NH); MS (FAB) m/z 544 (MH+).
Example 104
Preparation of 5-(2-ethoxy-5-(4-(hydroxycarbonyl)piperidinylsulfonyl)phenyl)-l-methyl-3-77-propyl- l,6-dihydro-7H-pyrrolo[4,3-<i]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NR6R7, R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(hydroxycarbonyl)piperidinyl)
The titled compound was prepared as described in Example 1 by using isonicopetic acid in place of 1 -methylpiperazine. yield: 96% mp 193-193. 5 °C (EtOAc/hexanes);
IR (neat) 3334, 3104 (NH and CO2H), 1669 (CO), 1 164 (SO2) cm'1;
Η NMR (CDCl/TMS) δ 0. 98 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 56 (t, J= 6. 9 Ηz, 3 Η, OCΗ,CH3), 1. 65-1. 77 (m, 2 Η, CΗ,CH2CΗ3), 1. 78-1. 86 (m, 2 H, 2 CHJ, 1.
90-2. 05 (m, 2 H, 2 CHJ, 2. 23-2. 32 (m, 1 H, CHCO,), 2. 50-2. 59 (m, 2 Ii, 2
NCHJ, 2. 70 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 67-3. 73 (m, 2 H, 2 NCHJ, 4. 07
(s, 3 H, NCH3), 4. 30 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 92 (s, 1 H, H-2), 7. 11 (d, J=
8. 7 FIz, 1 H, H-3'), 7. 81 (dd, J- 8. 7 Hz, 2. 1 Hz, 1 H, H-4'), 8. 61 (d, J= 2. 1 Hz, 1
H, H-6'), 11. 08 (br s, 1 H, NH); MS (FAB) 777/z 503 (MH+).
Example 105
Preparation of 5-(5-(4-(hydroxycarbonyl)piperidinylsulfonyl)-2-77-piOpoxyphenyl)-l-methyl-3-77-pro pyl-l ,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 - H, R3 = CH2CH,CH3, R4 = CH2CH,CH3;
NR6R7 is 4-(hydroxycarbonyl)piperidinyl)
The titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo
[4,3-_f]pyrimidin-7-one and isonicopetic acid in place of
5 -(5 -chlorosulfonyl-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrro lo [4,
3-_ ]pyrimidin-7-one and 1 -methylpiperazine. yield: 92% mp 155-155. 5 °C (EtOAc/Et2O/hexanes);
IR (neat) 3349, 3101 (NΗ and CO2Η), 1691, 1654 (CO), 1164 (SO2) cm'1;
Η NMR (CDCl/TMS) δ 0. 99 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 11 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 65-1. 77 (m, 2 Η, CΗ2CH2CΗ3), 1. 78-2. 04 (m, 6 H,
OCH,CH,CH3 and 2 CH2), 2. 23-2. 35 (m, 1 H, CHCO2), 2. 53-2. 60 (m, 2 Ii, 2 NCHJ, 2. 70 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 63-3. 69 (m, 2 H, 2 NCHJ, 4. 07
(s, 3 H, NCH3), 4. 19 (t, J= 6. 6 Hz, 2 H, OCH2CH,CH3), 6. 93 (s, 1 H, H-2), 7. 13 (d,
J= 9. 0 Hz, 1 H, H-3'), 7. 81 (dd, J= 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 8. 56 (br s, 1 H,
H-6'), 11. 08 (br s, 1 H, NH); MS (FAB) m/z 517 (MIL).
Example 106
Preparation of
5-(2-ethoxy-5-(4-(hydroxycarbonyImethyl)piperidinylsulfonyI)phenyl)-l-methyl-3-77- propyl-l,6-dihydro-7H-pyrrolo[4,3-<i]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 - H, R3 = CH2CH,CH3, R4 = CH,CH3; NR6R7
is 4-(hydroxycarbonylmethyl)piperidinyl)
A suspension of
5-(2-ethoxy-5-(4-(ethoxycarbonylmethyl)piperidinylsulfonyl)phenyl)-l-methyl-3-77-pr opyl-l ,6-dihydro-7H-pyrrolo[4,3-_ |pyrimidin-7-one (146 mg, 0. 28 mmol) and 1. 0 N OΗ methanolic solution (0. 70 mL, 0. 70 mmol) in a 1 :4 mixture of Η2O and EtOH (7 mL) was heated at 50 °C for 2-5 h, and was cooled to room temperature. Ethanol was removed under vacuum, and the mixture was diluted with H2O (50 mL). The reaction mixture was acidified to pH 4 using 1 N HCl aqueous solution, and was extracted with 5% MeOH in CHCL, (70 mL x 2). The combined organic layer was dried (MgSO4), filtered, and the filtrate was evaporated to dryness under reduced pressure to give a white solid. The resulting residue was purified by MPLC on silica gel (5% MeOH in CHC13) to afford the titled compound (136 mg, 99%) as a white solid. Analytically pure compound was obtained by crystallization from CHCl3/Et2O. mp l 38. 5-139. 5 °C;
IR (neat) 3328, 3098 (NH and CO,H), 1685, 1661 (CO), 1163 (SO2) cm'1; 'H NMR (CDCl/TMS) δ 0. 98 (t, J= 7. 5 Hz, 3 H, CH2CH,CH3), 1. 32-1. 46 (m, 2 Η, 2 CΗJ, 1. 56 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 65-1. 80 (m, 5 Η, CΗ, 2 CΗeq and CH2CH2CH3), 2. 25 (d, J= 6. 6 Hz, 2 H, CH,CO2), 2. 37 (td, J= 12. 0 Hz, 2. 4 Hz, 2 H, 2 NCHJ, 2. 70 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 82 (br d, J= 11. 4 Hz, 2 Ii, 2 NCHJ, 4. 07 (s, 3 H, NCH3), 4. 29 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 91 (s, 1 H, H-2), 7. 09 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 80 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 8. 65 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 02 (br s, 1 H, NH); MS (FAB) m/z 517 (MH÷).
Example 107
Preparation of
5-(5-(4-(hydroxycarbonylmethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l -methyl-3 -77-propyl-l,6-dihydro-7H-pyrrolo[4,3-<^pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-(hydroxycarbonylmethyl)piperidinyl)
The titled compound was prepared as described in Example 103 by using
5-(5-(4-(ethoxycarbonyImethyl)piperidinylsulfonyI)-2-77-propoxyphenyl)-l-methyl-3-
77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one in place 5-(2-ethoxy-5-(4-(ethoxycarbonylmethyl)piperidinylsulfonyl)- phenyl)-l-methyl-3-77-propyl-l ,6-dihydiO-7H-pyrrolo[4,3-c ]pyrimidin-7-one. yield: 89% mp 181. 5-182 °C (EtOAc/Et2O/hexanes);
IR (neat) 3350 (NΗ and CO2Η), 1720, 1658 (CO), 1 157 (SO2) cm'1; 'H NMR (CDC13/TMS) δ 0. 98 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 13 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 33-1. 46 (m, 2 Η, 2 CΗJ, 1. 65-1. 83 (m, 5 Η, CΗ, 2 CΗeq and CH2CH2CH3), 1. 91-2. 03 (m, 2 H, OCH,CH2CH3), 2. 25 (d, J = 6. 6 Hz, 2 H,
CH2CO2), 2. 32-2. 41 (m, 2 H, 2 NCHJ, 2. 70 (t, J = 7. 5 Hz, 2 H, CH,CH2CH3), 3.
82 (br d, J= 11. 1 Hz, 2 H, 2 NCHJ, 4. 07(s, 3 H, NCH3), 4. 19 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 91 (s, 1 H, H-2), 7. 1 1 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J= 8. 7
Hz, 2. 4 Hz, 1 H, H-4'), 8. 68 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 98 (br s, 1 H, NH); MS
Example 108 Preparation of
5-(2-etboxy-5-(4-(2-hydroxycarbonylethyl)piperidinylsυlfonyl)phenyl)-l-methyl-3-77- piOpyl-l,6-dihydro-7H-pyrrolo[4,3-rf]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH,CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-hydroxycarbonylethyl)piperidinyl) The titled compound was prepared as described in Example 103 by using
5-(2-ethoxy-5-(4-(2-ethoxycarbonylethyl)piperidinylsulfonyl)phenyl)-l-methyl-3-77-pr opyl-l,6-dihydro-7H-pyrrolo[4,3-d]pyrimidin-7-one in place
5-(2-ethoxy-5-(4-(ethoxycarbonylmethyl)piperidinylsulfonyl)phenyl)-l-methyl-3-77-pr opyl-l,6-dihydro-7H-pyrrolo[4,3-^pyr_m_dhι-7-one.
yield: 92% mp 129-130. 5 °C (CHCl3/Et,O);
IR (neat) 3114, 3044 (NH and CO2H), 1708, 1671 (CO), 1164 (SO2) cm'1; Η NMR (CDCyTMS) δ 0. 98 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 17-1. 40 (m, 3 Η, CΗ and 2 CΗJ, 1. 56 (t, J = 6. 9 Hz, 3 Η, OCΗ2CH3), 1. 48-1. 64 (m, 2 Η, CΗCH2CΗ2), 1. 65-1. 79 (m, 4 H, 2 CHeq and CH2CH,CH3), 2. 30 (t, J= 7. 5 FIz, 2 Ii, CH,CO,), 2. 32 (br t, J = 12. 0 Hz, 2 H, 2 NCHJ, 2. 70 (t, J = 7. 5 Hz, 2 H, CH2CH,CH3), 3. 81 (br d, J= 12. 0 Hz, 2 H, 2 NCHJ, 4. 07 (s, 3 H, NCH3), 4. 31 (q, J= 6. 9 Hz, 2 H, OCH,CH3), 6. 90 (s, 1 H, H-2), 7. 10 (d, J= 9. 0 Hz, 1 FI, H-3'), 7. 78 (dd, J= 9. 0 Hz, 2. 1 Hz, 1 H, H-4'), 8. 69 (d, J= 2. 1 Hz, 1 H, H-6'), 10. 95 (br s, 1 H, NH); MS (FAB) 777/z 531 (MH+).
Example 109
Preparation of 5-(5-(4-(2-hydroxycarbonylethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l -methyl-3
-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-c/]pyrimidin-7-one (a compound of the formula
(1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3;
NR6R7 is 4-(2-hydroxycarbonylethyl)piperidinyl)
The titled compound was prepared as described in Example 103 by using 5-(5-(4-(2-ethoxycarbonylethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-
77-propyl-l ,6-dihydro-7H-pyrroIo[4,3-6/]pyrimidin-7-one in place
5-(2-ethoxy-5-(4-(ethoxycarbonylmethyl)piperidinylsulfonyl)- phenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-( |pyrimidin-7-one. yield: 95% mp 182-183 °C (EtOAc/Et2O/hexanes);
IR (neat) 3112, 3039 (NΗ and CO2Η), 1741, 1706, 1672 (CO), 1163 (SO2) cm'1;
Η NMR (CDCl/TMS) δ 0. 99 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 16 (t, J= 7. 5 Ηz,
3 Η, OCΗ2CΗ2CH3), 1. 23-1. 30 (m, 3 Η, CΗ and 2 CΗJ, 1. 48-1. 63 (m, 2 Η,
CΗCH,CΗ2), 1. 69-1. 78 (m, 4 H, 2 CHeq and CH2CH2CH3), 1. 97-2. 04 (m, 2 H,
OCH2CH2CH3), 2. 32 (t, J= 7. 5 Hz, 2 H, CH2CO2), 2. 33-2. 41 (m, 2 H, 2 NCHJ, 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 78-3. 84 (m, 2 H, 2 NCHJ, 4. 08 (s, 3 H, NCH3), 4. 22 (t, J= 6. 6 Hz, 2 H, OCH2CH2CH3), 6. 90 (s, 1 H, H-2), 7. 12 (d, J= 8. 7 Hz, 1 Ii, H-3'), 7. 81 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 76 (d, J= 2. 4 Hz, 1 H, H-6'), 10. 80 (br s, 1 H, NH); MS (FAB) m/z 545 (MH+).
Example 110
Preparation of
5-(5-(4-(amidinomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-propyl-l, 6-dihydro-7H-pyrrolo[4,3-<JJpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(amidinomethyl)piperidinyl)
A suspension of
5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)- 1 -methyl-3-77-propyI- 1 ,6- dihydro-7H~pyrrolo[4,3-<JJpyrimidin-7-one (327 mg, 0. 44 mmol) in anliydrous EtOΗ (30 mL) was saturated with anhydrous ΗC1 gas at -10 °C for 30 min, and was tightly stoppered. The resulting clear mixture was warmed to room temperature, and was stirred at room temperature for 15-24 h, after which all the volatile materials were completely removed under vacuum. The crude yellow solid was dissolved in anhydrous MeOΗ (20 mL), saturated with anliydrous ammonia at 0 °C for 30 min, and was tightly stoppered. The reaction mixture was warmed to room temperature, and was stirred at room temperature for 15-24 h. The reaction mixture was evaporated to dryness under reduced pressure and the resulting residue was purified by MPLC on silica gel (gradient elution: 10% MeOΗ in CΗC1, followed by 20% 2 N ammonia methanolic solution in CΗC13) to afford the titled compound (197 mg, 58%) as a yellowish solid. Analytically pure compound was obtained by crystallization from EtOH/Et2O. mp 168 °C dec; IR (neat) 3323, 3140 (ΝH), 1683 (CO), 1163 (SO2) cm'1;
'H NMR (DMSO-d6) δ 0. 92 (t, J= 7. 2 Hz, 3 H, CH,CH2CH3), 1. 23-1. 32 (m, 2 Η, 2 CΗJ, 1. 36 (t, J= 6. 9 Hz, 3 Η, OCΗ,CH3), 1. 57-1. 74 (m, 5 Η, CΗ, CΗ2CH2CΗ3 and 2 CHJ, 2. 25 (br t, J = 11. 7 Hz, 2 H, 2 NCHJ, 2. 30 (d, J = 7. 2 Hz, 2 Ii, CHCH2), 2. 57 (t, J = 7. 5 Ηz, 2 Η, CH2CΗ2CΗ3), 3. 66 (br d, J = 11. 7 Hz, 2 Ii, 2 NCHJ, 3. 99 (s, 3 H, NCH3), 4. 22 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 23 (s, 1 H, H-2), 7. 36 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 81 (dd, J= 9. 0 Hz, 2. 1 Hz, 1 H, H-4'), 7. 92 (d, J = 2. 1 Hz, 1 H, H-6'), 8. 62 (br s, 1. 5 H, amidine NH), 8. 95 (br s, 1. 5 H, a idine NH), 11. 68 (br s, 1 H, NH); MS (FAB) m/z 515 (MH+).
Example 1 1 1
Preparation of
5-(5-(4-(amidinomethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propy l-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH,CH3; NR6R7 is 4-(amidinomethyl)piperidinyl)
The titled compound was prepared as described in Example 107 by using 5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyl- l,6-dihydro-7H-pyrrolo[4,3--idpyrimidin-7-one in place of
5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-piOpyI-l ,6- dihydro-7H-pyrrolo[4,3-<flpyrimidin-7-one. yield: 69% mp 181. 5 °C dec (EtOΗ/Et2O);
IR (neat) 3324, 3089 (NH), 1682 (CO), 1 164 (SO,) cm'1; Η NMR (DMSO-fiQ δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH,_CH2CH3), 0. 97 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 21-1. 32 (m, 2 Η, 2 CΗJ, 1. 60-1. 79 (m, 7 Η, CΗ, 2 CΗ,CH,CΗ3 and 2 CH , 2. 21-2. 31 (m, 4 H, 2 CHCH, and NCΗJ, 2. 57 (t, J= 7. 5 Ηz, 2 Η, CH2CΗ,CΗ3), 3. 66 (br d, J= 11. 4 Hz, 2 H, 2 NCHJ, 3. 99 (s, 3 H, NCH,), 4. 13 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 22 (s, 1 H, H-2), 7. 37 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 92 (d, J= 2. 4 Hz, 1 H, H-6'), 8. 57
(br s, 1. 5 H, amidine NH), 8. 93 (br s, 1. 5 H, amidine NH), 11. 63 (br s, 1 H, NH); MS (FAB) m/z 529 (MIL).
Example 1 12 Preparation of
5-(5-(4-(2-amidinoethyl)piperidinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-propyl-l, 6-dihydro-7H-pyrrolo[4,3-(fJpyrimidin-7-one (a compound of the formula (1) wherem R3 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-amidinoethyl)piperidinyl) The titled compound was prepared as described in Example 107 by using
5-(5-(4-(2-cyanoethyl)piperidinylsulfonyl)-2-ethoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6- dihydro-7H-pyr_-olo[4,3-_ ]pyrimidin-7-one in place of
5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6- dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one. yield: 55% mp 186-186. 5 °C (EtOΗ/Et2O);
IR (neat) 3399, 3346, 3080 (NH), 1690 (CO), 1 157 (SO2) cm'1;
Η NMR (DMSO- 6) δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 15-1. 25 (m, 2 Ii, 2
CΗJ, 1. 35 (t, J = 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 50-1. 75 (m, 7 Η, CHCH2, CΗ2CH2CΗ3 and 2 CHJ, 2. 21-2. 27 (m, 2 H, 2 NCHJ, 2. 32-2. 37 (m, 2 H, CH2CH2C(=NH)NH2), 2. 57 (t, J= 7. 5 Hz, CH,CH2CH3), 3. 63 (br d, J= 10. 8 Hz, 2 H, 2 NCHJ, 3. 99 (s, 3 H, NCH3), 4. 22 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 23 (s, 1 H, H-2), 7. 36 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 91 (d, J = 2. 4 Hz, 1 H, H-6'), 8. 55 (br s, 1. 5 H, amidine NH), 8. 93 (br s, 1. 5 H, amidine NH), 11. 68 (br s, 1 H, NH); MS (FAB) m/z 529 (MH+).
Example 1 13
Preparation of
5-(5-(4-(2-amidinoethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propy
l-l,6-dihydro-7H-pyrrolo[4,3-< ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NRδR7, R1 = CΗ3, R2 = H, R3 = CH2CH,CH3, R4 = CH2CH2CH3; NR6R7 is 4-(2-amidinoethyl)piperidinyl)
The titled compound was prepared as described in Example 107 by using 5-(5-(4-(2-cyanoethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyl- l ,6-dihydro-7H-pyrrolo[4,3-<i]pyrimidi_ι-7-one in place of
5-(5-(4-(cyanomethyl)piperidinylsulfonyl)-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6- dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one. yield: 55% p 135 °C dec (EtOΗ/Et2O);
IR (neat) 3331, 3070 (NH), 1685 (CO), 1161 (SO,) cm'1;
Η NMR (DMSO-d6) δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 0. 97 (t, J= 7. 2 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 15-1. 25 (m, 2 Η, 2 CΗJ, 1. 49-1. 71 (m, 5 Η, CHCH2 and CΗ2CH2CΗ3), 1. 72-1. 78 (m, 4 H, OCH,CH2CH3 and 2 CHJ, 2. 20-2. 27 (m, 2 Ii, 2 NCHJ, 2. 32-2. 37 (m, 2 H, CH2CH,C(=NH)NH2), 2. 57 (t, J = 7. 5 Hz, CH2CH2CH3), 3. 63 (br d, J= 11. 1 Hz, 2 H, 2 NCHJ, 3. 99 (s, 3 H, NCH3), 4. 12 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 22 (s, 1 H, H-2), 7. 36 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 91 (d, J= 2. 4 Hz, 1 H, H-6'), 8. 57 (br s, 1. 5 H, amidine NH), 8. 94 (br s, 1. 5 H, amidine NH), 11. 64 (br s, 1 H, NH); MS
Example 1 14
Preparation of
5-(2-ethoxy-5-(lH-tetrazol-5-yl)phenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo [4,3 J]pyrimidin-7-one (a compound of the formula (1) wherein R5 = lH-tetrazol-5-yl, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 - CH2CH3)
A suspension of
5-(5-cyano-2-etlιoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3- ]pyri midin-7-one (150 mg, 0. 45 mmol), tributyltin chloride (133 μL, 0. 49 mmol) and
sodium azide (29 mg, 0. 45 mmol) in anhydrous toluene (1. 0 mL) was heated at 120 °C for 70 h, after which the mixture was cooled to room temperature. The reaction mixture was diluted with 5% aqueous NaOH solution (25 mL), and was extracted with CHCl, (15 mL x 3). The organic layers were discarded, and the aqueous layer was acidified to pH 2 using 10% aqueous HCl. The resulting white precipitates were collected and was dried under vacuum to afford the titled compound (148 mg, 87%) as a white solid. Analytically pure compound was obtained by crystallization from CHCyMeOH/hexanes. mp 245 °C dec; IR (neat) 3325, 3023 (NH), 1666 (CO) cm'1;
Η NMR (DMSO-d6) δ 0. 93 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 37 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 59-1. 70 (m, 2 Η, CΗ2CH2CΗ3), 2. 60 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 4. 00 (s, 3 H, NCH3), 4. 22 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 23 (s, 1 Ii, H-2), 7. 38 (d, J= 8. 7 Hz, 1 H, H-3'), 8. 12 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4*), 8. 31 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 69 (br s, 1 H, NH); MS (FAB) m/z 380 (MH+).
Example 1 15
Preparation of l-methyl-5-(2-77-propoxy-5-(lH-tetrazol-5-yl)phenyl)-3-77-propyl-l,6-dihydro-7H-pyrr olo[4,3-fiT|pyrimidin-7-one (a compound of the formula (1) wherein R5 = lH-tetrazol-5-yl, R1 = CΗ3, R2 = H, R3 = CH,_CH2CH3, R4 = CH2CH2CH3)
The titled compound was prepared as described in Example 111 by using
5-(5-cyano-2-77-propoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-_ ]p yrimidin~7~one in place of 5-(5-cy ano-2-ethoxypheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,3 -tfjpyri midin-7-one. yield: 58% mp 250. 5 °C dec (CΗCl3/Et2O);
IR (neat) 3324, 3023 (NH), 1671 (CO) cm'1;
'HNMR (DMSO- β) δ 1. 01 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 06 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 66-1. 78 (m, 2 Η, CΗ2CH2CΗ3), 1. 79-1. 91 (m, 2 H, OCH,CH2CH3), 2. 67 (t, J= 7. 5 Hz, 2 H, CH,CH2CH3), 4. 13 (s, 3 H, NCH,), 4. 19 (t, J= 6. 6 Hz, 2 H, OCH,CH2CH3), 7. 30 (s, 1 H, H-2), 7. 44 (d, J= 8. 7 Hz, 1 H, H-3'), 8. 19 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 39 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 70 (br s, 1 H, NH); MS (FAB) 777/z 394 (MH+).
Example 1 16
Preparation of 5-(2-ethoxy-5-(4-(lH-tetrazol-5-ylmethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-p ropyl-l,6-dihydro-7H-pyrrolo[4,3-c |pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NR6R7, R1 = CΗ3, R2 = Ii, R3 = CH2CH2CH3, R4 = CH,CH3; NR6R7 is 4-(lH-tetrazol-5-ylmethyl)piperazinyl)
A mixture of l-(tert-butoxycarbonyI)-4-(l-trityItetrazol-5-ylmethyI)piperazine (325 mg, 0. 63 mmol) and IH-tetrazole (222 mg, 3. 17 mmol) in tetrahydrofuran (2. 5 mL) was treated with 10% aqueous ΗC1 (1. 2 mL) at room temperature for 2 h, after which it was completely evaporated to dryness under vacuum. The resulting crude 1 -( 1 H-tetrazol-5-ylmethyl)piperazine, 5-(5-chIorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrroIo[4, 3- ]pyrimidin-7-one (200 mg, 0. 49 mmol) and triethylamine (0. 44 mL, 3. 17 mmol) were suspended in anhydrous EtOΗ (8 mL), and the mixture was stirred at room temperature for 1-2 h under nitrogen. The reaction mixture was evaporated to dryness under reduced pressure, and the crude residue was purified by MPLC on silica gel (0. 5% AcOΗ/7% MeOΗ in CΗCl3to obtain a pale yellow solid. The resulting solid was dissolved in 5% MeOH in CHCL, (20 mL), washed with H2O (20 mL), dried (MgSO4), filtered and the filtrate was evaporated to dryness under reduced pressure to afford the titled compound (265 mg, 99%) as a yellowish solid. Analytically pure compound was obtained by crystallization from CHCl3/MeOH/Et2O. mp 188 °C dec (CHCl3/MeOH/Et2O);
IR (neat) 3319, 3104 (NH), 1667 (CO), 1168 (SO2) cm'1;
Η NMR (DMSO- ) δ 0. 90 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 36 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 56-1. 69 (m, 2 Η, CΗ,CH2CΗ3), 2. 49-2. 59 (m, 6 H, 2 NCH, and CH2CH2CH3), 2. 91-2. 98 (m, 4 H, 2 SO2NCH2), 3. 87 (s, 2 H, NCH2N), 3. 99 (s, 3 H, NCH,), 4. 23 (q, J= 6. 9 Hz, 2 Ii, OCH2CH3), 7. 22 (s, 1 H, H-2), 7. 37 (d, J= 8. 7 Hz,
1 H, H-3'), 7. 80 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 89 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 71 (br s, 1 H, NH); MS (FAB) m/z 542 (MH+).
Example 1 17 Preparation of
5-(2-77-propoxy-5-(4-(lH-tetrazol-5-ylmethyl)piperazinylsulfonyl)phenyl)-l-methyl-3 -77-propyl- l,6-dihydro-7H-pyrrolo[4,3-<fJpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 4-(lH-tetrazol-5-ylmethyl)piperazinyl) The titled compoimd was prepared as described in Example 113 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo [4,3-c |pyrimidin-7-one in place of
5~(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3 ~d] py rimidin-7-one . yield: 86% mp 150 °C dec (CΗCl3/MeOΗ/Et,O);
IR (neat) 3393, 331 1 (NH), 1667 (CO), 1 163 (SO2) cm'1;
Η NMR (DMSO-.J δ 0. 90 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 0. 97 (t, J= 7. 5 Ηz, 3
Η, OCΗ2CΗ2CH3), 1. 56-1. 68 (m, 2 Ii, CΗ2CH2CΗ3), 1. 69-1. 81 (m, 2 H, OCH2CH2CH3), 2. 49-2. 58 (m, 6 H, 2 NCH, and CH2CH2CH3), 2. 90-2. 98 (m, 4 H,
2 SO2NCH2), 3. 88 (s, 2 H, NCH2N), 3. 99 (s, 3 H, NCH3), 4. 13 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 22 (s, 1 H, H-2), 7. 38 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 80 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 7. 89 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 67 (br s, 1 H, NH); MS (FAB) m/z 556 (MH+).
Example 1 18
Preparation of
5-(2-ethoxy-5-(4-(2-(lH-tetrazol-5-yl)ethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77 -propyI-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one (a compound of the formula
(1) wherein R5 = SO,NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH,CH3;
NR6R7 is 4-(2-(lH-tetrazol-5-yl)ethyl)piperazinyl)
The titled compound was prepared as described in Example 113 by using l-(tert-butoxycarbonyl)-4-(2-(l-trityltetrazol-5-yl)ethyl)piperazine in place of l-(teι-t-butoxycarbonyl)-4-(l-trityltetrazol-5-ylmethyI)piperazine. yield: 83% mp 231. 5 °C dec (CΗCl3/MeOΗ/Et2O);
IR (neat) 3317, 3245 (NH), 1687 (CO), 1 169 (SO,) cm'1;
'H NMR (DMSO-^,) δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH,CH2CH3), 1. 35 (t, J= 6. 9 Iiz, 3 Η, OCΗ,CH3), 1. 57-1. 68 (m, 2 Η, CΗ2CH2CΗ3), 2. 45-2. 54 (m, 4 H, 2 NCH2), 2.
56 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 68 (t, J= 6. 9 Hz, 2 H, NCH2CH,), 2. 83-2.
92 (m, 4 H, 2 SO2NCH2), 2. 99 (t, J= 6. 9 Hz, 2 H, NCH2CH2), 3. 98 (s, 3 Η, NCΗ,),
4. 21 (q, J= 6. 9 Ηz, 2 Η, OCH2CΗ3), 7. 22 (s, 1 H, H-2), 7. 35 (d, J= 9. 0 Hz, 1 H,
H-3'), 7. 79 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 7. 88 (d, J= 2. 4 Hz, 1 H, H-6'), 1 1. 68 (br s, 1 H, NH); MS (FAB) 777/z 556 (MH+).
Example 119
Preparation of l-methyl-5-(2-77-propoxy-5-(4-(2-(lH-tetrazol-5-yl)ethyl)piperazinylsulfonyl)phenyl)- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-c |pyrimidin-7-one (a compoimd of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH,CH2CH„ R4 = CH,CH2CH3; NR5R7 is 4-(2-(lH-tetrazol-5-yl)ethyl)piperazinyl)
The titled compound was prepared as described in Example 113 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-dihydro- 7H-pyrrolo
[4,3~_ ]pyrimid_n-7-one and l-(tert-butoxycarbonyl)-4-(2-(l-trityltetrazol-5-yl)ethyl)piperazine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo[4, 3-< ]pyrimidin-7-one and l-(tert-butoxycarbonyl)-4-(l-trityltetrazol-5-ylmethyl)piperazine yield: 88% mp 181 °C dec (CΗCyMeOΗ/E^O); IR (neat) 3317, 3173 (NΗ), 1678 (CO), 1 166 (SO2) cm'1; Η NMR (DMSO- ) δ 0. 92 (t, J= 7. 2 Ηz, 3 Η, CΗ,CΗ2CH3), 0. 96 (t, J= 7. 2 Ηz, 3 Η, OCΗ,CΗ2CH3), 1. 57-1. 69 (m, 2 Η, CΗ2CH2CΗ3), 1. 68-1. 80 (m, 2 Ii, OCH2CH,CH3), 2. 49-2. 52 (m, 4 H, 2 NCH2), 2. 56 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 69 (t, J= 7. 2 Hz, 2 H, NCH2CH2), 2. 84-2. 91 (m, 4 H, 2 SO2NCH2), 3. 00 (t, J= 7. 2 Hz, 2 H, NCH,CH2), 3. 99 (s, 3 Η, NCΗ3), 4. 12 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 22 (s, 1 H, H-2), 7. 36 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 79 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 88 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 64 (br s, 1 H, NH); MS (FAB) m/z 570 (MH+).
Example 120
Preparation of 5-(2-ethoxy-5-(4-(lH-tetrazol-5-ylmethyl)piperidinylsulfonyl)phenyl)-l-methyl-3-77-p ropyl-l,6-d_hydro-7H-pyrrolo[4,3-<J]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NRύR7 is 4-(1 H-tetrazol-5-ylmethyl)piperidinyl)
The titled compound was prepared as described in Example 113 by using l-(teι-t-butoxycarbonyl)-4-(l-trityltetrazol-5-ylmethyl)piperidine in place of l-(tert-butoxycarbonyl)-4-(l-trityltetrazol-5-ylmethyl)piperazine. yield: 83% mp 215-216 °C dec (CΗCl3/MeOΗ/Et,O);
IR (neat) 3396, 3103 (NH), 1662 (CO), 1166 (SO2) cm'1;
'HNMR (DMSO- ) δ 0. 90 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 22-1. 33 (m, 2 Η, 2 CΗJ, 1. 36 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 57-1. 69 (m, 5 Η, CΗ, 2 CΗeq and CH2CH,CH3), 2. 27 (br t, J = 11. 1 Hz, 2 H, 2 NCHJ, 2. 56 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 81 (d, J = 6. 6 Hz, 2 H, CHCH2), 3. 64 (br d, J = 12. 0 Ηz, 2 Η, 2 NCΗ , 3. 98 (s, 3 Η, NCΗ3), 4. 22 (q, J= 6. 9 Hz, 2 H, OCH,CH3), 7. 22 (s, 1 H, H-2), 7. 35 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 79 (dd, J- 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 91 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 66 (br s, 1 H, NH); MS (FAB) m/z 541 (MH+).
Example 121 Preparation of l-methyl-5-(2-77-piOpoxy-5-(4-(lH-tetrazol-5-ylmethyl)piperidinylsulfonyl)phenyl)-3- 77-propyl- l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NRόR7 is 4-(lH-tetrazol-5-ylmethyl)piperidinyl) The titled compound was prepared as described in Example 113 by using
5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyπOlo [4,3-/|pyrimidin-7-one and l-(/eι-t-butoxycarbonyl)-4-(l-trityltetrazol-5-ylmethyl)piperidine in place of 5-(5-chIorosulfonyl-2-ethoxyphenyI)- 1 -methyl-3-77-propyI- 1 ,6-dihydro-7H-pyrrolo [4, 3-c]pyrimidin-7-one and l-(tert-butoxycarbonyl)-4-(l-trityltetrazol-5-ylmethyl)piperazine. yield: 81% mp 231 °C dec (CΗCl3/MeOΗ/Et2O); IR (neat) 3313, 3109 (NH), 1665 (CO), 1167 (SO2) cm'1; Η NMR (DMSO- ) δ 0. 90 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 0. 97 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 20-1. 35 (m, 2 Η, 2 CΗJ, 1. 58-1. 80 (m, 7 Η, CΗ, 2 CΗeq and 2 CH,CH2CH3), 2. 27 (br t, J = 11. 1 Hz, 2 H, 2 NCHJ, 2. 56 (t, J = 7. 5 Hz, 2 H, CH2CH,CH3), 2. 81 (d, J = 6. 6 Hz, 2 H, CHCH2), 3. 64 (br d, J = 11. 7 Ηz, 2 Η, 2 NCΗ , 3. 98 (s, 3 Η, NCΗ3), 4. 12 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 22 (s, 1 H,
H-2), 7. 35 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 79 (dd, J= 8. 7 Hz, 2. 7 Hz, 1 H, H-4'), 7. 91 (d, J= 2. 7 Hz, 1 H, H-6'), 11. 62 (br s, 1 H, NH); MS (FAB) m/z 555 (MIL).
Example 122 Preparation of
5-(2-ethoxy-5-(4-(2-(lH-tetrazol-5-yl)ethyl)piperidinylsulfonyl)phenyl)-l-methyl-3-77 -propyl-l,6-dihydro-7H-pyrrolo[4,3-</Jpyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 4-(2-(lH-tetι-azol-5-yl)ethyl)piperidinyl) The titled compound was prepared as described in Example 113 by using l-(tert-butoxycarbonyl)-4-(2-(l-trityltetrazol-5-yl)ethyl)piperidine in place of l-(tert-butoxycarbonyl)-4-(l-trityltetrazol-5-ylmethyl)piperazine. yield: 75% mp 192 °C dec (CΗCyMeOΗ/Et.O); IR (neat) 3327, 3227 (NΗ), 1690 (CO), 1146 (SO2) cm'1 ;
Η NMR (DMSO- ) δ 0. 91 (t, J= 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 12-1. 26 (m, 3 Η, CΗ and 2 CΗJ, 1. 34 (t, J = 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 54-1. 67 (m, 4 Η, CΗCH2CΗ, and CH2CH2CH3), 1. 67-1. 80 (m, 2 H, 2 CHJ, 2. 20 (br t, J= 10. 8 Hz, 2 H, 2 NCHJ, 2. 56 (t, J = 7. 5 Hz, 2 H, CH2CH2CH3), 2. 85 (t, J = 7. 5 Hz, 2 Ii, CHCH2CH2), 3. 63 (br d, J= 10. 5 Ηz, 2 Η, 2 NCΗJ, 3. 98 (s, 3 Η, NCΗ3), 4. 21 (q, J = 6. 9 Hz, 2 H, OCH,CH3), 7. 21 (s, 1 H, H-2), 7. 34 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 79 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 7. 90 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 65 (br s, 1 H, NH); MS (FAB) m/z 555 (MH+).
Example 123
Preparation of l-methyl-5-(2-77-propoxy-5-(4-(2-(lH-tetrazol-5-yl)ethyl)piperidinylsulfonyl)phenyl)- 3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3- ]pyrπτιidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 =
CH2CH2CH3; NR6R7 is 4-(2-(lH-tetrazol-5-yl)ethyl)piperidinyl)
The titled compound was prepared as described in Example 113 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)- 1 -methyl-3-«-propyl- 1 ,6-dihydro-7H-pyrrolo [4,3--Jpyriιnidin-7-one and l-(tert-butoxycarbonyI)-4-(2-(l-trityltetrazoI-5-yl)ethyl)piperidine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-< Jpyrimidin-7-one and
L(tert-butoxycarbonyl)-4-(l-trityltetrazol-5-ylmethyl)piperazine. yield: 81% mp 145 °C dec (CΗCl3/MeOΗ/Et2O);
IR (neat) 3326, 3224 (NH), 1694 (CO), 1144 (SO2) cm'1;
Η NMR (DMSO-_ 6) δ 0. 86 (t, J- 7. 5 Hz, 3 H, CH2CH2CH3), 0. 91 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ,CH3), 1. 02-1. 24 (m, 3 Η, CΗ and 2 CΗJ, 1. 47-1. 62 (m, 4 Η, CΗCH,CΗ2 and CH,CH2CH3), 1. 60-1. 78 (m, 4 H, OCH2CH2CH3 and 2 CHJ, 2. 14 (br t, J= 10. 5 Hz, 2 H, 2 NCHJ, 2. 51 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 2. 74 (t, J= 7. 5 Hz, 2 H, CHCH2CH2), 3. 57 (br d, J = 11. 4 Ηz, 2 Η, 2 NCΗJ, 3. 93 (s, 3 Η, NCΗ3), 4. 07 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 16 (s, 1 H, H-2), 7. 30 (d, J= 9. 0 Hz, 1 Ii, H-3'), 7. 74 (dd, J= 9. 0 Hz, 2. 4 Hz, 1 H, H-4'), 7. 85 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 58 (br s, 1 H, NH); MS (FAB) 777/z 569 (MH+).
Example 124
Preparation of
5-(5-(di-(2-fluoroethyl)aminosulfonyl)-2-ethoxyphenyl)- 1 -methyl-3-77-propyl- 1 ,6-dih ydro-7H-pyrrolo[4,3- ]pyrhnidiιι-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH,CH3, R4 = CH2CH3; R6 = R7 = 2-fluoroethyl)
The titled compound was prepared as described in Example 1 by using bis(2-fluoroethyl)amine hydrochloride in place of 1 -methylpiperazine. yield: 80%
mp 210-210. 5 °C (MeOH/CHCyEtjO); IR (neat) 3320 (NH), 1694 (CO), 1162 (SO2) cm'1;
'H NMR (CDC13/TMS) δ 0. 92 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 35 (t, J= 6. 9 Ηz, 3 Ii, OCΗ2CH3), 1. 56-1. 71 (m, 2 Η, CΗ2CH2CΗ3), 2. 57 (t, J = 7. 5 Hz, CH2CH2CH3), 3. 50 (dt, J = 24. 6 Hz, 5. 1 Hz, 4 H, 2 NCH2CH2F), 3. 99 (s, 3 H, NCH3), 4. 22 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 4. 54 (dt, J= 47. 4 Hz, 5. 1 Hz, 4 H, 2 NCH2CH2F), 7. 22 (s, 1 Η, Η-2), 7. 33 (d, J= 8. 7 Ηz, 1 Η, Η-3'), 7. 92 (dd, J= 8. 7 Ηz, 2. 4 Ηz, 1 Η, Η-4'), 8. 02 (d, J= 2. 4 Ηz, 1 Η, Η-6'), 11. 69 (br s, 1 Η, NΗ); MS (FAB) m/z 483 (MΗ+).
Example 125
Preparation of
5-(2-ethoxy-5-((S)- 1 -hydroxycarbonyl-2-methylpropyl)aminosulfonyl)phenyl)- 1 -meth yl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-(3 pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is ((S)-l-hydroxycarbonyl-2-methylpropyl)amino)
A mixture of
5-(5-((S)- 1 -benzyloxycarbonyl-2-methylpropyl)aminosulfonyl)-2-ethoxyphenyl)- 1 -m ethyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-< |pyrimidin-7-one (190 mg, 0. 33 mmol) and 5% Pd/C (68 mg) in EtOΗ was vigorously stirred overnight under Η2 atmosphere (1 atm; a balloon) at room temperature. The reaction mixture was filtered tlirough a Celite pad, and the filtrate was evaporated to dryness under reduced pressure. The resulting residue was purified by MPLC on silica gel (gradient elution: 1% MeOH in CHC13 followed by 20% MeOH in CHC13) to afford the titled compound (158 mg, 99%) as a pale yellow solid. Analytically pure compound was obtained by crystallization from EtOAc/Et2O/hexanes. mp 196-196. 5 °C dec;
IR (neat) 3320 (NH and CO2H), 1682 (CO), 1155 (SO2) cm'1; 'H NMR (DMSO- ) δ 0. 80 (d, J= 6. 6 Hz, 3 H, CHCH3), 0. 85 (d, J= 7. 2 Ηz, 3 Η,
CHCH3), 0. 93 (t, J = 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 1. 35 (t, J = 6. 9 Ηz, 3 Η, OCΗ,CH3), 1. 59-1. 69 (m, 2 Η, CΗ2CH2CΗ3), 1. 98-2. 06 (m, 1 H, CH(CH3)2), 2. 58 (t, J= 7. 5 Hz, 2 H, CH,CH,CH3), 3. 23 (d, J= 6. 6 Hz, 1 H, NCHCO2), 3. 98 (s, 3 H, NCH,), 4. 19 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 7. 21 (s, 1 H, H-2), 7. 26 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 83 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 02 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 65 (br s, 1 H, NH); MS (FAB) 777/z 491 (MH+).
Example 126
Preparation of 5-(5-((S)- 1 -hydiOxycarbonyl-2-methylpropyl)aminosulfonyl)-2-77-propoxyphenyl)- 1 - methyl-3-77-propyI-l,6-dihydro-7H-pyrrolo[4,3-(f]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NR6R7, R1 = CΗ3, R2 = H, R3 = CH2CH2CH„ R4 = CH2CH,CH3; NR6R7 is ((S)-l -hydroxy carbonyl-2-methylpropyl)amino)
The titled compound was prepared as described in Preparative Example 122 by using
5-(5-((S)-l -benzyloxycarbonyl-2-methylpropyl)sulfonamido-2-77-propoxyphenyl)- 1 -m ethyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one in place of 5-(5-((S)-l-benzyloxycarbonyl-2-methylpropyl)sulfonamido-2-ethoxyphenyl)-l -meth yl-3-77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-(fjpyrimidin-7-one. yield: 99% mp 193-194 °C (EtOAc/Et2O/hexanes);
IR (neat) 3322 (NΗ and CO2Η), 1675 (CO), 1157 (SO2) cm'1;
■H NMR (DMSO-c.6) δ 0. 79 (d, J= 6. 9 Hz, 3 H, CHCH3), 0. 85 (d, J= 6. 9 Ηz, 3 Η,
CΗCH3), 0. 92 (t, J = 7. 5 Ηz, 3 Η, CΗ2CΗ2CH3), 0. 97 (t, J = 7. 2 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 57-1. 78 (m, 4 Η, 2 CΗ2CH2CΗ3), 1. 95-2. 05 (m, 1 H, CH(CH3),), 2. 58 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 20 (d, J= 6. 0 Hz, 1 H, NCHCO,), 3. 98 (s, 3 H, NCH3), 4. 09 (t, J- 6. 3 Hz, 2 H, OCH2CH2CH3), 7. 21 (s, 1 H, H-2), 7. 26 (d, J = 8. 7 Hz, 1 H, H-3'), 7. 83 (dd, J= 8. 7 Hz, 2. 4 Hz, 1 H, H-4'), 8. 03 (d, J= 2. 4 Hz, 1 H, H-6'), 11. 58 (br s, 1 H, NH); MS (FAB) 777/z 405 (MH+).
Example 127
Preparation of
5 -(2-ethoxy-5 -( 1 -imidazolosulfony l)pheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-p yr rolo[4,3- ]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO,NR6R7,
R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3; NR6R7 is 1-imidazolo)
The titled compound was prepared as described in Example 1 by using imidazole in place of 1 -methylpiperazine. yield: 97% mp 171 -172 °C (CHCl3/Et2O/hexanes);
IR (neat) 31 12 (NH), 1671 (CO), 1186 (SO2) cm'1;
'H NMR (CDCl TMS) δ 1. 04 (t, J= 7. 2 Hz, 3 H, CH2CH2CH3), 1. 63 (t, J= 6. 9 Hz,
3 H, OCH2CH3), 1. 70-1. 82 (m, 2 Η, CΗ2CH2CΗ3), 2. 74 (t, J = 7. 2 Hz, 2 Ii,
CH2CH2CH3), 4. 08 (s, 3 H, NCH3), 4. 36 (q, J= 6. 9 Hz, 2 Ii, OCH2CH3), 6. 91 (s, 1 H, H-2), 7. 1 1 (s, 1 H, ImH-4), 7. 14 (d, J= 9. 0 Hz, 1 H, H-3'), 7. 35 (s, 1 H, ImH-5),
7. 96 (dd, J- 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 8. 05 (s, 1 H, ImH-2), 9. 05 (d, J= 2. 7 Hz,
1 H, H-6'), 10. 52 (br s, 1 H, NH); MS (FAB) m/z 442 (MH+).
Example 128 Preparation of
5 -(5 -( 1 -imidazolosulfony l)-2-77-propoxyphenyl)- 1 -methyl-3-77-propy 1- 1 ,6-dihydro-7H- pyrrolo[4,3-3]pyrimidin-7-one (a compound of the formula (1) wherein R5 = SO2NR6R7, R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3; NR6R7 is 1 -imidazolo) The titled compound was prepared as described in Example 1 by using
5-(5-chlorosulfonyl-2-77-piOpoxyphenyl)-l -methyl-3-77-piOpyI-l,6-dihydro-7H-pyrroIo [4,3-d]pyrimidin-7-one and imidazole in place ' of
5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4, 3-_/]pyrimidin-7-one and 1 -methylpiperazine.
yield: 99% mp 163-164 °C (CHCl3/Et2O/hexanes); IR (neat) 31 16 (NH), 1668 (CO), 1184 (SO2) cm'1 ;
'H NMR (CDC TMS) δ 1. 04 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 17 (t, J= 7. 5 Iiz, 3 Η, OCΗ2CΗ2CH3), 1. 70-1. 82 (m, 2 Η, CΗ2CH2CΗ3), 1. 97-2. 08 (m, 2 H, OCH2CH2CH3), 2. 75 (t, J= 7. 5 Hz, 2 H, CH2CH2CH,), 4. 08 (s, 3 H, NCH3), 4. 25 (t, J= 6. 6 Hz, 2 H, OCH2CH,CH3), 6. 91 (s, 1 H, H-2), 7. 11 (s, 1 H, ImH-4), 7. 15 (d, J = 9. 0 Hz, 1 H, H-3'), 7. 35 (s, 1 H, ImH-5), 7. 96 (dd, J= 9. 0 Hz, 2. 7 Hz, 1 H, H-4'), 8. 06 (s, 1 H, ImH-2), 9. 07 (d, J= 2. 7 Hz, 1 H, H-6'), 10. 55 (br s, 1 H, NH); MS (FAB) 7/z 456 (MH+).
Example 129
Preparation of
5 -(2-ethoxy-5 -methy lsulfonaminopheny 1)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrol o[4,3-_ ]pyrimidin-7-one ((a compound of the formula (1) wherein R1 = CΗ3, R2 = H, R3 = CH2CH2CH3, R4 = CH2CH3, R5 = methylsulfonamino)
To a stirred solution of
5-(5-amino-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo [4,3-_f]pyrimidin-7-one (232 mg, 0. 71 mmol) and triethylamine (0. 20 mL, 1. 42 mmol) in anhydrous CΗ2C12 (7 mL) was added methanesulfonyl chloride (0. 13 mL, 1. 62 mmol) at 0 °C, and the mixture was stirred at 0 °C for 2 h. The reaction mixture was evaporated to dryness under reduced pressure, and the resulting residue was dissolved in MeOH (20 mL) and THF (5 mL). The pH of the mixture was adjusted' to about 11 using 1 N NaOH aqueous solution, after which it was stirred at room temperature for 30 min. The mixture was acidified to pH 5-6 using 1 N HCl aqueous solution, and was extracted with 10%> MeOH in CHC13 (100 mL x 5). The combined organic layer was evaporated to dryness under reduced pressure, and the resulting yellow residue was purified by MPLC on silica gel (gradient elution: 2% MeOH in CHC13 followed by 3% MeOH in CHC13) to afford the titled compound (250 mg,
87%) as a pale yellow solid. Analytically pure compound was obtained by crystallization from CHCl3/Et2O. mp 223. 5-224 °C;
IR (neat) 3287, 3122 (NH), 1657 (CO) 1147 (SO2) cm'1; Η NMR (CDCl/TMS) δ 1. 00 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 58 (t, J= 6. 9 Ηz, 3 Η, OCΗ2CH3), 1. 69-1. 79 (m, 2 Η, CΗ2CH2CΗ3), 2. 70 (t, J = 7. 5 Hz, 2 Ii, CH2CH,CH3), 3. 02 (s, 3 H, CH3SO2), 4. 08 (s, 3 H, NCH3), 4. 26 (q, J= 6. 9 Hz, 2 H, OCH2CH3), 6. 63 (br s, 1 H, SO2NH), 6. 87 (s, 1 H, H-2), 7. 02 (d, J= 9. 0 Hz, 1 H, H-3*), 7. 47 (dd, J= 9. 0 Hz, 3. 0 Hz, 1 H, H-4'), 8. 25 (d, J= 3. 0 Hz, 1 H, H-6'), 10. 87 (br s, 1 H, 6-NH); MS (FAB) m/z 405 (MH+).
Example 130
Preparation of
5-(5-methylsulfonamino-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-py rrolo[4,3-_i]pyrimidin-7-one ((a compound of the formula (1) wherein R1 = CΗ„ R2 = H, R3 = CH2CH2CH3, R4 = CH2CH2CH3, R5 = methylsulfonamino)
The titled compound was prepared as described in Example 126 by using 5-(5-amino-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-/|p yrimidin-7-one in place of 5-(5-amino-2-ethoxyphenyl)-l -methyl-3-77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-_i]pyri midin-7-one. yield: 54% mp 219-219. 5 °C (CΗCl3/Et2O); IR (neat) 3310, 3231 (NH), 1690 (CO) 1155 (SO,) cm'1; Η NMR (CDCl/TMS) δ 1. 01 (t, J= 7. 5 Hz, 3 H, CH2CH2CH3), 1. 16 (t, J= 7. 5 Ηz, 3 Η, OCΗ2CΗ2CH3), 1. 67-1. 80 (m, 2 Η, CΗ2CH2CΗ3), 1. 94-2. 05 (m, 2 H, OCH2CH2CH3), 2. 71 (t, J= 7. 5 Hz, 2 H, CH2CH2CH3), 3. 02 (s, 3 H, CH3SO,_), 4. 08 (s, 3 H, NCH3), 4. 16 (t, J= 6. 3 Hz, 2 H, OCH2CH2CH3), 6. 55 (s, 1 H, SO2NH), 6. 88 (s, 1 H, H-2), 7. 04 (d, J= 8. 7 Hz, 1 H, H-3'), 7. 48 (dd, J= 8. 7 Hz, 3. 0 Hz, 1 H,
H-4'), 8. 26 (d, J= 3. 0 Hz, 1 H, H-6'), 10. 92 (br s, 1 H, 6-NH); MS (FAB) m/z 419 (MH+).
Example 131 Production of tablets (Direct compression) mg/tablet
Active ingredient 5. 0
Lactose 14. 1
Crospovidone USNF 0. 8 Magnesium Stearate 0. 1
Total weight 20 mg
The active ingredient was sieved and blended with the excipients. The resultant mix was compressed into tablets. Alternatively, the active ingredient and lactose were dissolved in water and freeze-dried. Then, the dried mixture was blended with the excipients and was compressed into tablets.
Example 132 Production of tablets (Wet granulation) mg/tablet Active ingredient 5. 0
Polysorbate 80 0. 3
Lactose 16. 0 Starch 4. 0
Colloidal Silicon Dioxide 2. 7
Magnesium Stearate 2. 0
Total weight 30 mg
The active ingredient was sieved and blended with the lactose and starch. The polysorbate 80 was dissolved in purified water. Suitable volumes of the polysorbate 80 solution were added and the powders were granulated. After drying, the granules were screened and blended with the colloidal silicon dioxide and magnesium stearate. The granules were then compressed into tablets.
Example 133
Production of powder and encapsulated medicine mg/capsule Active ingredient 5. 0
Lactose 14. 8
Polyvinyl pyrrolidone 10. 0
Magnesium Stearate 0. 2
Total weight 30 mg
The active ingredient was sieved and blended with the excipients. The mix was filled into No. 5 hard gelatin capsules using suitable equipment.
Example 134: Biological activity The cyclic nucleotide PDE V activity was determined using PDE SPA assay kit
(Amersham Pharmacia biotech, UK). Each reaction mixture (100 μL total volume) consisted of the column elute containing PDE V (10 μL), [3H]-cGMP (5 μCi/mL), bovine serum albumin (0. 5 mg/mL), and MgCl2(5 mM) in Tris-HCl buffer (15 mM, pH 7. 5). The reactions were initiated by the addition of PDE V and the samples were incubated at 30 °C for 30 min, after which the reaction was stopped by the addition of 50 μL of SPA beads. The reaction tube was then settled for 20 min and was counted on the scintillation counter (Tri-carb 1500, Packard, USA). For the inhibition study of PDE V activity, the sildenafil and test compounds were dissolved in dimethyl sulfoxide (DMSO) and was diluted with distilled water. The final
concentration of DMSO was less than 0. 2% (v/v). All the inhibition experiments were conducted under the conditions where the level of cGMP hydrolysis did not exceed 15%, and the product formation increased linearly with time and the amount of enzyme.
The following Table illustrates the in vitro activities for a range of the compounds of the invention as inhibitors of cGMP PDE V.
TABLE
Example 135: Safety Profile
Several compounds of the invention have been tested at doses of up to 10 mg/kg p. o. in rats with no untoward effects being observed, and up to 100 mg/kg p. o. in rats with no death being obsei-ved
Claims (15)
1. A compound of the formula (1) and pharmaceutically acceptable salts and solvates (e. g. hydrates) thereof,
wherein R1 is H; C,-C3 alkyl optionally substituted with one or more fluoro atoms; or C3-C6 cycloalkyl;
R2 is H; a halogen atom; C,-C6 alkyl optionally substituted with OH, C -C, alkoxy, C3-C6 cycloalkyl, or with one or more fluoro atoms; C3— C6 cycloalkyl; C2-C6 alkenyl; or C2-C6 alkynyl;
R3 is H; C,-C6 alkyl optionally substituted with OH, C,-C3 alkoxy, C,-C6 cycloalkyl, or with one or more fluoro atoms; C3-C6 cycloalkyl; C2-C6 alkenyl; or C2-C6 alkynyl;
R4 is C -C6 alkyl optionally substituted with C,-C6 cycloalkyl or with one or more fluoro atoms; C2-C6 alkenyl; C2-C6 alkynyl; or C3-C6 cycloalkyl;
R5 is SO2NR6R7; NHSO,NR R7; NHCOCONR6R7; NHSO2R8; NHCOR8; or phenyl or heterocyclyl either of which is optionally substituted with one or more fluoro atoms or C,-C, alkyl;
R6 and R7 are each independently H or C -C6 alkyl optionally substituted with OH, CO2H, C,-C3 alkoxy, C3-C6 cycloalkyl, or with one or more fluoro atoms; or together with the nitrogen atom to which they are attached form either a mono-cyclic ring such as imidazole, aziridene (aziridine), azeridine (azetidine), pyrroiidine, piperidine, morpholine, piperazine and homopiperazine, or a bicyclic ring such as 2,5-diazabicyclo[2. 2. ljheptane and 3,7-diazabicyclo[3. 3. Ojoctane, wherein said group is optionally substituted with R9;
R8 is C - alkyl optionally substituted with one or more fluoro atoms; or C3-C7 cycloalkyl;
R9 is C,-Cfi alkyl optionally substituted with one or more halide atoms, OH, C,-C, alkoxy which is optionally substituted with one or more fluoro atoms, CO2R10,
NR"R12, C=NR13(NR14R15), or with a tetrazole group which is optionally substituted with C,-C3 alkyl; or one or more nitrogen containing heteroaryl group which is optionally substituted with one or more fluoro atoms;
R10 is H; or C,-C4 alkyl optionally substituted with OH, NR"R12, one or more fluoro atoms, or with a nitrogen containing heterocyclic ring such as pyrroiidine, piperidine, piperazine, morpholine, pyrrole, and imidazole wherein nitrogen atom is directly bound to C,-C4 alkyl;
R" and R'2 are each independently H or C -C4 alkyl;
R13 is H; C -C4 alkyl optionally substituted with one or more fluoro atoms; or C3-C6 cycloalkyl;
R14 and R15 are each independently H or C,-C4 alkyl optionally substituted with one or more fluoro atoms; C3-C6 cycloalkyl; or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, piperazinyl, or homopiperazinyl group wherein said group is optionally substituted with C -C3 alkyl.
2. The compound according to Claim 1 , wherein
R1 is H; methyl; or ethyl;
R2 is H; methyl; or a halogen atom;
R3 is C,-C4 alkyl; R4 is ethyl; 77-propyl; or allyl;
R5 is SO2NR6R7; orNHSO2R8;
R6 and R7 taken together with the nitrogen atom to which they are attached form a piperidino, piperazinyl or homopiperazinyl group wherein said group is substituted with 9; R8 is methyl;
R9 is C -C4 alkyl optionally substituted with one or more halide atoms, OH, CO2Ri0, or with a tetrazole group wliich is optionally substituted with C,-C3 alkyl; and R'° is H.
3. The compound according to Claim 2, wherein R' is methyl;
R2 is H;
R3 is ethyl; 77-propyl; 3-fluoropropyl; or cyclopropylmethyl; R4 is ethyl; or 77-propyl;
R5 is SO2NR6R7; or NHSO2R8;
R6 and R7 taken together with the nitrogen atom to which they are attached form a piperidino or piperazinyl group wherein said group is substituted with R9;
R8 is methyl; R9 is C,-C4 alkyl optionally substituted with one or more fluoro or chloro atoms,
CO,R10, or with a tetrazole group; and
R'° is H.
4. The compound according to Claim 3, wherein said compound is selected from the group consisting of:
5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dih ydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one;
5-(5-(4-methylpiperazinylsulfonyl)-2-77-propoxyphenyl)- 1 -methyl-3 -77-propy 1- 1 ,6- dihydro-7H-pyrrolo[4,3-< Jpyrimidin-7-one; 5-(2-ethoxy-5-(4-77-propylpiperazinylsulfonyl)phenyl)-l -methyl-3-77-propyl- 1 ,6-di hydro-7H-pyrrolo[4,3-^pyrimidin-7-one;
5-(2-ethoxy-5-(4-isopropylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl- l ,6-d ihy dro-7H-pyrrolo [4,3 -_ ]pyrimidin-7-one;
5-(2-ethoxy-5-(4-(2-fluoroethyl)piper_ιzinylsulfoπyl)phenyl)-l -methyl-3-/7-propyl- l,6-dihydro-7H-pyrrolo[4,3-_/jpyrimidin-7-one;
5-(5-(4-(2-fluoroethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-pro pyl- 1 ,6-dihydro-7H-pyrrolo[4,3-_i]pyrimidin-7-one;
5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propy 1- 1 ,6-dihydro-7H-pyrrolo[4,3-(S,Jpyrimidin-7-one;
5-(2-ethoxy-5-(4-(3-fluoropropy piperazinylsulfony l)phenyl)-3-ethyI- 1 -methyl- 1 , 6-dihydro-7H-pyιτolo[4,3--7^pyrimidin-7-one;
5-(2-ethoxy-5-(4-(3-fluoiOpropyl)piperazinylsulfonyl)phenyl)-3-(3-fluoiOpropyl.- l -ιτιc thyl-l ,6-dihydro-7H-pyrrolo[4,3-t/jpyrimidin-7-one; 3-cyclopropylmethyl-5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyI)phenyl)-
I -methyl- 1 ,6-dihydro-7H-pyrrolo[4,3-_r pyriιτιidin-7-one;
5-(5-(4-(3-fluoropropyl)piperazinyIsulfonyl)-2-77-propoxyphenyI)-l-methyl-3-77-pr opyl-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one;
5-(2-ethoxy-5-(4-(2-hydroxyethyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-piOp y 1- 1 ,6-dihydro-7H-pyrrolo[4-3-d]pyrimidin-7-one;
5-(5-(4-(2-hydroxyethyl)piperazinylsulfonyl)-2-77-piOpoxyphenyl)-l-methyl-3-77-p ropyl- 1 ,6-dihydro-7H-pyrrolo[4,3-_i]pyrimidin-7-one;
5-(5-(2-ethoxy-4-(3-hydroxypropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-pro pyl-l ,6-dihydro-7H-pyrrolo[4,3-_i]pyrimidin-7-one; 5-(5-(4-(3-hydroxypropyl)piperazinylsιιlfonyl)-2-77-propoxyphenyl)-l-methyl-3-77- propyl- 1 ,6-dihydro-7H-pyrroJo[4,3-c/]pyrimidin-7-one;
5-(2-ethoxy-5-(4-(hydroxycarbonylmethyl)piperidinylsulfonyI)phenyl)-l -methyl-3 -77-propyl-l,6-dihydro-7H-pyrrolo[4,3-<fJpyrimidin-7-one;
5-(5-(4-(hydroxycarbonylmethyl)piperidinylsulfonyl)-2-77-piOpoxyphenyl)-l-meth yl-3-/7-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one;
5-(2-ethoxy-5-(4-(2-hydroxycarbonylethyl)piperidinylsulfonyl)phenyl)-l-methyl- 3-77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3-^pyrimidin-7-or_e;
5-(5-(4-(2-hydroxycarbonylethyl)piperidinylsulfonyl)-2-77-propoxyphenyl)-l-meth yl-3-77-propyl-l,6-dmydro-7H-pyrrolo[4,3-^pyrimidin-7-one; 5-(2-ethoxy-5-(4-(lH-tetrazol-5-ylmethyI)piperazinylsulfonyl)phenyl)-l-methyI-3 -77-propy l-l ,6-dihydro-7H-pyrrolo [4,3 -i]pyrimidin-7-one; l-methyl-5-(2-77-propoxy-5-(4-(2-(lH-tetrazol-5-yl)ethyl)piper_izinylsulfonyl)phen yl)-3-77-propyl-l,6-dihydro-7H-pyrrolo[4,3-_ ]pyrimidin-7-one;
5-(2-ethoxy-5-(4-(lH-tetrazol-5-ylmethyl)piperidinylsulfonyl)phenyl)-l-methyl-3- 77-propyl-l ,6-dihydro-7H-pyrrolo[4,3-<f]pyrimidin-7-one; l-methyl-5-(2-77-propoxy-5-(4-(lH-tetrazol-5-ylmethyl)piperidinylsulfonyl)phenyl )-3 -77-propy l-l,6-dihydro-7H-pyrrolo [4,3 -c ]pyrimidin-7-one; and physiologically acceptable salts and solvates (e. g. hydrates) thereof.
5. A pharmaceutical composition comprising a compound of the formula (1) or a pharmaceutically acceptable salt thereof according to any one of Claims 1 to 4, together with a pharmaceutically acceptable diluent or carrier therefor.
6. A compound of the formula (1) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity according to any one of Claims 1 to 5, for use in the treatment of impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome).
7. The use of a compound of the formula (1) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity according to any one of Claims 1 to 5, for the manufacture of a medicament for the treatment of impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome).
8. A method of treating or preventing impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary
' angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome), in a mammal (including a human being), which comprises administering to said mammal a therapeutically effective amount of a compound of formula (1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, according to any one of Claims 1 to 5.
9. A compound of the formula (2), (3) and (9):
20
wherein R1, R2, R3 and R4 are as previously defined in Claim 1 and Y is a chloro, bromo or fluoro atom.
10. A compound of the formula (12) and (13):
wherein R , R , R and R are as previously defined in Claim 1.
11. A compound of the formula (15):
wherein R1, R2 and R3 are as previously defined in Claim 1.
12. Processes for preparing a compound of the formula (1):
wherein R1, R2, R3, R4 and R3 are as previously defined in Claim 1 , and pharmaceutically acceptable salts thereof, (a) which comprises reacting a compound of the formula (2)-(4):
(2) X = SO,Y (3) X = NH. (4) X = CN~
wherein R1, R2 R3 and R4 are as previously defined in Claim 1 and Y represents a halogen atom, with an appropriate compound of the formula (5) -(8) under an appropriate reaction condition, wherein R6, R7 and Rs are as previously defined in Claim 1, or (b) which comprises cyclizing a compound of the formula (25):
wherein R1, R2, R3 and R4 are as previously defined in Claim 1 and R16 is a group R5 as previously defined in Claim 1 or a precursor to a group R5 thereof.
13. Processes for preparing a compound of the formula (2), (3) and (9):
wherein R , R~, R and R are as previously defined in Claim 1 and Y is a chloro, bromo or fluoro atom, which comprises cyclizing a compound of the formula (12) or (13) followed by an appropriate transformation:
wherein R , R , R and R are as previously defined in Claim 1.
14. Processes for preparing a compound of the formula (12) and (13):
wherein R1, R2, R3 and R4 are as previously defined in Claim 1, which comprises reacting a compound of the formula (15) with a compound of the formula (16) or (17):
(15) (16): X = H (17): X = N02
wherein R1, R2, R3 and R4 are as previously defined in Claim 1 and Y is a chloro, bromo or fluoro atom.
15. Processes for preparing a compound of the formula (15):
wherein R1, R2 and R3 are as previously defined in Claim 1, which comprises cyclizing a compound of the formula (19):
(19)
wherein R1, R2 and R3 are as previously defined in Claim 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR2000/7625 | 2000-02-17 | ||
KR20000007625A KR100358083B1 (en) | 2000-02-17 | 2000-02-17 | Pyrrolopyrimidinone derivatives, process of preparation and use |
PCT/KR2001/000227 WO2001060825A1 (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2001236140A1 true AU2001236140A1 (en) | 2001-11-08 |
AU2001236140B2 AU2001236140B2 (en) | 2006-01-12 |
AU2001236140B9 AU2001236140B9 (en) | 2006-08-31 |
Family
ID=19647449
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001236140A Expired AU2001236140B9 (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
AU3614001A Pending AU3614001A (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU3614001A Pending AU3614001A (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
Country Status (23)
Country | Link |
---|---|
US (1) | US6962911B2 (en) |
EP (1) | EP1257553B1 (en) |
JP (1) | JP4845076B2 (en) |
KR (1) | KR100358083B1 (en) |
CN (1) | CN1312153C (en) |
AT (1) | ATE267829T1 (en) |
AU (2) | AU2001236140B9 (en) |
BR (1) | BRPI0108395B8 (en) |
CA (1) | CA2400268C (en) |
DE (1) | DE60103508T2 (en) |
DK (1) | DK1257553T3 (en) |
ES (1) | ES2222344T3 (en) |
HU (1) | HU230344B1 (en) |
IL (2) | IL151234A0 (en) |
MX (1) | MXPA02007942A (en) |
NO (1) | NO323553B1 (en) |
NZ (1) | NZ520842A (en) |
PL (1) | PL210796B1 (en) |
PT (1) | PT1257553E (en) |
RU (1) | RU2263676C2 (en) |
TR (1) | TR200402101T4 (en) |
WO (1) | WO2001060825A1 (en) |
ZA (1) | ZA200206587B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100358083B1 (en) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | Pyrrolopyrimidinone derivatives, process of preparation and use |
EP1362858A1 (en) * | 2002-05-15 | 2003-11-19 | SK Chemicals Co., Ltd. | Pyrrolopyrimidinone derivates, process of preparation and use |
DE10229778A1 (en) * | 2002-07-03 | 2004-01-29 | Bayer Ag | New use of imidazotriazinones |
FR2842809A1 (en) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOVEL SUBSTITUTED PYRAZOLO [1,5-a] -1,3,5-TRIAZINES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, USE AS A MEDICAMENT AND METHODS FOR THEIR PREPARATION |
CN100374441C (en) | 2003-06-06 | 2008-03-12 | 天津倍方科技发展有限公司 | 2-substituted benzyl-5,7-dihydrocarbyl-3,7-dihydro pyrroline [2,3-d] pyromidine-4-one derivative ,its preparation and medicinal use |
AR058071A1 (en) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | DERIVATIVES OF DIHYDROPIRAZOLO (3,4-E) (1,4) DIAZEPINA. PROCESSES OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS. |
WO2008004796A1 (en) | 2006-07-03 | 2008-01-10 | Sk Chemicals Co., Ltd. | Salts of pyrrolopyrimidinone derivatives and process for preparing the same |
KR20080003599A (en) * | 2006-07-03 | 2008-01-08 | 에스케이케미칼주식회사 | Gentisate of pyrrolopyrimidinone derivative and process for preparing it |
KR101002490B1 (en) * | 2007-06-09 | 2010-12-17 | 동아제약주식회사 | Pharmaceutical compositions for the treatment of chronic heart failure comprising Udenafil |
ES2683311T3 (en) | 2009-10-16 | 2018-09-26 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods for manufacturing and using them |
EA023350B1 (en) | 2009-10-16 | 2016-05-31 | Мелинта Терапьютикс, Инк. | Antimicrobial compounds, methods of making and using the same |
ES2675798T3 (en) | 2009-10-16 | 2018-07-12 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods for manufacturing and using them |
EP2556820A4 (en) | 2010-04-05 | 2015-01-21 | Sk Chemicals Co Ltd | Composition containing pde5 inhibitor for relieving skin wrinkles |
CN102372730B (en) * | 2010-08-19 | 2014-03-26 | 山东轩竹医药科技有限公司 | Bridged ring substituted phosphodiesterase inhibitor |
CN102134242B (en) * | 2011-01-21 | 2013-08-28 | 浙江大德药业集团有限公司 | Novel compounds for quickly treating impotence with long-lasting action |
TWI490220B (en) * | 2011-04-04 | 2015-07-01 | Sk Chemicals Co Ltd | Composition for reducing skin wrinkles including pde5 inhibitor |
JP6317669B2 (en) | 2011-04-15 | 2018-04-25 | メリンタ セラピューティクス インコーポレイテッド | Antibacterial compounds and methods of making and using the same |
JP2014526461A (en) * | 2011-09-09 | 2014-10-06 | エスケー ケミカルズ カンパニー,リミテッド | Composition for improving skin wrinkle containing PDE5 inhibitor |
WO2014088326A1 (en) | 2012-12-04 | 2014-06-12 | 주식회사 아리바이오 | Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells |
JP2016529325A (en) | 2013-09-09 | 2016-09-23 | メリンタ セラピューティクス,インコーポレイテッド | Antimicrobial compounds and methods for their production and use |
US10106543B2 (en) | 2013-09-09 | 2018-10-23 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
MX2017011616A (en) | 2015-03-11 | 2018-04-11 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same. |
CN104744478B (en) * | 2015-03-20 | 2016-08-24 | 中国人民解放军第二军医大学 | A kind of prevent and treat the compound of radiation damage, monocrystalline and its preparation method and application |
EP3377495B1 (en) * | 2015-11-16 | 2022-03-16 | Topadur Pharma AG | 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof |
JP2019515041A (en) | 2016-05-06 | 2019-06-06 | メリンタ セラピューティクス、 インコーポレイテッドMelinta Therapeutics, Inc. | Antimicrobial agents and methods of making and using the same |
MX2019013626A (en) * | 2017-05-22 | 2020-01-13 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof. |
EP3833395A1 (en) | 2018-08-06 | 2021-06-16 | Nicox S.A. | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
CA3117068A1 (en) | 2018-11-28 | 2020-06-04 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
KR102271305B1 (en) | 2020-05-21 | 2021-06-30 | 주식회사 아리바이오 | Composition for preventing and treating dementia |
WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
CN111825593B (en) * | 2020-08-19 | 2023-04-07 | 上海成澄科技有限公司 | Synthetic method of 3-aminopyrrole-2-formamide compound |
KR102272907B1 (en) | 2020-11-05 | 2021-07-05 | 주식회사 아리바이오 | Composition for preventing and treating dementia |
KR102272910B1 (en) | 2021-01-28 | 2021-07-06 | 주식회사 아리바이오 | Composition for prevention and treating dementia with diabetes |
KR20220140960A (en) | 2021-04-12 | 2022-10-19 | 주식회사 아리바이오 | Composition for prevention and treating dementia with diabetes |
KR102311224B1 (en) | 2021-04-23 | 2021-10-13 | 주식회사 아리바이오 | Composition for prevention and treating dementia through the combination of PDE5 inhibitors and glucocorticoid receptor antagonists |
KR20220146095A (en) | 2021-04-23 | 2022-11-01 | 주식회사 아리바이오 | Composition for prevention and treating dementia through the combination of PDE5 inhibitors and glucocorticoid receptor antagonists |
KR20240064630A (en) | 2021-09-29 | 2024-05-13 | 토파두르 파마 아게 | Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,L-F][1,2,4]triazinone derivatives and their uses |
WO2023166013A1 (en) | 2022-03-02 | 2023-09-07 | Topadur Pharma Ag | Topical compositions and uses therof |
KR20230129639A (en) * | 2022-03-02 | 2023-09-11 | 연세대학교 산학협력단 | A dual mode of action PDE5 inhibitor/organic nitrate ester in a transdermal dosage form to increase local blood flow |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5761734B2 (en) * | 1973-09-27 | 1982-12-25 | Takeda Chemical Industries Ltd | |
JPS5761734A (en) * | 1980-10-02 | 1982-04-14 | Teijin Ltd | Spun like fabric |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
JP3713783B2 (en) * | 1995-01-20 | 2005-11-09 | 大正製薬株式会社 | 1H-pyrazolo [3,4-d] pyrimidin-4-one derivatives |
IL132276A0 (en) * | 1997-04-25 | 2001-03-19 | Pfizer | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cgmp pde5) for the treatment of sexual dysfunction |
KR100449790B1 (en) * | 1998-04-20 | 2004-09-22 | 화이자 인코포레이티드 | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
KR100358083B1 (en) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | Pyrrolopyrimidinone derivatives, process of preparation and use |
-
2000
- 2000-02-17 KR KR20000007625A patent/KR100358083B1/en active IP Right Grant
-
2001
- 2001-02-15 TR TR2004/02101T patent/TR200402101T4/en unknown
- 2001-02-15 JP JP2001560209A patent/JP4845076B2/en not_active Expired - Lifetime
- 2001-02-15 PT PT01908397T patent/PT1257553E/en unknown
- 2001-02-15 NZ NZ520842A patent/NZ520842A/en not_active IP Right Cessation
- 2001-02-15 DK DK01908397T patent/DK1257553T3/en active
- 2001-02-15 CA CA002400268A patent/CA2400268C/en not_active Expired - Lifetime
- 2001-02-15 PL PL358188A patent/PL210796B1/en unknown
- 2001-02-15 ES ES01908397T patent/ES2222344T3/en not_active Expired - Lifetime
- 2001-02-15 DE DE60103508T patent/DE60103508T2/en not_active Expired - Lifetime
- 2001-02-15 CN CNB018075002A patent/CN1312153C/en not_active Expired - Lifetime
- 2001-02-15 US US10/204,327 patent/US6962911B2/en not_active Expired - Lifetime
- 2001-02-15 AT AT01908397T patent/ATE267829T1/en active
- 2001-02-15 MX MXPA02007942A patent/MXPA02007942A/en active IP Right Grant
- 2001-02-15 RU RU2002124872/04A patent/RU2263676C2/en active
- 2001-02-15 IL IL15123401A patent/IL151234A0/en unknown
- 2001-02-15 AU AU2001236140A patent/AU2001236140B9/en not_active Expired
- 2001-02-15 HU HU0300527A patent/HU230344B1/en unknown
- 2001-02-15 AU AU3614001A patent/AU3614001A/en active Pending
- 2001-02-15 EP EP01908397A patent/EP1257553B1/en not_active Expired - Lifetime
- 2001-02-15 BR BRPI0108395A patent/BRPI0108395B8/en not_active IP Right Cessation
- 2001-02-15 WO PCT/KR2001/000227 patent/WO2001060825A1/en active IP Right Grant
-
2002
- 2002-08-13 NO NO20023823A patent/NO323553B1/en not_active IP Right Cessation
- 2002-08-13 IL IL151234A patent/IL151234A/en active IP Right Grant
- 2002-08-16 ZA ZA200206587A patent/ZA200206587B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1257553B1 (en) | Pyrrolopyrimidinone derivatives, process of preparation and use | |
AU2001236140A1 (en) | Pyrrolopyrimidinone derivatives, process of preparation and use | |
AU744388B2 (en) | 1H-imidazopyridine derivatives | |
US5260303A (en) | Imidazopyridines as serotonergic 5-HT3 antagonists | |
KR20020038963A (en) | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase | |
EP1323719A1 (en) | Thienopyrimidine compounds and salts thereof and process for the preparation of the same | |
US20060235020A1 (en) | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein | |
JP2004526768A (en) | Tricyclic diazepines as uterine contractile inhibitory oxytocin receptor antagonists | |
FI64597C (en) | REFERENCE FOR TREATMENT OF THERAPEUTIC ANALYZED 5-UBSTITUERADE 1,2-DIHYDRO-3H-PYRROLO (1,2-A) PYRROL-1-CARBOX EXTRACTOR OF MOTOR VARIETIES NITRILER | |
US5280029A (en) | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof | |
EP1663105B1 (en) | Cycloalkyl heterocycles for treating hepatitis c virus | |
KR20110028445A (en) | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | |
EP0557526B1 (en) | Pyrroloazepine compound | |
IE922342A1 (en) | Imidazo[2,1-b]benzothiazole-3-acetamide derivatives, their¹preparation and their use in therapeutics | |
WO2001087888A1 (en) | Pyrazolopyrimidinone derivatives, process for their preparation and their use | |
US20030153558A1 (en) | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | |
US20090239853A1 (en) | Fused heterocycle derivative | |
KR100297814B1 (en) | Pyrazolopyrimidinone derivatives, processes for their preparation and uses thereof | |
US5227377A (en) | Meso-azacyclic amides of certain bicyclic carboxylic acids | |
TWI300778B (en) | Pyrrolopyrimidinone derivatives, process of preparation and use | |
US20050130983A1 (en) | Pyrrolopyrimidinone derivatives, process for preparation thereof, and method of using and composition comprising them | |
HU188071B (en) | Process for producing pyrrolo-benzodiazepine derivatives | |
JP2000513013A (en) | Pyrrolopyrrolones derivatives | |
EP1362858A1 (en) | Pyrrolopyrimidinone derivates, process of preparation and use |